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Abstract 
 
MicroRNAs (miRNAs) are small non coding RNAs of 18-25 nt, capable of regulating mRNA 
translation and gene expression at post-transcriptional level. Alteration of miRNAs 
expression is often associated with human diseases, such as cancers and neurodegenerative 
pathologies. The main objective of this study is an analysis of the post-transcriptional 
regulation played by miRNAs of two important genes, MAPT and GRN, involved in 
Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17). This is 
one of the major degenerative dementia syndromes, characterized by atrophy of the 
prefrontal and anterior temporal lobes. Several studies identified 44 pathogenic mutations 
in MAPT, which encodes for microtubule associated tau protein. In the brain tau has 
important functions in the assembly and stability of microtubules, that are fundamental for 
neuronal integrity and function. Disruption of tau role due to tau aggregations cause 
devastating effects that trigger neurodegeneration. To date 69 different mutations were 
found in GRN in the presence of FTD. GRN encodes a secreted precursor protein called 
progranulin that is expressed in neurons, microglia and represents an important growth 
factor involved in the regulation of multiple processes. The study identified miRNAs that can 
bind to GRN and MAPT mRNAs, affecting the translation efficiency of these transcripts, with 
a consequently reduction of the protein production. The project combined standard 
bioinformatic tools with a novel capture affinity assay, called miR-CATCH, in order to 
identify the best putative miRNAs. The assay was performed with specific biotinylated anti-
sense oligonucleotides for the pull-down of GRN and MAPT mRNAs in different 
neuroblastoma cell lines. The binding of selected miRNAs on the 3’UTR regions of these 
genes, was validated using over-expressing vectors and reporter constructs to perform 
luciferase assays. Regulation of selected miRNAs over-expression on progranulin and tau 
proteins was investigated in a neuroblastoma cell line, using western blot. This effect was 
further analyzed with Real Time PCR reactions and polysomal analysis to understand if the 
selected miRNAs control progranulin and tau expression through a mechanism of 
translational repression or transcripts degradation. Two of the analyzed candidates, miR-
659-3p and miR-608 were found important for the regulation of both genes, GRN and MAPT 
implicated in the disease, with a subsequent control on the endogenous progranulin and tau 
production in neuroblastoma cell line. Whereas miR-939-5p and miR-615-5p are only 
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involved in the regulation of GRN expression. In addition we identified several SNPs located 
on miRNAs binding sites that are predicted to increase or decrease miRNAs binding. Since 
neurological disorders are strongly influenced by common genetic variability, SNPs or 
variations that overlapped miRNA-binding sites, could represent potential and important 
risks factors for generation of FTD.  
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CHAPTER ONE: INTRODUCTION 
1.1 Frontotemporal Dementia (FTD): General Introduction 
 
Frontotemporal dementia (FTD) is a neurodegenerative disease, characterized by 
atrophy of the frontal and anterior temporal lobe that determines behavior and personality 
changes with a gradual deterioration of languages skills. All the pathological manifestations 
associated with FTD are collectively termed frontotemporal lobar degeneration (FTLD) 
(Nicholson A.M. et al. 2011). After Alzheimer’s disease, the second most common cause of 
early-onset dementia is Frontotemporal lobar degeneration (FTLD) (Graff-Radford N.R and 
Woodruff B.K. 2007). Indeed FTLD affects mainly individuals under the age of 65 (Nicholson 
A.M. et al. 2011). The 30-50% of FTLD cases have a familial component (Lashley T. et al. 
2011), although sporadic forms of FTLD are also known. In 10-23% of cases the disorder 
segregates with an autosomal dominant inheritance pattern (Goldman J.S. et al. 2005 and 
2007). Molecular genetic studies have identified so far seven genes that cause FTLD in 
presence of mutations: the microtubule associated protein tau gene (MAPT), progranulin 
gene (GRN), the gene encoding valosin-containing protein (VCP), the charged multivesicular 
body protein 2B (CHMP2B), abnormal expansion of a hexanucleotide repeat in C9orf72, 
TARDBP and FUS genes (Cruts M. et al. 2012). The last three genes can also cause a clinical 
picture of amyotrophic lateral sclerosis (ALS), or a combination of FTD and ALS (ALS/FTD) 
(Pearson J.P. et al. 2011; Neumann N. et al. 2006, Yan et al. 2010). Frontotemporal 
dementia appears to be a complex pathology caused by an heterogeneous group of 
different genes that lead to different neuropathological characteristics (Cairns NJ, et al. 
2007). Most cases of FTLD are classified into different categories according to the abnormal 
intracellular accumulations of specific protein that are found in patients (Table 1). The first 
identified subgroup is characterized by aggregation of hyperphosphorylated tau protein in 
neuron and glia (FTLD-tau), a second group is characterized by neuronal inclusion originally 
positive for ubiquitin (FTLD-U), afterwards called FTLD-TDP since in most cases the 
ubiquitinated protein found in the pathological inclusions is the transactive response DNA 
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binding protein (TDP-43) (Arai T et al. 2006). Subsequently a third subgroup was identified 
with inclusions immunoreactive for FUS termed (FTLD-FUS) (Neumann N et al. 2009). 
 
 
Table 1. Molecular classification of FTLD with the genes involved in the pathology and 
the clinical phenotypes. * Pathological subtype indicates the pattern of pathology (Adapted 
from Riedl et al. 2014). 
 
1.1.1 The Molecular Genetics of FTLD 
 
A large proportion of FTD patients have a family history, the first two genes that were 
identified associated with FTD were MAPT and GRN, located on chromosome 17 (Baker et 
al. 2006). These genes will be further discussed in the following chapters (Chapter three and 
Chapter four). TDP-43, encoded by TARDBP (TAR DNA Binding Protein) gene is a ubiquitous 
protein of 43 KDa and 414 amino acids (Wang et al. 2008; Neumann et al. 2006). This 
protein is mainly localized in the nucleus, however a cytosolic expression was observed in 
large motor neurons, with a role in mRNA transport and dendritic branching (Ayala et al. 
2005, Wang et al. 2008; Barmada et al., 2010; Kabashi et al. 2010). After oxidative stress, 
TDP-43 can also accumulate in cytoplasmic stress granules, which usually represent a 
temporarily storage of non-translating mRNAs, RNA-binding proteins, small ribosome 
subunits and translation initiation factors (Colombrita et al. 2009; Buchan and Parker, 2009). 
Different works showed that TDP-43 can regulate more than 6,000 RNA targets, through a 
binding to introns, 3’UTRs and non-coding RNAs (Polymenidou et al. 2011, Tollervey et al. 
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2011). TDP-43 is not only involved in mRNA transport, stability and maturation but 
increasing evidences reveals its role on splicing process, influencing the splice site selection 
through a binding on exon-intron junctions and intronic regions (Tollervey et al. 2011). 
TDP-43 was also found involved in miRNA biogenesis, since it is able to associate with 
the Drosha microprocessor and directly interact with Drosha at different levels, influencing 
miRNAs production (Di Carlo et al. 2013). i-CLIP experiments demonstrated that TDP-43 
could interact and bind to long non coding RNAs (lncRNAs) such as the nuclear-enriched 
autosomal transcript 1 (NEAT1) and the metastasis lung adenocarcinoma transcript 1 
(MALAT1) (Tollervey et al. 2011). Even though the binding and regulation of non coding 
RNAs (ncRNAs) and miRNAs on TDP-43 expression need to be further investigate, TDP-43 
can autoregulate its own expression through the activation of a cryptic polyA site and a 
nuclear retention mechanism (Avendaño-Vázquez et al. 2012). So far 34 different TDP-43 
mutations have been found in different FTD or ALS/FTD families (Cruts et al. 2012), 
indicating that an altered role of TDP-43 can lead to neurodegeneration and frontotemporal 
dementia. Another RNA and DNA binding protein that present similar localization and 
functions is FUS, a multifunctional protein, often associated with TDP-43. Indeed FUS is 
actively implicated in mRNA transport, stability and translation, shuttling between the 
nucleus and the cytoplasm through a nuclear localization signal, as reported for TDP-43 (Iko 
et al. 2004). Different papers reported colocalization for FUS and TDP-43 in some nuclear 
complexes (Kim et al. 2010, Ling et al. 2010) or cytoplasmic aggregates of ALS/FTD affected 
neurons (Da Cruz and Cleveland, 2011). However, their colocalization seems to occur in 
specific situations and not all the aggregates found in post-mortem brain from FTLD patients 
contain both proteins (Neumann et al. 2009). Through the interaction of different splicing 
factors such as SRm160, PTB, serine/arginine proteins (SR proteins) and the direct binding to 
intronic or splice site sequences, FUS influences the splicing process (Meissner et al. 2003; 
Yang et al. 1998; Colombrita et al. 2012). It was reported that FUS could also affect the 
transcription process, through the binding of the C-terminal domain of RNA polymerase II, 
preventing the premature hyperphosphorylation of Ser2 in the C-terminal part of the RNA 
polymerase II (Schwartz et al. 2012). Similarly to TDP-43, FUS is involved in miRNA 
biogenesis, interacting with pri-miRNAs and helping the recruitment of Drosha for the 
correct production of miRNAs. The biogenesis of different miRNAs such as miR-9, miR-132 
and miR-125b, that are found to be important for neuronal differentiation and 
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synaptogenesis, is controlled by FUS (Morlando et al. 2012). FUS can also bind ncRNAs such 
as CCND1, inducing an allosteric change of FUS and allowing the interaction between FUS 
and CBP/p300 that lead to the inhibition of histone acetyltransferase function of CBP/p300 
(Wang X. et al. 2008). FUS was also found to interact with NEAT1 ncRNA, which assembles 
and organizes the core proteins of paraspeckles (Wang X. et al. 2008; Hoell et al. 2011; 
Lagier-Tourenne et al. 2012). Paraspeckles are present in almost all the cultured cells and in 
tissues with high levels of NEAT1 RNA, representing a nuclear retention of long hyperedited 
transcripts or a storage for the rapid release of RNAs during stress conditions (Prasanth et 
al. 2005; Chen and Carmichael, 2009). Reported mutations and aberrations localized mainly 
in the glycine rich region and C-terminal part of FUS are linked to the pathogenesis of FTD, 
ALS or ALS/FTD (Kwiatkowski et al. 2009; Vance et al. 2009; Lagier-Tourenne et al. 2010). 
So far 18 different VCP mutations have been found in families with ALS/FTD, inclusion 
body myopathy and Paget disease (Cruts et al. 2012). A mutation identified on the VCP gene 
in a French family leaded to the Inclusion Body Myopathy with Paget’s disease of the bone 
and frontotemporal dementia (IBMPFD), with a psychiatric onset of front temporal 
dementia and aggregation of TDP-43 (Jacquin et al. 2013). 
VCP is one of the most abundant cytosolic protein in mammals and member of the AAA-
ATPase gene superfamily (ATPase Associated with diverse cellular Activities) (Woodman, 
2003; Wang et al. 2004). The protein is formed by 806 amino acids, with a N-terminal 
domain implicated in ubiquitin binding function and C-terminal domain with a strong 
ATPase activity (Wang et al. 2004). VCP is involved in the extraction of polyubiquitin chains 
from ubiquitinated proteins to facilitate the delivery to the proteasome (Meyer et al. 2012), 
especially in ER-associated degradation (Stolz et al. 2011). The first role that was associated 
with VCP was the regulation of the membrane dynamics, since VCP affects the reformation 
of the Golgi apparatus after mitosis and the ER network maintenance (Uchiyama and Kondo, 
2005). Recently, evidences connect VCP with other membrane-mediate processes: 
endosomal trafficking and autophagy (Ramanathan and Ye, 2011; Ritz et al. 2011; Zehner et 
al. 2011). Another protein with a similar function in these two processes and implicated in 
the pathogenesis of frontotemporal dementia is the charged multivesicular body protein 
(CHMP2B). 
CHMP2B is a 213 amino acids protein, component of the Endosomal Sorting Complex 
Required for Transport-III (ESCRT-III complex). This complex has an important role in the 
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endocytosed protein trafficking from endosome to lysosomes, acting at the sorting phase of 
protein and regulating their efficient lysosomal degradation (Urwin et al. 2010). Endosomal 
trafficking represents a fundamental process for the internalization, transport and secretion 
of signaling molecules or neuronal growth factors and an alteration of this mechanism could 
have heavy effects on communication between cells (Bronfman et al. 2007). In the cytosol, 
the C-terminal domain interacts with the N-terminal part, creating an autoinhibitory 
structure that require an activation done by VPS4, through a binding on the C-terminal 
domain of CHMP2B (Whitley et al. 2003; Shim et al. 2007). VPS4 is indeed a member of the 
AAA-ATPase family, with a role in catalyzing the dissociation of ESCRT complexes from 
endosomes and its activity is essential for the correct function of the endosomal sorting 
(Katzmann et al. 2002; Obita et al. 2007). CHMP2B is expressed in all the major parts of the 
brain, with an enhanced expression in the hippocampus, in the frontal, temporal lobes and 
in the cerebellum observed through an in situ hybridization of mouse brain (Skibinski et al. 
2005). Mutations found in the CHMP2B gene are reported in frontotemporal dementia 
linked to chromosome 3 (FTD-3), an autosomal dominant dementia with an onset of 48-67 
years, usually characterized by TDP-43 negative, ubiquitin positive inclusions (FTLD-U) 
(Urwin et al. 2010). Different missense mutations in the CHMP2B gene are connected with 
FTD-3 (Skibinski et al. 2005), with familial or sporadic cases of ALS (Urwin et al. 2010, 
Parkinson et al. 2006), familial frontotemporal lobar degeneration (FTLD) (Ghanim et al. 
2010) or cortico-basal degeneration (CBD) (Van der Zee et al. 2008), however only few 
studies analyzed the pathogenic features of these mutations. 
Recently a large expansion of the hexanucleotides non-coding repeat GGGGCC in the 
C9ORF72 was demonstrated to cause ALS and FTD (De Jesus-Hernandez et al. 2011; Renton 
et al. 2011). The 20%-80% of familial and 5%-15% of sporadic ALS and FTD patients show the 
expansion with a range of 700-1600 repeats, whereas the normal healthy individuals have 
less than 30 repeats (De Jesus-Hernandez et al. 2011; Renton et al. 2011; Smith et al. 2013). 
C9ORF72 is composed by 12 exons, whereof 2 alternative non-coding first exons with the 
hexanucleotide repeat region localized within (De Jesus-Hernandez et al. 2011). Therefore, 
depending on the alternative transcription initiation, the repeat can be on the promoter of 
transcript variant 1 or in the intron 1 of transcript variant 2 and 3. C9ORF72 RNA was found 
in different CNS tissues, through analysis of expression array data (Renton et al. 2011). A 
recent work showed that C9ORF72 protein can have a function in the regulation of 
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intracellular trafficking processes of the endosomal and autophagy-lysosomal 
compartments (Farg et al. 2014). Similarly to what reported for CHMP2B, in neuronal cell 
lines and primary cortical neurons, C9ORF72 colocalizes with four Rab proteins involved in 
endosomal trafficking, with a higher colocalization with Rab7 that is implicated in the 
biogenesis of lysosomes, the transport of endosomes and the maturation of 
autophagosomes (Gutierrez et al. 2004). So far the pathological mechanism involved in the 
presence of the hexanucleotides repeats is not known, however some studies found that 
the repeats transcripts tend to accumulate and create structure in the nucleus called RNA 
foci, which can produce neurodegeneration through a toxic effect (De Jesus-Hernandez et 
al. 2011). The repeat-associated non-ATG (RAN) translation can aberrantly express these 
transcripts with all the possible reading frame, producing poly(GP), poly(GA) and poly(GR) 
proteins. Inclusions in neurons composed by RAN proteins are considered an hallmark of the 
disease (Mori et al. 2013b; Ash et al. 2013) RNA foci could also sequester important 
proteins, causing alterations or dysfunctions inside the cells (Mori et al. 2013a; Reddy et al. 
2013; Xu et al. 2013; Lee et al. 2013; Gendron et al. 2013). A recent work described a 
molecular mechanism for ALS/FTD with hexanucleotide repeats in C9ORF72. The 
mechanism consists in the alteration of RNA transcription, with transcriptional pausing and 
abortion due to the DNA and RNA-DNA structure formed in the repeat expansion regions. 
The accumulation of abortive transcripts with hexanucleotides repeats, creates G-
quadruplexes and hairpins structures that lead to the binding of essential proteins, causing 
nuclear stress and further defects (Haeusler et al. 2014). 
 
1.1.2 Frontotemporal Dementia in an RNA Perspective 
 
An emerging branch of research in neurodegeneration is focusing on the process by 
which RNA could influence and lead to dysfunctions or neuronal death. For several diseases, 
alterations in RNA splicing, in non-coding RNA and RNA binding protein can accompany or 
drive neurodegeneration in different ways (Gallo et al. 2005; Cooper et al. 2009; Lagier-
Tourenne et al. 2010). In the attached manuscript, we collected all the information related 
to the genes involved in frontotemporal dementia, focusing on their possible interactions 
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and regulations played by RNA. The review provides a broad summary of the recent 
literature in order to identify a common network of combined regulations, with an RNA 
perspective. RNA and its processing could have a key role for the unique integration of all 
the known genes involved in FTD and for the possible explanations of their pathological role 
or dysfunction mechanisms. The long non coding RNA regulations is still at the beginning 
phase and further work has to be done, however a global picture of interactions could help 
to open new questions, different experimental approaches to better decipher the signs of 
neurodegeneration. Please refer to the attached review “A network of RNA and protein 
interactions in Fronto Temporal Dementia” pubblished in Frontiers in Molecular 
Neuroscience in March 2015. 
 
 
 
Figure 1. Network of possible interactions between proteins and RNAs, at the basis of 
Fronto Temporal Dementia. Green arrows indicate binding interactions or processes that 
result in activation or increased expression. Red arrows indicate binding interactions or 
processes that result in inhibition of activity or reduced expression. Black arrows indicate 
binding interactions or processes whose result can be either positive or negative. Purple 
arrows indicate binding interactions or processes which are hypotetical. Symbols as in 
Legend. lncRNAs= long non coding RNA. TDP-43= TAR DNA binding protein. FUS= Fused in 
Sarcoma. GRN=progranulin. MAPT= Microtubule-Associated Protein Tau. VCP= Valosin 
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Containing Protein. C9ORF72=. CHMP2B= Charged multivesicular body protein 2b. 
Rab7=Ras-related protein 7 (Fontana and Siva 2015). 
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1.2 GRN and Progranulin Structure 
 
GRN is a gene localized on the long arm of chromosome 17, at the locus q21.31, with a 
distance of 1,7 Mb from MAPT (Cruts et al. 2006; Baker et al. 2006). The gene is composed 
by 13 exons. Exon 1, part of exon 2 and the entire 13 are non-coding (Nicholson et al. 2011). 
GRN encodes for a precursor protein of 593 amino acids and 68,5 kDa called progranulin. 
This protein was discovered in an independent way by different investigators that used 
several names such as granulin-epithelin precursor, prostate cancer, proepithelin, 
acrogranin and prostate cancer cell derived growth factor (He and Bateman, 2003). 
Progranulin can be N-glycosylated at five potential sites and secreted as a mature protein of 
88 kDa (Songsrirote et al. 2010; Chen-Plotkin et al. 2010). As represented in Figure 2 the 
protein is formed by 7.5 cysteine-rich granulin domains, separated through linker sequences 
that contain disulfide bridges (He and Bateman, 2003). The intra-linker sequences can be 
cleaved to produce seven non identical granulins containing cysteine rich motif and a range 
size from 6 to 25 KDa. The cleavage is made by different proteases such as matrix 
metalloproteinase-14 (Butler et al. 2008), elastase (Zhu et al. 2002), proteinase 3 and 
neutrophil elastase (NE) (Kessenbrock and Froehlich, 2008). The full-length progranulin, 
once secreted, is protected from cleavage by the high-density lipoprotein 
(HDL)/Apolipoprotein A-I complex (Okura et al. 2010) and the secretory leukocyte protease 
inhibitor (SLPI) (Zhu et al. 2002). 
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Figure 2. Schematic representation of progranulin structure. GRN gene encodes for a 
protein of 593 amino acids composed by intra-linked granulin peptides that can be cleaved 
by protease such as elastase or protect in the full-length PGRN conformation through the 
presence of protease inhibitor such as the secretory leukocyte protease inhibitor (SLPI) 
(Gass et al. 2012). 
 
1.2.1 Progranulin Localization and Function 
 
Progranulin and its fragments are both expressed in different tissues of the periphery, as 
well as in the central nervous system (Nicholson et al. 2011), especially in cerebral cortex, 
hippocampus and cerebellum (Daniel et al. 2000; Ahmed et al. 2007). In the brain, 
progranulin is expressed in different levels in neurons and microglia. In neurons the 
expression of progranulin increases with age, while in glial cells the level of progranulin 
depends on cells state of activation. Indeed an upregulation of proganulin is part of the 
proliferative and inflammatory response (Petkau et al. 2010). The subcellular location of 
progranulin seems to be the endoplasmic reticulum (ER) and Golgi, where it is particularly 
abundant in mouse cortical neurons and microglia (Almeida et al. 2011).  
Progranulin has an N-terminal signal peptide and several N-glycosilation sites, it is 
usually secreted and found in serum and cerebrospinal fluid of animals, for these reasons 
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several groups have concentrated their attention to search for potential progranulin 
receptors. Sortilin (SORT1), the neuronal growth factor receptor (Jansen et al. 2007; Teng et 
al. 2005) has been identified as a receptor of progranulin by two different studies 
(Carrasquillo et al. 2010; Hu et al. 2010). Indeed a knockdown of SORT1 in HeLa cells 
increased the extracellular levels of progranulin, while overexpression of SORT1 led to a 
reduction of progranulin levels (Carrasquillo et al. 2010). Progranulin is able to directly 
interact with SORT1 on the surface of neuronal cells. Moreover it was demonstrated that 
SORT1 could mediate progranulin levels in mouse brain (Hu et al. 2010). However another 
potential identified progranulin receptor is the tumor necrosis factor receptor (TNFR), 
suggesting a role for progranulin as TNFα antagonist (Tang et al. 2011). 
Progranulin is implicated in a wide range of biological processes such as embryogenesis 
(Diaz-Cueto et al. 2000; Daniel et al. 2003; Bateman and Bennet, 2009), cell survival and cell 
growth (Plowman et al. 1992; He and Bateman, 1999), inflammation and wound repair (Zhu 
et al. 2002; Kessenbrock and Froehlich, 2008; Yin et al. 2010), transcriptional repression 
(Hoque et al. 2003; Hoque et al. 2010) and several reports suggest its role in neuronal 
development (Van Damme et al. 2008). Interestingly, progranulin and the proteolytically 
cleaved granulins can have coherent functions, such as in the regulation of neurite 
outgrowth (Van Damme et al. 2008), or they can have contrasting roles, since granulin were 
found to have both agonistic and antagonistic role in cellular proliferation (Nicholson et al. 
2011) and a pro-inflammatory function in inflammation processes (He and Bateman, 2003). 
 
1.2.2 GRN Mutations Causing FTLD-TDP 
 
 In 2006 mutations found on GRN were discovered to be the cause of FTLD, with 
ubiquitinated positive inclusions (Baker et al. 2006). So far 69 different GRN mutations have 
been discovered in 231 families (Cruts et al. 2012). The GRN mutations frequency ranges 
from 1 to 11,7% in FTD patients, but the frequency rises to 12-25% in familial FTD (Cruts et 
al. 2006; Gass et al. 2006; Huey et al. 2006; Bronner et al. 2007; Borroni et al. 2008). The 
majority of GRN mutations are nonsense, frameshift and splice site that cause a premature 
stop codon (Cruts et al. 2006; Baker et al. 2006). However missense mutations with a partial 
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decrease of progranulin and a loss of its function (Mukherjee and Pastor, 2006; Mukherjee 
et al. 2008; Shankaran et al. 2008; Wang et al. 2010), silent and intronic mutations with 
unknown pathology can also occur. Usually all these type of mutations lead to a decrease of 
GRN through nonsense-mediated mRNA decay and subsequent haploinsufficiency (Baker et 
al. 2006; Cruts et al. 2006). However GRN mutations can cause a reduction of cellular 
progranulin levels through additional mechanisms, such as a decrease observed in the 
amount of secreted protein due to the presence of mutations that affect the signal peptide 
sequences (Gass et al. 2006; Le Ber et al. 2008) or a loss of GRN mRNA translation due to 
mutations located in the Kozak sequence of the GRN gene (Baker et al. 2006; Cruts et al. 
2006; Gass et al. 2006; Le Ber et al. 2008). In any case the result is a reduction of 
progranulin levels that can also be observed in either serum or cerebrospinal fluid (CSF) of 
GRN mutation patients, where progranulin is ~30-50% of the normal amount (Van Damme 
et al. 2008). A decrease in progranulin levels was also measured in plasma of GRN mutation 
patients (Finch et al. 2009) and a reduced GRN mRNA level was detected in patient whole 
blood samples (Coppola et al. 2008). 
The major component of the ubiquitinated positive inclusions found in GRN mutation 
patients with FTLD-U is TDP-43, subsequently termed FTLD-TDP (Mackenzie et al. 2006, 
Mackenzie et al. 2010; Sampathu et al. 2006). The relation between TDP-43 and progranulin 
is not fully understood, however recent works indicated that TDP-43 has a post-
transcriptional regulation on GRN mRNA. TDP-43 was shown to bind GRN 3’UTR, controlling 
the stability of GRN mRNA and the level of progranulin protein (Polymenidou et al. 2011; 
Colombrita et al. 2012). Moreover a knock-down of TDP-43 in mice showed an increase in 
the amount of GRN mRNA level (Polymenidou et al. 2011; Colombrita et al. 2012). The 
relation between GRN and TDP-43 was also demonstrated in vitro: cells that were treated 
with siRNA against GRN for 72h, showed a caspase-dependent cleavage of TDP-43 into 
fragments (Zhang et al. 2007); whereas primary neuronal cultures upon knowckdown of 
GRN showed a re-localization of TDP-43 in the cytoplasm (Guo A. et al. 2010). 
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1.3 MAPT and Tau Structure 
 
 The microtubule associated protein tau, termed MAPT gene is located on the 
chromosome 17 at the locus q21.3. The gene contains 16 exons, out of which 11 are 
expressed in CNS (Wolfe et al. 2012). The primary transcript contains 13 exons with eight 
constitutive exons: 1, 4, 5, 7, 9, 11, 12, 13, three alternative spliced exons: 2, 3, and 10 and 
two transcribed but not translated exons: -1 and 14 (Luna-Munoz et al. 2013). The extensive 
alternative splicing process gives rise to six different mRNAs, translated in six different 
isoforms present in the CNS. MAPT gene encodes for tau protein, whose largest isoform is 
composed by of 441 amino acids. The isoforms differ for 29 amino acids encoded by exon 2 
or exon 3 and the presence of three (3R) or four (4R) C-terminal repeat-regions, according 
to the presence or the absence of exon 10 that encodes for the additional microtubule 
binding domain. Indeed as reported in Figure 3, the tau protein structure contains in the C-
terminal part several repeated microtubule binding domains of 18 residues that regulate 
the rate of microtubules polymerization. Whereas the N-terminal projection domain 
includes an acid and proline rich regions which interacts with cytoskeletal elements (Luna-
Munoz et al. 2013). 
 
Figure 3. Schematic representation of tau functional domains (the largest isoform, 441 
amino acids).The projection domain, including an acidic and a proline-rich region, interacts 
with cytoskeletal elements. The N-terminal part is also involved in signal transduction 
pathways by interacting with proteins such as PLC-γ and Src-kinases. (manuscript Fontana, 
Siva, Denti 2015). 
 14 
 
 
1.3.1 Tau Localization and Function 
 
Tau is expressed in different tissues and highly enriched in neurons in the CNS. Indeed 
considering its association and interaction with microtubules that are particularly important 
for neuronal structure and function, tau is primarily found in axons and also in dendrites 
(Binder et al. 1985; Ittner et al. 2010). All the six isoforms are expressed in adults and the 
shorter tau isoform, containing three microtubule binding domains and the skipping of 
exons 2 and 3 is expressed also in fetal brain (Goedert et al. 1989; Goedert and Jakes 1990).  
It has been reported that tau can be secreted unconventionally in naked form (Chai et 
al. 2012) or associated to exosomes (Saman et al. 2012) and/or to other membrane vesicles 
(Simón et al. 2012). Detectable level of tau was also measured in the CSF of human tau 
transgenic mice (Andorfer et al. 2003; Yamada et al. 2011) and comparable levels was found 
in the CSF of healthy individuals (Hampel et al. 2010), leading to the hypothesis that tau 
release occurs under physiological conditions in vitro and in vivo. It is still unclear if the 
secretion of tau could have a physiological or pathological role. However the 
unconventional secretion of tau species could represent the way required for spreading and 
transmission of tauopathy observed in mice brain (Clavaguera et al. 2009; Chai et al. 2012). 
 
Tau has a role in the assembly, stabilization and dynamic of the microtubular network, 
particularly important for the neuronal structural integrity of the cytoskeleton (Fellous et al. 
1977). Indeed microtubules are important for the neuronal function, creating the structure 
for the axonal process growing from the neuronal cell body and forming a path for the 
transport of material to the synapses (Wolfe et al. 2012). An increased level of tau 
expression was indeed observed at the synapses, suggesting a role in the axonal transport 
(Mandell and Banker, 1996). Tau was also shown to regulate the axonal transport of 
organelles, including mitochondria (Medina and Avila, 2014). Tau protein can be 
phosphorylated at many different sites, both in physiological and pathological conditions 
(Johnson and Stoothoff, 2004). The alternative phosphorylation can control its biological 
function to interact with microtubules or its ability to self-assemble into neuronal filaments 
during neurodegenerative disorders. Different kinases show the capability to phosphorylate 
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tau in vitro, however the process in vivo seems quite unclear (Mandelkow et al. 2004; Doble 
and Woodgett, 2003). Phosphatases such as PP1 and PP2A can dephosphorylate tau and the 
balance between kinase or phosphatase activity will determine tau functionality.  
 
1.3.2 MAPT Mutations in FTLD 
 
In frontotemporal dementia (FTLD-Tau), patients show inclusions in neurons and glia of 
hyperphosphorylated tau called neurofibrillary tangles (NFT) (Lee et al. 2005). However if 
the hyperphosphorylation of tau precede or is a consequence of the filament assembly and 
which site is relevant for the pathology is still not clear (Wolfe et al. 2012). It was reported 
that through its tandem repeats, with the amino-terminal and the carboxy-terminal part, 
tau can assemble into filaments (Wischik et al. 1988; Wegmann et al. 2013). These filaments 
can also be assembled from non-phosphorylated full length recombinant tau with the 
interaction of negatively charged compounds such as free fatty acids and RNA (Kampers et 
al. 1996; Wilson et al. 1997). However the tangles found in patient neurons consist of 
hyperphosphorylated aggregates of insoluble tau. A direct toxic effect of these inclusions 
and/or a loss of the axonal functionalities of tau have been considered to contribute to the 
disease. So far 44 different MAPT mutations have been discovered in FTD population (Cruts 
et al. 2012). These are all missense mutations, splice mutations or both and the major part 
is located in the region encoding the C-terminal part or nearby exon 10. Therefore most of 
the mutations are affecting the correct ability to bind and promote the microtubule 
assembly (Goedert and Jakes, 2005). Approximately half of the mutations associated with 
exon 10 are altering the splicing of this exon, causing an increase of the ratio 4R to 3R. In 
neurons this ratio is always controlled and an imbalance of 4R to 3R can lead to 
neurodegeneration and the assemble of 4R isoforms into filaments (Wolfe et al. 2012; 
Spillantini and Goedert, 2013). Mutations located close to exon 10 5’ splice site could 
increase the inclusion of exon 10, either by altering the linear cis-splicing elements or 
through a destabilization of a stem-loop structure localized at the exon-intron junction 
(Spillantini and Goedert, 2013; Grover et al. 1999; D’Souza et al. 1999). The stem-loop is 
originated from the self-complementarity between bases located in that region and it has a 
role in masking the 5’ spice site. Therefore mutations that disrupt the stem-loop make the 5’ 
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splice site more accessible to splicing factors that lead to the inclusion of exon 10 (Wolfe et 
al. 2012). Interestingly, silencing of FUS (another protein involved in the pathology of FTD, 
previously described) was reported to alter the splicing of MAPT. In particular, FUS was 
shown to help the skipping of MAPT exon 10 in primary cortical neurons (Ishigaki et al. 
2012). 
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1.4 miRNAs Biogenesis and Function 
 
microRNAs (miRNAs) are a group of small non-coding RNAs with important regulatory 
roles on the post-transcriptional expression of target mRNAs (Bartel, 2009; Ghildiyal and 
Zamore, 2009), they are identified in animals, plants, green algae and viruses (Griffiths-
Jones et al. 2008). To date more than 10000 miRNAs have been found, around 940 of which 
are in the human organism (Sayed et al. 2011). Specifically miRNAs are 18-22 nt-long single-
stranded RNA molecules, firstly discovered by Lee et al. (1993), generated from longer 
transcripts of different lengths (pri-miRNA), usually transcribed by RNA polymerase II, from 
intragenic or intergenic DNA regions (Lee et al. 2004; Garzon et al. 2010). However some 
miRNAs could also be transcribed by RNA polymerase III as reported by Borchert and 
collegues (Borchert et al. 2006). The primary transcript termed as primary miRNA (pri-
miRNA) transcript is processed by the micro-processor complex in the nucleus. The 
microprocessor complex is composed by an RNase III enzyme, Drosha and its cofactor Pasha 
found in flies or its ortholog DiGeorge syndrome critical region gene 8 (DGCR8) found in 
mammals and Caenorhabditis elegans (Han et al. 2006). The process lead to the cleavage of 
pri-miRNA and formation of a small hairpin structure of 70-100 nt called precursor miRNA 
(pre-miRNA). Afterwards the pre-miRNA is exported to the cytoplasm through a RanGTP-
dependent double stranded RNA binding protein called Exportin 5. In the cytosol the pre-
miRNA is further processed by Dicer (Kim et al. 2005), an RNAse-III nuclease and additional 
proteins such as the transactivation response RNA-binding protein (TRBP) and the protein 
activator of the interferon-induced protein kinase PKR (PACT). Dicer produces an imperfect 
double-stranded RNA (Hutvagner et al. 2001, Lee et al. 2004). Subsequently, the RNA duplex 
is unwound by an RNA helicase and one strand is loaded on the RNA-Induced Silencing 
Complex (RISC) and associates with Argonaute-2 (Ago2; Meister et al. 2004 a and b). The 
other strand was believed to be degraded (Chendrimada et al. 2005), however recent 
studies demonstrated that can associate with different Ago protein and have a role in 
downregulation of target mRNA (Czech and Hannon, 2011). In any case the procedure of 
strand selection is not yet fully clarified. The miRNA-RISC complex interacts with the target 
mRNAs using classic base-paring. The binding involved the seed region of the miRNA, 
localized on its 5’ end between nucleotides 2 to 8 (Bartel, 2009). However a significant 
fraction of non-canonical interactions, that involve non-seed base pairing can occur 
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between the miRNA-RISC complex and the target mRNA (Helwak et al. 2013). Frequently 
these sequences are located in the 3’untranslated region (UTR) of target mRNAs, however 
they were subsequently localized in the coding region and the 5’UTR of a mRNA (Rigoutsos, 
2009; Orom et al. 2008). The RISC complex induces mRNA downregulation through two 
different functional pathways: either the mRNA cleavage if there is a perfect 
complementarity between the sequences of the miRNA and its target mRNA, or translation 
inhibition in case of imperfect binding (Bartel, 2009). In animals translational repression is 
the most frequent way of action for miRNAs, however in case of perfect complementarity, 
Ago2 is the protein involved in the cleavage of the target mRNA in humans. (Liu et al. 2004). 
The whole process is summarized in Figure 4. The mechanisms for translational repression 
played by miRNAs are still unclear, however different works suggested the promotion of 
target mRNA deadenylation, sequestration of miRNAs and target mRNAs by stress granules 
and P bodies, disruption of translation initiation or degradation caused by RISC after 
translation (Tang et al. 2008). For this reasons the translational repression induced by 
miRNAs seems to be a complex process that lead to a fine tuning downregulation effect at 
the protein level. miRNAs modulate through their binding the transcriptome of cells (Guo H. 
et al. 2010). Indeed one single miRNA could potentially target hundreds of different mRNAs 
and one single mRNA could be controlled by many different miRNAs. Moreover miRNAs 
themselves can be regulated post-transcriptionally as suggested by Farajollahi and Maas 
(Farajollahi and Maas, 2010), creating an increasingly intricate network of regulation. 
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Figure 4. Scheme of miRNAs biogenesis. The primary transcript (pri-miRNA) is cleaved by 
Drosha and DGCR8, generating a miRNA precursor (pre-miRNA) that is exported to the 
cytoplasm through Exportin5 and Ran-GTP61. Dicer and TRBP process the pre-miRNA to 
produce the mature miRNA, that is incorporated to the RISC and subsequently binds to the 
3’UTR of a target mRNA leading to either mRNA degradation or translational repression. 
(Adapted from Sapadaro and Bredy, 2012) 
 
1.4.1 Non-Canonical Biogenesis 
 
Latest findings revealed that many miRNAs are generated through an alternative process 
that does not require the action of Drosha. These miRNAs (dubbed “mirtrons”) are encoded 
by region located on intron or intron-exon junctions. In general they are short introns with 
hairpin potential that can be spliced and exported out of the nucleus. After the nuclear 
export the mirtrons follow the canonical miRNA pathway, with the cleavage of Dicer and 
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incorporation into the silencing complex (Okamura et al. 2007; Berezikov et al. 2007). 
Originally mirtrons were identified in flies and worms, however similar loci were recognized 
in rodents and primates (Berezikov et al. 2007; Babiarz et al. 2008). These loci give rise to 
shorter precursor stem lengths, lacking the lower stem which usually recruits 
Drosha/DGCR8 for the cleavage (Han et al. 2006). As depicted in Figure 5, in all the spliced 
intron, the initial product is a lariat that is processed by a debranching enzyme, and 
subsequently transported as pre-miRNA to the cytoplasm through Exportin-5. However 
some mirtron loci are not located at a distance from splice site and the small RNA-
generating hairpin is at one end of the intron. These “tailed” mirtrons have an unstructured 
extensions at the 5’ or 3’ to the hairpin (Ruby et al. 2007; Babiarz et al. 2008). The 3’tailed 
mirtron have a tail extension to the splice acceptor site, such as reported for miR-1017 
sequence (Flynt et al. 2010). During the biogenesis the 3’ tail is trimmed in the nucleus by 
RNA exosome, after the splicing and debranching processes, as reported in the Figure 5. 
Whereas the biogenesis of 5’ talied mirtrons has not been investigated in details, even 
though a number of 5’ tailed mirtrons have been identified in various mammals (Barbiaz et 
al. 2008; Chiang et al. 2010). 
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Figure 5. Representation of the canonical miRNAs and mirtrons biogenesis pathways. A) 
Canonical miRNAs biogenesis, through Drosha cleavage of pri-miRNA transcripts. B) Lariat 
debranching enzyme (Ldbr) debranch the spliced introns to produce pre-miRNA hairpins. C) 
Tailed mirtrons are spliced, debranched and the tails is trimmed by an RNA exosome in case 
of 3’tails. 5’ trimming is performed by unknown enzymes. The pre-miRNA hairpins 
generated from these alternative pathways are export to the cytoplasm where they 
undergo the usual process for the production of a mature and active miRNAs (Westholm 
and Lai, 2011). 
 
1.4.2 miRNAs in Neurodegenerative Diseases 
 
The assumption that miRNAs dysregulation could lead to neurodegeneration derived 
from different experiments in which knockout of Dicer, with consequent disruption of 
miRNAs biogenesis causes neurodegenerative phenotypes. In particular, deletion of Dicer 
was performed in mouse cerebellar neurons (Schaefer et al. 2007), in midbrain dopamine 
neurons (Kim et al. 2007), in striatal, retinal, spinal and cortical neurons (Cuellar et al. 2008; 
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Damiani et al. 2008; Davis et al. 2008; Haramati et al. 2010) and in glial cells (Tao et al. 2011; 
Shin et al. 2009; Wu et al. 2012). Several studies showed that the DGCR8 haploinsufficiency 
leads to a decreased production of miRNAs, with neuronal alteration as result (Stark et al. 
2008; Fenelon et al. 2011; Schofield et al. 2011). Hebert and colleagues found an altered 
phosphorylation pattern of tau after the deletion of Dicer, suggesting the presence of 
miRNAs’ control on specific aspects of the neurodegeneration process (Hebert et al. 2010). 
Microarray analyses demonstrated a specific brain expression of different miRNAs (Lim 
et al. 2005; Manakov et al. 2009), which is particularly relevant during mouse or zebrafish 
brain development (Miska et al. 2004; Kapsimali et al. 2007), such as miR-17-5p, miR-199a, 
miR-92 found important and higher expressed during the embryonic and post-natal days, 
while miR-29b, miR-138 were more expressed in the adult stages of mouse development 
(Miska et al. 2004). Sequencing data lead to the development of a mammalian miRNAs 
expression atlas in different cell types (Landgraf et al. 2007). In particular the neuronal 
specific miRNAs clusters miR-9 and miR-124 or the miRNAs clusters miR-15a and miR-126 
were found abundant in the adult frontal cortex, cerebellum, hippocampus regions and 
higher expressed in neuroblastoma cell lines such as SH-SY5Y (Landgraf et al. 2007). Recent 
studies showed an interesting correlation between the expression pattern of miRNAs in 
brains of different primates and human development (Somel et al. 2011 and 2010; Hu HY et 
al. 2011) suggesting that changes in miRNAs profiles induced significant differences at 
mRNA and protein levels between human and other primates’ brain. Therefore, not only the 
global loss of miRNAs can cause neurodegeneration, but in some cases a specific alteration 
of a single miRNA pattern in the brain could be linked to a particular disease. For this 
reasons in the last years different research groups focused their efforts on exploring 
circulating miRNAs as possible biomarkers for neurodegenarative disorders. 
For a better analysis of miRNAs dysfunctional mechanisms related to different 
neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, Amyotrophic Lateral Sclerosis and their use as potential biomarkers, please refer to 
the attached chapter: “Circulating cell-free microRNAs as biomarker for 
neurodegenerative diseases”, accepted for publication in the book “Mapping Nervous 
System Diseases via MicroRNAs”. The volume will appear in a new book series “Frontiers in 
Neurotherapeutics” by CRC Press-Taylor & Francis Group (Boca Raton FL, USA). 
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CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Cloning of Reporter Vectors 
 
GRN 3’UTR was amplified through RT-PCR, starting from RNA extracted from HeLa 
cells and retro-transcribed into cDNA. The full length GRN 3’UTR of 304 bp was amplified 
using GRN Forward and GRN Reverse Primers containing restriction sites for XbaI enzyme 
(refer to table 2.1a). The amplified product of 304 bp was purified using PCR purification kit 
from Qiagen and cloned inside pmirGLO plasmid vector, in the multiple cloning site, located 
at the 3’ of firefly luciferase (Figure 2.1). The cloning was performed through the sticky ends 
produced with XbaI digestion. pmirGLO plasmid (from Promega) is a dual-luciferase plasmid 
containing both firefly luciferase gene (luc2), under the control of PGK promoter, and Renilla 
luciferase gene, under the control of SV40 promoter. The vector is designed to measure 
miRNAs activity, through the inclusion of the putative miRNA binding sites or the entire 
3’UTR of interest at the 3’ of luc2. Firefly luciferase assay is used to analyze mRNA 
regulation, while Renilla luciferase is a control reporter for normalization. 
In order to investigate the effect of miRNAs on different parts of GRN 3’UTR, the GRN 3’UTR 
full lenght was firstly divided in two parts, using the restriction site for SacI, located after 
114 bp. The first part of GRN 3’UTR of 114 bp was called GRNIPart, while the second part of 
190 bp was called GRNIIPart. Following the digestion with SacI, the products were run on 
agarose gel and extracted through gel extraction kit from Qiagen. The samples were then 
purified using PCR purification kit from Qiagen and used for the cloning procedure. GRNIPart 
and GRNIIPart were both cloned inside pmirGLO plasmid vector at the multiple cloning site, 
using sticky ends derived from the digestion with XbaI and SacI respectively. 
The fragment GRNIPart was further divided in two different parts, using specific primers for 
the amplification of the desired products. GRN Forward and RevIGRNa Primers were used 
for the amplification of the first 65 bp product called GRNa fragment. ForIIGRNb and 
RevIIGRNb Primers were used for the amplification of the 61 bp product called GRNb 
fragment (refer to the table 2.1a for primer sequences). GRNa and GRNb products were 
amplified, purified through PCR purification kit (Qiagen) and cloned inside pmirGLO vector, 
using XbaI and SalI restriction sites. 
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MAPT 3’UTR was amplified from human genomic DNA using MAPT Forward and MAPT 
Reverse Primers, containing SacI and NheI restriction sites (refer to the table 2.1b for primer 
sequences). The amplified product of 4167 bp was purified using PCR purification kit from 
Qiagen and cloned inside pmirGLO plasmid vector, in the multiple cloning site, located at 
the 3’ of luc2. 
MAPT 3’UTR was further divided into 8 different partially overlapped fragments of 700 bp. 
Amplification of the fragments was obtained with specific primers reported in table 2.1b. 
The different fragments were cloned inside pmirGLO vector, using SacI and NheI or XbaI and 
SalI restriction sites.  
 
 
 
Figure 2.1. Map of pmirGLO Vector with specific features (Promega) 
 
 
 
 
 25 
 
Table 2.1a 
GRN PRIMERS SEQUENCES 
 GRN Forward Primer 5’- AAATCTAGAGGGACAGTACTGAAG -3’  
 GRN Reverse Primer 5’- ATCTAGAGAAAGTGTACAAACTTTATTG-3’ 
RevIGRNa 5’- AAAGTCGACAGGCCTGAGCAGA- 3’ 
ForIIGRNb 5’-AAATCTAGACCTCCCTAGCACCTCC-3’ 
RevIIGRNb 5’- AAAGTCGACGTGATGGGGAGCTCA- 3’ 
 
 
Table 2.1b 
MAPT PRIMERS SEQUENCES 
MAPT Forward primer 5'-AAAGAGCTCTTTGTGATCAGGCCC-3' 
MAPT Reverse primer 5’-AAAGCTAGCAATCAGAGTAATAACTTTATTTCC-3’ 
MAPT Reverse I 5'-ATAGCTAGCACTGACCCACAGCAG-3' 
MAPT Forward II 5'-ATAGAGCTCTGAGTGTGACGGGG-3' 
MAPT Reverse II 5'-ATAGCTAGCTGGGAATTCGGGACA-3' 
MAPT Forward III 5'-ATAGAGCTCCTAACCAGTTCTCTT-3' 
MAPT Reverse III 5'-ATAGCTAGCCTGATACTATGCATG-3' 
MAPT Forward IV 5'-ATAGAGCTCGAGAGAGCCCTTTCC-3' 
MAPT Reverse IV 5'-ATAGCTAGCACCTAGTCTGTGCCC-3' 
MAPT Forward V 5'-ATAGAGCTCACGAGGTGTCTCTCA-3' 
MAPT Reverse V 5'-ATAGCTAGCCAAACCAGAAGTGGC-3' 
MAPT Forward VI 5'-GGATCTGCTC TAG AGGCCCAAG-3' 
MAPT Reverse VI 5'-ATAGTCGACGGGATTGTCCTCATTT-3' 
MAPT Forward VII 5'-ATAGAGCTCGGTTCCTCTTCCTGA-3' 
MAPT Reverse VII 5'-ATAGCTAGCGCTTAGAGGGAAGGA-3' 
MAPT Forward VIII 5'-ATAGAGCTCGGTTTCTCTTTTCCAC-3' 
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2.2 Cloning of Over-Expressing Plasmids 
 
 The miRNA constitutive-expression cassette has been generated by cloning a 
fragment containing the precursor region of miRNAs (pre-miRNA) in the psiUx plasmid 
(Figure 2.2), using BglII and XhoI or BglII and KpnI restriction sites (Denti et al., 2004). All the 
primers used for the amplification of fragments containing the pre-miRNA region are 
reported in table 2.2. Pre-miR-939 was amplified from human genomic DNA using 5’- ACT 
GCT CGA GGG TCC TCC AGA ACG TGT TCA - 3’ (forward primer) and 5’- ACT GAG ATC TCG 
CTA CCA GGA GGA AAG CAA - 3’ (reverse primer); pre-miR-659 was amplified from human 
genomic DNA using 5’- ACT GCT CGA GCA CTG TCA TTA TTT TCT CAC - 3’ (forward primer) 
and 5’- ACT GAG ATC TGC GTT CTT GTT TTG TGT TTC - 3’ (reverse primer); pre-miR-615 was 
amplified from human genomic DNA using 5’- ACT GAG ATC TCG ACG ACA TAA TTG GAT CAT 
- 3’ (forward primer) and 5’- ACT GGG TAC CAG GAA GGG GTG AAT AGC TTG - 3’ (reverse 
primer); pre-miR-608 was amplified from human genomic DNA using 5’- CTG AGA TCT GGT 
AAT GGC TCC ATC TGG AG - 3’ (forward primer) and 5’- CTG CTC GAG TTG CAG ACT CTT GGG 
CCC TT - 3’ (reverse primer). miR-181a over-expressing plasmid was already present in the 
laboratory. Whereas I cloned two additional over-expressing plasmids for the over-
expression of miR-29a and miR-1207-5p, used for a project in collaboration with Assistant 
Professor Nikolaos Balatsos from the University of Athens in Greece, and an additional over-
expressing plasmid for miR-612. However, these over-expressing plasmids were not used for 
the functional analysis of GRN and MAPT post-transcriptional regulation. 
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Figure 2.2 Map of psiUX vector used for the production of miRNAs over-expressing plasmid. 
This vector was produced and published by Prof. Michela Denti in 2004 (Denti et al. 2004). 
 
Table 2.2 
miRNAs PRIMERS SEQUENCES 
Pre-miR-939 Forward 5'-ACTGCTCGAGGGTCCTCCAGAACGTGTTCA-3' 
Pre-miR-939 Reverse 5'-ACTGAGATCTCGCTACCAGGAGGAAAGCAA-3' 
Pre-miR-659 Forward 5'-ACTGCTCGAGCACTGTCATTATTTTCTCAC-3'  
Pre-miR-659 Reverse 5'-ACTGAGATCTGCGTTCTTGTTTTGTGTTTC-3' 
Pre-miR-615 Forward 5'-ACTGAGATCTCGACGACATAATTGGATCAT-3' 
Pre-miR-615 Reverse 5'-ACTGGGTACCAGGAAGGGGTGAATAGCTTG-3'  
Pre-miR-608 Forward 5'-ACTGAGATCTGGTAATGGCTCCATCTGGAG-3' 
Pre-miR-608 Reverse 5'-ACTGCTCGAGTTGCAGACTCTTGGGCCCTT-3' 
 
 
2.3 Cell Cultures and Transfection Experiments 
 
 Human cervical carcinoma HeLa cell line was grown in DMEM medium (Gibco®, Life 
Technologies) supplemented with 2 mM L-Glutamine, Penicillin/Streptomycin and 10% Fetal 
Bovine Serum (FBS). Human neuroblastoma KELLY cell line was cultivated in RPMI-1640 
medium (Gibco®, Life Technologies) supplemented with 2 mM L-Glutamine, 
Penicillin/Streptomycin and 10% Fetal Bovine Serum (FBS). Human neuroblastoma SH-SY5Y 
and SK-N-BE cell lines were grown in 1:1 mixture of Eagle’s Minimum Essential Medium and 
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F12 Medium (Gibco®, Life Technologies) supplemented with 2 mM L-Glutamine, 
Penicillin/Streptomycin and 10% Fetal Bovine Serum (FBS). All cell cultures were maintained 
at 37°C in a humidified atmosphere of 5% CO2.  
Cells were seeded on 24-well plate (Luciferase Assay) and 6-well plate (Western Blotting and 
ELISA assay). Cells were transfected at 80% confluence with Lipofectamine LTX and Plus 
reagent (Life Technologies) for Luciferase and ELISA Assays and with with Lipofectamine 
3000 (Life Technologies) for Western Blot analysis. Whereas cells were plated on culture 
dishes and transfected with Lipofectamine 3000 (Life Technologies) for polysomes analysis. 
 
2.4 miR-CATCH Experiments 
 
2.4.1 Formaldehyde Cross-Linking and Cell Lysis 
 
A detailed description of miR-CATCH protocol is reported in a recent paper (Vencken 
et al. 2014). Cultures of three selected neuroblastoma cell lines (KELLY, SK-N-BE, SH-SY5Y) 
were grown in T75 culture flasks. Three T75 full confluent flasks were used as a starting 
material for each miR-CATCH experiment. Cells (approximately 3x106) were fixed with 2% 
formaldehyde to a final concentration of 1% for ten minutes. Formaldehyde allows all the 
factors, such as miRNAs and proteins to GRN and MAPT mRNAs, to be cross-linked. The 
reaction was stopped with the addition of 3M glycine to the final concentration of 0,2 M. 
Then, cells were washed several times with ice-cold DPBS and repeatedly centrifuged at 4°C 
for 5 minutes at 2500 g. Cell lysis was prformed with 1,4 ml of FA lysis buffer (50mM HEPES, 
140 mM NaCl, 1mM EDTA, 1% v/v Triton-X100, 0,1% w/v sodium deoxycholate) with PMSF, 
protease inhibitors and RNase inhibitor added just before the lysis reaction. Cells were 
homogenized in 0,4 ml of FA lysis buffer and 0,4 ml of glass beads using the FastPrep 24 
homogenizer used 4 times for 30 seconds at speed 5,5. The lysate was filtered into a second 
tube and glass beads were washed by adding 1 ml of FA lysis buffer, centrifuging for 5 
minutes at 3500 g, 4°C. Finally cell debris was pelleted by centrifuging at 4°C for 5 minutes 
at 18000 g and the supernatant was transferred to a new tube. 
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2.4.2 Streptavidin Bead Preparation and miRNA:GRN or MAPT mRNAs Pulldown 
 
 Dynabeads MyOne Streptavidin C1 magnetic beads (Life Technologies, Grand Island, 
USA) were prepared to the manufacturer’s instructions. An excess of 800 pmol of 
biotinylated capture oligonucleotides was immobilised to the magnetic beads in 1X B&W 
buffer (1X TE buffer, 1M NaCl), rotating the tubes for 15 minutes at room temperature. 
Oligo-prepared beads were subsequently washed with hybridization buffer (2X TE buffer, 1 
M LiCl) and resuspended with 0,7 ml hybridization buffer, 0,5 ml 1X TE buffer and mixed 
with 0,2 ml of formaldehyde-treated cell lysates for 90 minutes under continuous tumbling 
at 37°C for adequate annealing. The beads were washed four times using washing buffers 
(0,1 M NaCl with 0,5% SDS and 0,1 M NaCl) and GRN or MAPT mRNA:miRNA complexes 
were captured using a Dynal magnet. The beads were suspended in TE buffer before heat 
treatment at 60°C for 5 minutes to reverse the interaction between the biotin-labelled 
DNA:mRNA:miRNA complexes and the magnetic beads. Cross-linked nucleic acids and 
proteins were incubated for 45 minutes at 70 °C to reverse the cross-linkages. Samples were 
subsequently used for validations studies. 
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Figure 2.4 miR-CATCH strategy. a) synthesis of a biotin oligonucleotide targeting a single 
strand region of a target mRNA. b) Formaldehyde cross-linking step. c) oligonucleotide 
immobilization to magnetic streptavidine beads. d) cell lysis. e) the target mRNA is captured 
and purified. f) Formaldehyde cross-links are reversed (Vencken et al. 2015). 
 
2.5 Luciferase assay 
 
 HeLa cells were plated in a 24-well plate (75.000 cells for each well) and transfected 
at 80% confluence using Lipofectamine LTX and Plus reagent (Life Technologies) with 15 ng 
of pGLO-3′UTR and 435 ng of miRNA-overexpressing plasmids. At 24 and 48h after 
transfection, cells were washed with PBS and lysed with Luciferase Assay Reagent 
(Promega). The lysates were used to measure Renilla and Firefly luciferase activity using 
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Dual-GLO Luciferase Assay System (Promega) with Infinite® M200 (Tecan) plate reader. The 
statistical significance was determined using Student’s t-test comparison. Data were 
considered significant when p<0,05. 
 
2.6 Western blotting and ELISA assay  
 
HeLa cells were seeded in a 6-well plate and transfected using Lipofectamine LTX 
and Plus reagent (Life Technologies) or Lipofectamine 3000 with 2,2 μg of miRNA-
overexpressing plasmids. At 48h after transfection, proteins were extracted with 
Radioimmunoprecipitation Assay Buffer (RIPA) supplemented with a protease inhibitor 
cocktail (Sigma-Aldrich) and analyzed by Western Blotting and ELISA assays. Proteins (20 µg) 
were separated on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred 
to a nitrocellulose membrane by using iBlot® Dry Blotting System (Life Technologies®) at 20V 
for 7 minutes. Blots were first blocked with 5% non-fat powdered milk in PBS/Tween 0.1%, 
then probed overnight at 4 °C with mouse monoclonal anti-GRN (Abcam® no. ab55167, 
1:500), rabbit polyclonal anti-Tau Dako (Agilent Technologies® A0024 , 1:1000) and rabbit 
polyclonal anti-HPRT (FL-218) (Santa Cruz Biotechnology® no. sc-20975, 1:500). Membranes 
were subsequently washed and incubated with anti-Mouse IgG and Anti-Rabbit IgG 
secondary antibodies (1:5000). Membranes were processed by ECL plus detection kit 
(Amersham®) according to manufacturer’s instructions. Densitometric analysis was 
performed using ImageJ program. 
Equal amount of proteins (1,5 μg) was used to perform ELISA assay (Adipogen®). Standards 
and samples were pipetted into the wells of a 96-well plate for binding to the pre-coated 
polyclonal antibody specific for progranulin. Washing steps were performed to remove 
unbound samples. Progranulin was recognized by the addition of a biotinylated polyclonal 
antibody and streptavidin labeled with HRP. After final washes, peroxidase activity was 
quantified using the substrate 3,3’,5,5’-tetramethylbenzidine (TMB) and the intensity of the 
color reaction. The intensity was directly proportional to the concentration of progranulin in 
the samples, measured at 450 nm. The quantification of progranulin in the analyzed 
samples was calculated with the use of a standard curve. 
 
 
 32 
 
2.7 Quantitative Real Time-PCR 
 
 Total RNA was extracted from transfected or non transfected cells using TRIzol 
reagent (Invitrogen®), according to the manufacturer’s instruction. For the quantification of 
GRN and MAPT transcripts from total RNA or polysomal/subpolysomal fractions, cDNA was 
synthesized by retrotranscription using RevertAid First Strand cDNA Synthesis Kit (Thermo 
Scientific®) with oligo (dT) primers, according to the manufacturer’s protocol. Real-Time PCR 
(RT-qPCR) was performed using Kapa SYBR fast qPCR master mix (Kapa Biosystem®) and 
specific primers reported in table 2.7. PCR reaction (10 µl) contains 0,3 µM of each primer, 5 
µl of master mix and 10 ng of cDNA. The expression of GRN and MAPT mRNAs was 
normalized with expression of different reference genes: glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase (HPRT1), succinate 
dehydrogenase complex subunit A (SDHA).  
TaqMan MicroRNA Reverse Transcription kit (Life Technologies®) was used for miRNAs 
quantification. Total RNA (10 ng) was retro-transcribed using miRNA-specific stem–loop 
primers: hsa-miR-659-3p, hsa-miR-181a-5p, hsa-miR-615-5p, has-miR-608, has-miR-939-5p 
and endogenous controls small nucleolar RNAs (RNU44, RNU48 and RNU6). The PCR reaction 
(20 µl), contains 1.33 µl of cDNA, 10 µl of TaqMan 2X Universal PCR Master Mix, 1 µl of 
TaqMan MicroRNA Assay (20X) containing specific probes for miRNAs of interest. The 
reaction was incubated at 95°C for 10 minutes, then at 95°C for 15 s and 60°C for 60 s for 40 
cycles. The relative expression of mRNAs and miRNAs was calculated by using the 
comparative Ct method. Data were expressed as fold-change relative to the mean of 
endogenous controls. The statistical significance was determined using Student’s t-test 
comparison. Data were considered significant when p<0,05. 
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Table 2.7 
Real Time PCR PRIMERS SEQUENCES 
Primer Forward GRN 5'-TTCTGGACAAATGGCCCAC-3' 
Primer Reverse GRN 5'-ACCCACGGAGTTGTTACCTG-3' 
MAPT Forward 5'-ACATCCATCATAAACCAGGAGGT-3' 
MAPT Reverse 5'-TGTCTTGGCTTTGGCGTTCT-3' 
HPRT I Forward 5'-TGACACTGGCAAAACAATGCA-3' 
HPRT I Reverse 5'-GGTCCTTTTCACCAGCAAGCT-3' 
SDHA Forward 5'-TGGGAACAAGAGGGCATCTG-3' 
SDHA Reverse 5'-CCACCACTGCATCAAATTCATG-3' 
GAPDH Forward 5'-TCTCCTCTGACTTCAACAGC-3 
GAPDH Reverse 5'-CGTTGTCATACCAGGAAATGA-3' 
 
 
2.8 Polysomal analysis 
 
 KELLY cells (2x106) were transfected in culture dishes (100mmx20mm, Corning®) with 
Lipofectamine 3000 (Life Technologies®). In every experiment two culture dishes were 
transfected with each miRNA over-expressing plasmid or empty control. After 48h the cells 
were incubated with cycloheximide to a final concentration of 100 µg/ml at 37°C for 3 
minutes. The plates were subsequently kept on ice, the media was removed and the cells 
were washed with cold phosphate buffer saline (PBS) with cycloheximide 0.01 mg/ml. Cells 
were scraped directly on the plate with 300 µl cold lysis buffer [10 mM NaCl, 10 mM MgCl2, 
10 mM Tris–HCl pH 7,5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/ml RNase 
inhibitor, 1 U/µl DNase I, 1 mM dithiothreitol and 0.1 mg/ml cycloheximide], scraped and 
transferred to a eppendorf tube. The extracts were centrifuged for 5 min at 13000 rpm at 
4°C. The supernatants were stored at -80°C and subsequently loaded on sucrose gradient 
containing 30 mM Tris–HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an 
ultracentrifuge on a swinging rotor for 100 min at 180000 g at 4°C. Fractions (polysomal and 
sub-polysomal) were collected monitoring the absorbance at 254 nm and stored at -80°C. 
The fractions were treated with 0.1 mg/ml proteinase K for2 hours at 37°C. After phenol–
chloroform extraction and isopropanol precipitation, polysomal and sub-polysomal RNAs 
were resuspended in 30 µl of RNAse free water and then used for Real Time PCR analysis. 
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CHAPTER THREE: IDENTIFICATION OF miRNAs INVOLVED IN THE 
POST-TRANSCRIPTIONAL REGULATION OF GRN EXPRESSION 
 
3.1 Introduction 
 
So far 69 different GRN mutations have been discovered as reported by the 
Alzheimer Disease and Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/FTDmutations/) (Cruts et al. 2012). Accumulating evidences 
have demonstrated that cases of FTD caused by mutations in GRN lead usually to the 
degradation of the mutant RNA by nonsense-mediated decay with the loss of 50% 
functional GRN (Baker et al. 2006). Most of these mutations are frameshift, non-sense and 
splice-site mutations that cause a haploinsufficiency pathogenic mechanism through the 
degradation of the mutant allele (Baker et al. 2006, Cruts et al. 2006). These processes lead 
to a general decrease in the amount of progranulin, as it is observed in the serum or in the 
cerebrospinal fluid (CSF) of patients with GRN mutations that show a ~30–50% of the 
normal level of progranulin (Van Damme et al. 2008). Decreased amount of progranulin can 
also be detected in plasma or whole blood of GRN mutations patients (Finch et al. 2009; 
Coppola et al. 2008). For this reason molecular interventions that allow the increase in the 
production of progranulin are important as potential therapeutic strategies (Jiao et al. 
2010). One way to control the production of progranulin is by acting at the translational 
level of GRN mRNA, where RNA binding proteins and miRNAs can play an important and 
relevant role. Little is known about miRNA regulation of GRN mRNA, except for two studies 
that identified binding sites on GRN mRNA for miR-29b and miR-107 that are reported to be 
significantly down-regulated in brains of Alzheimer’s disease patients (Hebért et al. 2008, 
Wang WX et al. 2008). miR-29b is a demonstrated regulator of progranulin through a 
binding site localized on the 3’UTR of GRN mRNA (Jiao et al. 2010), whereas miR-107 can 
regulate progranulin through sequences present in the open reading frame of GRN mRNA 
(Wang-Xia et al. 2010). In particular in the last paper the binding of miR-107 and miR-103 
was considered, since these miRNAs belong to the same gene family (miR-103/107) and 
they present a similar sequence (Wang-Xia et al. 2010). The authors found proof that 
glucose metabolism pathways can recruit miR-103/107 to down-regulate GRN expression 
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(Wang-Xia et al. 2010). Later on it was demonstrated that this miRNA family regulates 
insulin sensitivity and its silencing leads to an improved glucose homeostasis (Trajkovski et 
al. 2011).  
Another scenario in which the decrease of GRN expression below a critical threshold can 
cause the development of FTD is due to the presence of SNPs (Rademakers et al. 2008). The 
genetic variability localized at the same loci implicated in Mendelian pathogenic diseases 
predisposes to sporadic forms of the pathology (Rademakers et al. 2005, Brouwers et al. 
2006). An interesting study found, through genetic association analysis that a common 
genetic variation localized on the 3’UTR of GRN (78 C>T, rs5848) represents a genetic risk 
factor for FTD (Rademakers et al. 2008). The SNP, with the presence of the T allele, is 
localized on the seed sequence of miR-659-3p, causing the formation of 3 additional base 
pairs at the 5’ end of miR-659-3p, that trigger a stronger binding and a more efficient 
repression compared to the wild type C allele. Indeed brain extracts derived from rs5848 TT 
homozygous FTD patients showed lower progranulin amounts compared to CC carriers, as 
observed through western blot analyses, ELISA assay and immunohistochemistry. The study 
proposed that a homozygous state of the T allele at rs5848 represents a risk factor which 
combined with environmental or other genetic factors will determine the individuals that 
develop FTD (Rademakers et al. 2008). 
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3.2 Results 
 
3.2.1 GRN mRNA as a direct target of putative microRNAs 
 
In order to identify the key miRNAs that could regulate GRN mRNA expression, three 
different bionformatic software programs were used to predict the potential miRNAs 
binding on the GRN 3’UTR sequence. Predictive results derived from PITA 
(http://genie.weizmann.ac.il/), Targetscan (http://www.targetscan.org/) and Targetprofiler 
(http://mirna.imbb.forth.gr/Targetprofiler.html) were integrated to increase the specificity. 
Each database predicted binding sites for hundreds of miRNAs, including one for miR-939-
5p and one for miR-615-5p on GRN 3’UTR that was predicted by all three programs. The 
results were further screened and miR-608, miR-939-5p, miR-615-5p and miR-659-3p were 
selected according to the best score in terms of free binding energy, site accessibility and 
seed type (Figure 3.2.1.1). A multiple alignment using GRN 3’UTR sequences of three 
different species (mouse, rat and human) demonstrated a relevant level of conserved 
regions that might represent or indicate possible regulatory sequences (Figure 3.2.1.2). As 
described in Figure 3.2.1.1, miR-659-3p presents only one binding site, whereas miR-939-5p 
and miR-615-5p show three recognition elements with different specificity and binding 
energy. miR-608 shows two binding sites that are partially overlapping with the binding 
recognized by miR-939-5p, since they have a similar seed region. Overall the less conserved 
regions on GRN 3’UTR seem to be regions without putative miRNA binding sites. 
 
 
Figure 3.2.1.1 Scheme of the potential miRNAs binding site on GRN 3’UTR. Schematic 
representation of the putative miRNAs binding sites present on GRN 3’UTR according to the 
computational prediction of PITA, Targetscan and Targetprofiler. 
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Figure 3.2.1.2 Conservation analysis of GRN 3’UTR between human, mouse and rat. 
Multiple alignment of GRN 3’UTR sequence between human, mouse and rat species 
performed through ClustalW and graphically represented with Jalview. Black squares below 
the alignment and dark blue color on the sequences indicate the 100% conservation 
between human, mouse and rat. 
 
3.2.2 GRN 3’UTR Analysis of SNPs Located on miRNAs Binding Sites and Sequencing of 
GRN 3’UTR in Different Cell Lines  
 
Neurodegenerative diseases are strongly influenced by the genetic variability 
present in the human population (Hulse and Cai, 2013; Lukiw, 2013). Indeed variants 
located in important regulatory regions could have important effects in different disorders. 
In the present study sixteen different SNPs were identified in the GRN 3’UTR using dpSNPs 
database. Six of these SNPs were found in miRNAs binding sites. RNAhybrid software was 
used in order to identify the capacity of these SNPs to alter the interaction between the 
predicted miRNAs and GRN 3’UTR. Indeed RNAhybrid computes in silico hybridization of the 
miRNA with the mRNA in presence of the common or variant allele. The common genetic 
variability could increase or decrease the interaction binding and this would be reflected in 
the alteration of the free binding energy (∆G) calculated by RNAhybrid. The difference 
between the free binding energy of the common and variant allele can be computed as 
variation (∆∆G) as reported by Saba and colleagues (Saba et al. 2014). ∆G values that are 
more negative correspond to higher stability of miRNA-mRNA interaction, whereas ∆G 
values that are more positive indicate a lower stability interaction. According to the method 
developed by Saba and coworkers, SNPs can be classified in three different groups based on 
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the ∆∆G values: (∆∆G>0 kcal/mol) SNPs that increase miRNA binding, (∆∆G<0 kcal/mol) 
SNPs that reduce miRNA binding and (∆∆G=0 kcal/mol) neutral SNPs that have no effect on 
miRNA binding (Saba et al. 2014). In the Figure 3.2.2a are reported the comparisons 
between the wild type and the variant miRNA-GRN 3’UTR interactions and the computed 
∆∆G value for each binding. Only two SNPs caused an enhanced miRNA binding, one is 
located on the I binding of miR-608 (Figure 3.2.2a D) and the other is present on the binding 
of miR-659-3p (Figure 3.2.2a G). This variation overlapped miR-659-3p interaction was 
already reported by Rademakers and colleagues and represented a genetic risk factor for 
FTD (Rademakers et al. 2008). All the other SNPs overlapping miRNAs interaction regions 
induced a decreased miRNA binding, except for one SNP found on the II binding of miR-615-
5p-5p that has no effect on the interaction, as represented in the Figure 3.2.2a I. 
 
 40 
 
 
 41 
 
 
Figure 3.2.2a. SNPs overlapping miRNA binding sites analysis for GRN 3’UTR 
Representation of the miRNA-GRN mRNA functional characterization technique following 
the method reported by Saba and colleagues (Saba et al. 2014). 
 
GRN 3’UTR was further characterized through sequencing in all the cell lines used: HeLa, 
KELLY, SH-SY5Y and SK-N-BE. Interestingly there was a different presence of the alleles T or 
C on the SNP rs5848 found in FTLD patients by Rademakers and colleagues (Rademakers et 
al. 2008). As reported in the Figure 3.2.2b HeLa and SH-SY5Y cell lines are homozygous C-
allele, while SK-N-BE cell line is heterozygous T/C allele, with a major prevalence of T allele 
and KELLY cell line is homozygous for T allele. 
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Figure 3.2.2b GRN 3’UTR sequencing in HeLa, KELLY, SH-SY5Y and SK-N-BE cell line. 
Representation of chromatograms of the GRN 3’UTR sequencing performed in different cell 
line. The images report the region of GRN 3’UTR characterized by the common genetic 
variant rs5848 (78 C>T).  
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3.2.3 Expression of GRN mRNA in different neuroblastoma cell lines 
 
Neuroblastoma cell lines were used as a neuronal-like system to study the regulation 
of our genes of interest, GRN and MAPT in normal cell condition. RT-PCR was used to better 
analyze GRN mRNA expression in different neuroblastoma cell lines. Amplification of a 200 
bp product, located on GRN mRNA between exon 1 and 4, was obtained with specific 
primers recognizing regions of exons junctions. In particular, forward primer binds to a 
region located between exon 1 and 2, while reverse primer recognizes a sequence located 
on exons 3 and 4.  
The level of progranulin expression as mRNA was quite similar in all cell lines analyzed: 
IMR32, LA-N-1, LA-N-2, SK-N-MC, SK-N-AS, SK-N-DZ, SK-N-SH, SK-N-BE, CHP134, CHP212, 
SIMA, KELLY, NB-69, except for SIMA and IMR32 cell lines, where GRN mRNA seems to be 
expressed at a lower level. In order to investigate GRN mRNA post-transcriptional regulation, 
KELLY, SH-SY5Y (derived from SK-N-SH) and SK-NBE cell lines were selected since they show a 
meaningful level of GRN mRNA expression.  
 
 
 
Figure 3.2.3 RT-PCR of GRN mRNA in different neuroblastoma cell lines. Image of an 
agarose gel showing amplification of 200 bp products of GRN mRNA in different 
neuroblastoma cell lines. Black circles represent the selected neuroblastoma cell lines. 
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3.2.4 miRNAs Basal Expression in different cell lines 
 
Using TaqMan quantitative RT-PCR (qRT-PCR), the endogenous expression of miR-
939-5p, miR-608, miR-659-3p and miR-615-5p was analyzed in four cell lines: HeLa, KELLY, 
SK-N-BE and SH-SY5Y. All CT levels were normalized against snRNU6 to calculate the values 2-
∆Ct. In Figure 3.2.4 we can observe that miR-939-5p, in all the different cell lines, is expressed 
at higher level compared to the other selected miRNAs. Indeed, miR-659-3p is expressed at 
low level, mainly in SH-SY5Y and SK-NBE cell lines, whereas miR-615-5p and miR-608 are 
present at minimal level or totally absent in the analyzed cells. 
 
Figure 3.2.4. miRNAs basal expression levels in HeLa, KELLY, SH-SY5Y and SK-NBE cell lines. 
Representation of fold change (2-∆Ct) values, derived from the normalization with RNU6 CT 
levels. qRT-PCR image is representative of one biological experiment with three technical 
replicates (Mean SD). 
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3.2.5 GRN microRNAs Capture Affinity Technology (miR-CATCH) 
 
 miRNA targets have been predicted through different bioinformatic programs that 
are based on the free binding energy, site accessibility, seed type and seed sequence 
conservation. However, the miRNAs target recognition mechanism remains challenging, due 
to the high false-positive rates and to the fact that computational analysis relies on different 
algorithms that yield different results. For this reason it became clear the necessity to use a 
biochemical strategy based on physiological interactions between miRNPs and their specific 
target mRNAs to reliably identify subset of miRNAs targeting GRN mRNA. The microRNA 
Capture Affinity Technology (miR-CATCH) developed by Prof. Catherine M. Greene and her 
team (Hassan et al. 2013, Vencken et al. 2015), allows to selectively identify miRNAs binding 
to a specific mRNA under different conditions, eliminating false positive mRNA:miRNA 
interactions that can be predicted in silico. This technique offers the possibility to identify 
miRNAs that bind to the entire mRNA transcripts, therefore it is not limited to the 3’UTR 
region. It is a novel way to bypass or complement the initial use of bioinformatic predictions. 
I moved to the laboratory of Prof. Catherine M. Greene, where I worked for four months to 
learn and applied this technique in collaboration with Dr. Sebastian Vencken*. Firstly, we 
used KELLY cells for the validation of the isolation method and the efficacy of the miR-CATCH 
protocol specificity. Then, the miR-CATCH strategy was used to investigate the regulation 
played by miRNAs of GRN mRNA in the selected neuroblastoma cell lines: KELLY, SH-SY5Y and 
SK-N-BE. 
 
 
 
 
 
 
 
 
*Optimization of the miR-CATCH technique for the isolation of GRN and MAPT mRNAs was 
done in collaboration with Dr. Sebastian Vencken, at the laboratory of Respiratory Research 
at the Royal College of Surgeons in Ireland, Beaumont Hospital. 
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3.2.5.1 Biotinylated DNA Oligonucleotides Design 
 
The secondary structure of GRN mRNA was modeled using M-Fold web server 
(http://mfold.bioinfo.rpi.edu). Two of the most thermodynamically stable structures were 
elaborated and analyzed through the UGENE program (http://ugene.unipro.ru/) for a better 
identification of single strand regions present with the highest probability in the GRN mRNA 
structures. The exposed single strand region localized between bases 1276 and 1303 of the 
GRN transcript was used as a target sequence to design the specific DNA capture 
oligonucleotide, that should have a low hairpin melting temperature and a high hybrid 
melting temperature to hybridize with the single strand region. The anti-sense capture DNA 
oligonucleotide was biotinylated at the 5’ end and was designed specifically against the 
single strand region identified on GRN mRNA (5’-TCT TCA AGG CTT GTG GGT CTG GCA GG-
3’), as represented in the Figure 3.2.5.1 and Table 3.2.5.1a. The region of 27 bp was 
analyzed with Basic Local Alignment Search Tool (BLAST, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi), obtaining an exclusive 100% of total coverage to 
GRN mRNA. However BLAST showed a 15 bp similarity with BDNF-Antisense RNA (BDNF-AS) 
and an 18 bp similarity with lymphocyte-specific protein tyrosine kinase (LCK). BLAST was 
also used to identify a scrambled sequence not specific for any transcripts in order to design 
a DNA scrambled 5' terminally biotinylated oligonucleotide (5’-ATA TAT TAG ATT GCG TAT 
AAT TAG G-3’) as a non specific control of the miR-CATCH. Finally, in order to control the 
sequence specificity of the GRN capture oligonucleotide, a mismatch DNA capture 
oligonucleotide biotinylated at the 5’end was designed, changing 3 nucleotides (underlined 
altered bases) from the original sequence (5’-TCT TCA AGG CTT ACA GGT CTG GCAGG-3’), as 
reported in the Table 3.2.5.1b.  
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Figure 3.2.5.1 Design of GRN mRNA Capture Oligonucleotide. Secondary structure of GRN 
mRNA was elaborated through M-Fold. The exposed single strand region located between 
bases 1276 and 1303 of the transcript was used as a target. 
 
SINGLE STRAND REGION :                                    5’-AGCCTGCCAGACCCACAAGCCTTGAAGA-3’ 
REVERSE AND COMPLEMENT SEQUENCE:    ………. 5’-TCTTCAAGGCTTGTGGGTCTGGCAGGCT-3’ 
OLIGO SEQUENCE:                                            Biotin 5’-TCT TCA AGG CTT GTG GGT CTG GCA GG-3’ 
LENGTH:                                                                                                               26 
GC CONTENT:                                                                                                   57,7% 
MELTING TEMPERATURE:                                                                              79,8°C 
HAIRPINS TM:                                                                            36,5°C 34,5°C 29,4°C 31,6°C 31,5°C 
HOMO DIMER ANALYSIS:                                                                          ≥-5,5 Kcal/mole 
 
Table 3.2.5.1a Sequence and characteristics of the designed GRN mRNA Capture 
Oligonucleotide  
 
Design of GRN Capture Oligo 
 48 
 
 
 
OLIGO SEQUENCE:                                         5’-TCT TCA AGG CTT GTG GGT CTG GCA GG-3’ 
MISMATCH OLIGO SEQUENCE: Biotin 5’-TCT TCA AGG CTT ACA GGT CTG GCAGG-3’ 
LENGTH       26 
GC CONTENT       53,8% 
MELT TEMP       76,5°C 
Hairpins Tm:                      39,4-36,5-29,9-31,6-30,6 
 
Table 3.2.5.1b Sequence and characteristics of the designed GRN mRNA Mismatch 
Capture Oligonucleotide  
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3.2.5.2 Validation of GRN mRNA:miRNA Isolation  
 
In order to validate the isolation method and the efficacy of the miR-CATCH 
technique to enrich GRN mRNA in the capture sample, we performed the first experiments 
in KELLY cells. Levels of GRN mRNA in the capture samples obtained by qRT-PCR were 
compared to the levels obtained from the same cell lysates that did not undergo the 
capture procedure. After normalization with GAPDH and using the 2-∆∆Ct method, we 
obtained an enrichment of 17,55 fold compared to the total RNA extracted from the same 
lysate of KELLY cells, as reported in the Figure 3.2.5.2a. Then, to investigate the efficiency of 
capture oligonucleotide sequence in the level of enrichment, another miR-CACTH 
experiment was performed using the capture oligonucleotide and the mismatch capture 
oligo containing 3 different bases. There was a GRN mRNA enrichment of 33,3 fold obtained 
with the capture oligonucleotide and reduction of 18,5 units obtained with the mismatch 
oligonucleotide. Indeed the mismatch capture oligonucleotide cause an enrichment of 14,7 
fold compared to the total RNA, as reported in the Figure3.2.5.2b. The reduction in the 
enrichment level demonstrated the importance of the sequence specificity of the capture 
oligonucleotide used to specifically pull down GRN mRNA. As reported previously the 
sequence of GRN capture oligonucleotide showed complementarity with other two 
transcripts: BDNF-Antisense RNA (BDNF-AS) and a lymphocyte-specific protein tyrosine 
kinase (LCK). Specific primers were designed for the detection of these two off targets in the 
capture samples. However the qRT-PCR did not show enrichment for these two additional 
transcripts in the capture samples compared to the total RNA (data not shown). 
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Figure 3.2.5.2a GRN mRNA enrichment. Representation of the real time PCR results 
showing the fold enrichment level (2-∆∆Ct) obtained with GRN capture oligonucleotide 
compared to the total RNA that did not undergo the miR-CATCH protocol. Expression of 
GRN mRNA was normalized against GAPDH expression. Representative data of one 
biological experiment and three technical replicates. 
 
 
Figure3.2.5.2b. Validation of GRN mRNA isolation. Representation of the qRT-PCR data, 
showing the fold enrichment level (2-∆∆Ct) obtained with GRN capture oligonucleotide 
compared to the total RNA that did not undergo the miR-CATCH protocol and to the level 
obtained with a biotinylated mismatch oligonucleotide. Expression of GRN mRNA was 
normalized against GAPDH expression. Representative data of one biological experiment 
with three technical replicates. 
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3.2.5.3 GRN mRNA Enrichment in KELLY, SK-N-BE and SH-SY5Y cell lines 
 
Following the validation of the miR-CATCH protocol in the KELLY cell line, the pull-
down method was performed in biological triplicates in selected neuroblastoma cell lines. 
“Scrambled” samples were obtained from the same cell lysate of each biological 
experiment, using a scrambled capture oligonucleotide biotinylated at the 5’end for the 
miR-CATCH strategy. Using qRT-PCR, the level of GRN mRNA enrichment was assayed 
individually in each biological experiment and compared to the scrambled control through a 
2-∆∆Ct method. In particular 47 fold enrichment of GRN mRNA was obtained in the KELLY cell 
line, whereas 66 fold enrichment was found in SH-SY5Y cell line and 23 fold enrichment for 
SK-N-BE cell line, as reported in the Figure 3.2.5.3. Data represents the mean of three 
biological replicates. 
 
 
 
Figure 3.2.5.3 GRN mRNA Enrichment in different neuroblastoma cell lines. 
Representation of the fold enrichment (2-∆∆Ct) values of GRN mRNA compared to a specific 
scrambled control. Data were normalized with GAPDH expression. Mean ± SEM of three 
biological replicates is shown in the figure (** p<0,001; *** p<0,0001 vs. scrambled control). 
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3.2.5.4 Selected miRNA Profiling on Capture Samples in KELLY, SH-SY5Y and SK-N-BE cell 
lines 
 
The enrichment of putative miRNAs of our interest (miR-659-3p, miR-939-5p, miR-
608 and miR-615-5p), predicted through the use of bioinformatic softwares, was detected 
by TaqMan qRT-PCR. The level of fold enrichment was calculated comparing the capture 
samples with the specific scrambled controls using the 2-∆Ct method. The figures represent 
the mean level of the specific miRNA enrichment derived from the biological triplicates for 
each different cell line. In Figure 3.2.5.4.a and 3.2.5.4.b are reported the specific level of 
enrichment for each miRNA. miR-659-3p shows an enrichment of 15 times in GRN capture 
samples derived from the KELLY cell line (Figure 3.2.5.4.a A), 1959 times and 259 times 
respectively in GRN capture samples derived from SH-SY5Y and SK-N-BE cell lines (Figure 
3.2.5.4.b A and B). Whereas miR-939-5p was found weakly enriched (1,6 times) in GRN 
capture samples derived from the KELLY cell line (Figure 3.2.5.4.a B), slightly enriched (1,5 
times) in GRN capture samples of SK-N-BE cells and not enriched in GRN capture samples of 
SH-SY5Y cell line (Figure 3.2.5.4.b A and B). miR-608 and miR-615-5p were also quantified 
by TaqMan qRT-PCR, however these miRNAs were not found enriched in capture samples, 
probably due to their lack of expression in all the analyzed neuroblastoma cell lines at 
physiological conditions (data not shown). The expression of miR-323 was used as a 
negative control in the KELLY cell line. miR-323 was not enriched in the capture samples 
compared to scrambled controls (Figure 3.2.5.4.a C). 
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Figure 3.2.5.4.a. Selected miRNA enrichment in KELLY cell line. Representation of miR-659-
3p A) and miR-939-5p B) enrichment in GRN capture samples compared to scrambled 
controls. Graphs on the right part of the figure C) represent the negative control miR-323 
that shows no enrichment in the capture samples. miRNAs expression was represented as 
fold enrichment value (2-∆Ct). 
A) and B) Mean±SEM of three different biological experiments (*P<0,05; *** P<0,0001). C) 
Representative figure of two biological samples with three technical replicates. 
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Figure 3.2.5.4.b Selected miRNAs enrichment in SH-SY5Y and SK-NBE cell lines. A) 
Representation of miR-659-3p and miR-939-5p enrichment found in capture samples 
compared to scrambled controls in SH-SY5Y samples. B) Graphs representing the 
enrichment of miR-659-3p and miR-939-5p compared to the scrambled controls in SK-NBE 
cell line. miRNA expression was represented as fold enrichment value (2-∆Ct). 
Mean ± SEM of three different biological experiments (* P < 0,05; *** P < 0,0001). 
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3.2.6.1 Luciferase Assays using reporter vectors of the full GRN 3’UTR in HeLa cell line 
 
Following the results obtained with miR-CATCH strategy, the putative miRNA’s regulation on 
GRN 3’UTR was further investigated using luciferase activity assays in HeLa cell line. HeLa 
cell line is a reliable cell system, easy to handle and useful to explore with high efficiency the 
regulation of our miRNAs of interest by co-transfection experiments. According to our 
bioinformatic prediction, miR-181a does not have binding sites localized on GRN 3’UTR and 
for this reason it was selected as a negative control. HeLa cells were co-transfected with 
reporter vectors containing the full length or different regions of GRN 3’UTR and miRNA 
over-expressing plasmids. 
 
3.2.6.1.1 Analysis of the miRNAs Overexpression in HeLa cell line 
 
Firstly, was checked the specific miRNA’s over-expression, during the luciferase 
analysis performed at 24h and 48h after transfection, the RNA was extracted and miRNAs 
quantified by qRT-PCR based on TaqMan assay. All the CT levels were normalized to RNU6, 
to calculate the fold change with the 2-∆Ct method. In Figure 3.2.6.1.1a the basal 
endogenous level of expression of selected miRNAs (light green) is compared to the level of 
miRNAs over-expressed from plasmids (dark green). Moreover the ∆∆Ct values were 
calculated using as normalizers the miRNA levels measured after transfection of backbone 
empty plasmid, utilized for miRNA cloning. These fold changes are reported in the Figure 
3.2.6.1.1b. 
 
 
Figure 3.2.6.1.1a Basal and Over-expression levels of selected miRNAs in HeLa cell line. 
TaqMan real time PCR was performed on the RNA extracted from parallel samples derived 
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from the luciferase analysis at 24h and 48h. Ct levels are normalized against RNU6 to 
calculate the fold change with the 2-∆Ct method. Data are obtained from biological duplicates 
and technical triplicates (Mean SEM). 
 
 
Figure 3.2.6.1.1b Over-expression levels of selected miRNAs in HeLa cell line. 
Representation of the 2-∆∆Ct values obtained through the comparison between the over-
expression of miRNAs and the endogenous basal level of expression in HeLa cell line. Data 
represent the summary of biological duplicates and technical triplicates (Mean SEM). 
 
3.2.6.1.2 Validation of mirtron-939 over-expression 
 
The human precursor region encoding miR-939-5p, overlaps with a 5’ splice site as 
reported in the Figure 3.2.6.1.2a taken from Ensembl Genome Browser. The stem-loop 
precursor region of miR-939-5p has the typical hairpin-end structure of mammalian 
mirtrons composed by GUGGG nucleotides, proposed by Berezikov and colleagues 
(Berezikov et al. 2007). miR-939-5p could be considered as a 3’tailed mirtron in which the 
spliceosome and the microprocessor complex compete for the same region, leading to a 
spliced product or the generation of a mature miRNA. The precursor region of miR-939-5p 
cloned inside the over-expressing plasmid for miRNAs, under the control of U1 promoter 
and U1 terminator, contains two exons with three entire introns as reported in the Figure 
3.2.6.1.2b. The precursor region of miR-939-5p that is unspliced has a length of 465 bp, 
whereas the spliced region will be of 272 bp. In order to validate if splicing competes with 
the miR-939-5p biogenesis and maturation, RT-PCR was performed using RNA extracted 
from cells that have been transfected with the over-expressing plasmid for miR-939-5p. 
Primers used for the cloning of miR-939-5p precursor region were used to amplify the 
region of interest. Samples were loaded on 2% agarose gel. Figure 3.2.6.1.2c depicts the 
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results, showing a stronger production of the unspliced product of 465 bp compared to the 
spliced product of 272 bp represented by a faint band. This result demonstrated a major 
recruitment of the microprocessor complex on the unspliced precursor region of miR-939-
5p. The production of miR-939-5p seems to be preferred compared to the splicing of that 
region that would lead otherwise to the disruption of the precursor sequence for miR-939-
5p. 
 
 
Figure 3.2.6.1.2a Ensembl Genome Browser representation of miR-939-5p precursor 
region. 
 
 
 
Figure 3.2.6.1.2b Scheme of the precursor region of miR-939-5p. The precursor region was 
cloned inside miR-939-5p over-expressing plasmid, under the control of U1 promoter and 
U1 terminator. Black bars represent the position of the specific primers used for the cloning 
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procedure and for the RT-PCR reaction. Red square indicates the precursor region of miR-
939-5p overlapping the 5’splice site. 
 
 
Figure 3.2.6.1.2c RT-PCR reaction of miR-939-5p precursor region. Figure of the 2% agarose 
gel where samples derived from the amplification of the precursor region of miR-939-5p 
were loaded. RT-PCR reactions performed with the RNA extracted from cells that were 
transfected with miR-939-5p over-expressing plasmid. Sample 1 and 2 are showing the 
amplification of the unspliced region cloned inside the over-expressing plasmid for miR-939-
5p (465 bp band) and the spliced product of the same region (272 bp band). Blank 
represents the specific control of the RT-PCR reaction that does not contain the cDNA 
sample.  
 
After the validation of the miRNAs over-expression, luciferase analyses were performed at 
24h and 48h from the transfection day. In particular after 24h, there was a down-regulation 
correlated with every miRNA overexpressed and a significant reduction was observed after 
transfection with miR-615-5p, miR-939-5p and miR-659-3p compared to miR-181a (Figure 
3.2.6.1a). At 48h there was an enhanced luciferase down-regulation for miR-615-5p, miR-
939-5p and miR-608, compared to the negative control. However there was a slightly 
increase on the results variability and only miR-659-3p showed a significant reduction of 
luciferase activity. (Figure 3.2.6.1b). 
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Figure 3.2.6.1a Luciferase assay at 24h, cotrasfection of pmiRGLOFullGRN3’UTR and 
putative miRNAs. Relative luciferase activity was measured in HeLa cells transiently co-
transfected with pmiRGLOFullGRN3’UTR and selected miRNAs (miR-181a, miR-615-5p, miR-
939-5p, miR-659-3p and miR-608) over-expressing plasmids. Firefly luciferase activity was 
normalized with Renilla luciferase activity. Percentage of luciferase reduction, reported 
above the graph bars, are related to negative control, miR-181a. Mean  SEM of three 
biological replicates is shown in the figure (*p<0,05). 
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Figure 3.2.6.1b Luciferase assay at 48h, cotrasfection of pmiRGLOFullGRN3’UTR and 
putative miRNAs. Relative luciferase activity was measured in HeLa cells transiently co-
transfected with pmiRGLOFullGRN3’UTR and selected miRNAs (miR-181a, miR-615-5p, miR-
939-5p, miR-659-3p and miR-608) over-expressing plasmids. Firefly luciferase activity was 
normalized with Renilla luciferase activity. Percentage of luciferase reduction, reported 
above the graph bars, are related to negative control, miR-181a. Mean  SEM of three 
biological replicates is shown in the figure(* p < 0,05). 
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3.2.6.2 Luciferase Assays using reporter vectors containing different regions of GRN 3’UTR 
in HeLa cell line 
 
In order to further investigate the different miRNAs contribution on the GRN 
regulation and to analyze the role of the different miRNAs binding sites, the GRN 3’UTR was 
divided in different parts, as represented in the Scheme 3.2.6.2. Luciferase assay analysis 
was performed at 24h and 48h after transfection. The Figure 3.2.6.2. (A and C) show a good 
level of luciferase reduction for all the selected miRNAs that have specific binding sites on 
the IPart of GRN 3’UTR (A) and on the fragment B of GRN 3’UTR (C). The reduction related 
to the IPart of GRN 3’UTR was significant at 24h and 48h. Whereas using the fragment B, the 
significant reduction was observed only at 48h, with a small and not significant down-
regulation at 24h with all the selected miRNAs. Since these constructs are produced with 
different regions of the GRN 3’UTR, the secondary structure of these transcripts could play a 
role on the dynamic of miRNAs binding process, exposing or blocking specific sequences 
important for the miRNAs targeting. The IIPart of GRN 3’UTR contains only one putative 
binding site for miR-615-5p. Indeed at 24h and 48h there was a significant luciferase down-
regulation only with miR-615-5p, while all the other miRNAs were not able to bind this 
specific region (Figure 3.2.6.2. B). In addition, the fragment A of GRN 3’UTR that contains 
only one binding site for miR-615-5p, showed a slightly luciferase reduction only at 24h, 
indicating a weak contribution for this miR-615-5p binding site on the regulation of this GRN 
3’UTR region (Figure 3.2.6.2. C). 
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Scheme 3.2.6.2. GRN 3’UTR and different miRNAs binding sites. Schematic representation 
of the full length GRN 3’UTR with the specific binding sites of different miRNAs and the 
regions in which GRN 3’UTR was divided for the luciferase assays analysis. 
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Figure 3.2.6.2. Luciferase assays of different regions of the GRN 3’UTR. A) Luciferase 
analysis performed at 24h and 48h, using pmiRGLO vector containing the IPart of GRN 3’UTR 
and all the over-expressing plasmids for the putative miRNAs. B) Luciferase analyzed at 24h 
and 48h, using pmiRGLO vector containing the IIPart of the GRN 3’UTR and all the over-
expressing plasmids for the putative miRNAs. Percentage of luciferase reduction, reported 
above the graph bars, are relative to miR-181a. Data derived from three biological replicate 
experiments (Mean SEM). C) Luciferase analysis performed at 24h, using pmiRGLO vector 
containing the fragment A of the GRN 3’UTR and the over-expressing plasmid for miR-615-
5p-5p. Data representative of two biological replicate experiments (Mean SEM). Luciferase 
assays performed at 24h and 48h, using pmiRGLO vector containing the fragment B of the 
GRN 3’UTR and the over-expressing plasmid for all the putative miRNAs.Data derived from 
three biological replicate experiments (Mean SEM). (* P<0,05, ** P<0,001). 
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3.2.7 Effect of Selected miRNAs Over-expression on Progranulin level in KELLY cell line 
 
The level of progranulin protein was measured using western blot analysis after 
miRNAs over-expression. KELLY cell line was transfected with the over-expressing plasmid 
for putative miRNAs entire panel and the backbone empty plasmid, used for miRNA cloning, 
as negative control. The efficiency of miRNAs over-expression was analyzed with TaqMan 
qRT-PCR, using RNA extracted from parallel samples, that underwent the same transfection 
experiments. In Figure 3.2.7a the basal endogenous level of expression of selected miRNAs 
(light grey) is compared to the level of miRNAs over-expressed plasmids (dark grey). 
Moreover the ∆∆Ct values were calculated using as normalizers the miRNA levels measured 
after transfection of backbone empty plasmid, utilized for miRNA cloning. These fold 
changes are reported in the Figure 3.2.7b. 
Proteins were extracted and used for western blot analysis as described in the Material and 
Methods section. HPRT protein was detected with specific antibody and used to normalize 
progranulin expression in all the analyzed conditions. Compared to the endogenous level, 
the entire panel of over-expressed miRNAs produced a decrease of progranulin protein. 
Percentage of progranulin expression is represented in Figure 3.2.7c. In particular the 
transfection of miR-615-5p leaded to 71,7% of progranulin expression, miR-608 leaded to 
81,6% of progranulin expression. Stronger effect of protein down-regulation was obtained 
with the over-expression of miR-659-3p and miR-939-5p, with respectively 64,9% and 64,7% 
of progranulin expression. 
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Figure 3.2.7a Basal and Over-expression levels of selected miRNAs in KELLY cell line. 
TaqMan real time PCR was performed on the RNA extracted after 48h from cells transfected 
with over-expressing miRNA plasmids. CT levels are normalized against RNU6 to calculate 
the fold change with the 2-∆Ct method. Data are obtained from biological duplicates and 
technical triplicates (Mean SD). 
 
 
Figure 3.2.7b Over-expression levels of selected miRNAs in KELLY cell line. Representation 
of the 2-∆∆Ct values obtained through the comparison between the over-expression of 
miRNAs and the endogenous basal level of expression in KELLY cell line. Data represent the 
summary of biological duplicates and technical triplicates (Mean SD). 
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Figure 3.2.7c Effect of miRNAs over-expression on progranulin. The over-expression of the 
putative miRNAs downregulated the endogenous progranulin protein expression 
represented by the sample transfected with pSP-Empty vector. Sample transfected with 
pSP-Empty vector were used as control to calculate the percentage of progranulin 
expression, reported below the images. Data normalized with HPRT protein expression. 
Representative western blot of an experiment repeated three times. 
 
3.2.8 Effect of miR-939-5p Inhibition on Progranulin Expression in HeLa cell line 
 
Quantification of miRNAs basal expression showed that miR-939-5p is expressed in a 
good level in HeLa cells at physiological condition. For this reason a specific miR-939-5p 
inhibitor, based on locked nucleic acid (LNA) technology was used to block the basal 
expression of miR-939-5p and subsequently analyzed progranulin expression using western 
blot. After 48h from the transfection of the miR-939-5p inhibitor and the specific control, 
proteins were extracted and used for western blot analysis. GAPDH protein was detected 
with specific antibody and used to normalize progranulin expression. Compared to the 
control level, progranulin expression was found increased with the transfection of miR-939-
5p inhibitor. Percentage of progranulin expression is represented in Figure 3.2.8 . 
Specifically progranulin expression increased up to 124% compared to the basal level. This 
result suggests a possible regulation played by miR-939-5p on progranulin expression. 
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Figure 3.2.8 Effect of miR-939-5p inhibitor on progranulin expression. Inhibition of miR-
939-5p caused an up-regulation of progranulin expression, compared to control. Sample 
transfected with a specific control vector was used to calculate the percentage of 
progranulin expression, reported below the images. Data normalized with GAPDH protein 
expression.* 
 
3.2.9 Effect of Selected miRNAs Over-expression on GRN mRNA level in KELLY cell line 
 
In order to determine if miRNAs over-expression can have an effect on the GRN 
mRNA levels, KELLY cells were transfected with over-expressing plasmid for all the putative 
miRNAs of interest and, as a negative control, the plasmid that does not contain any miRNA 
precursor region. RNA was extracted after 48h from the transfection day and GRN mRNA 
levels were measured by quantitative RT-PCR and normalized with two housekeeping genes: 
the hypoxanthine phosphoribosyltransferase I (HPRTI) and the succinate dehydrogenase 
complex subunit A (SDHA). The fold changes were calculated with the 2-∆∆Ct method, 
comparing the levels of GRN mRNA present in the samples where specific miRNAs were 
over-expressed with the levels of GRN mRNA measured in the samples transfected with the 
negative control, the empty vector (Figure 3.2.8). Only samples transfected with the over-
expressing plasmid for miR-615-5p showed a significant down-regulation of GRN mRNA 
level, whereas the cells transfected with the other putative miRNAs had a small and not 
significant down-regulation of GRN mRNA level compared to negative control. 
 
*This work was performed in collaboration with Dr.Margherita Grasso, at the laboratory of 
RNA Biology and Biotechnology, CIBIO 
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Figure 3.2.9 Effect of miRNAs over-expression on the GRN mRNA level. KELLY cells were 
transfected with the putative miRNAs and the empty control. RNA was extracted after 48h 
and analyzed through real time PCR for the detection of GRN mRNA and two specific 
normalizators, SDHA and HPRTI mRNAs. Representation of the fold changes calculated with 
the 2-∆∆Ct method. Data derived from biological duplicate experiments (Mean SEM).(*** 
P<0,0001). 
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3.2.10 Effect of miRNAs Over-expression on GRN mRNA in polysomal and sub-polysomal 
compartments in KELLY cell line 
 
The over-expression of the miRNAs of interest seems to reduce progranulin protein 
level, but not strongly alter and degrade the GRN mRNA level. Therefore, to verify whether 
the selected miRNAs regulate the level of progranulin by affecting the translation efficiency 
of GRN mRNA, KELLY cell line was transfected with the miRNAs over-expressing vectors and 
the empty vector as control. 48h after transfection the mRNA-ribosomal complexes were 
separated through sucrose gradient centrifugation in polysomal and sub-polysomal fractions 
containing the effectively translated transcripts and the untranslated mRNAs respectively. 
For each transfection condition, RNA was extracted and a Real Time PCR was performed in 
order to quantify the GRN mRNA amount in both polysomal and sub-polysomal 
compartments. The expression of HPRTI mRNA was used as normalizator to calculate the 2-
∆Ct values and results are represented in Figure 3.2.10b. The relative distributions of GRN 
mRNA in the two compartments were indicated as percentages calculated on the sum of the 
transcript extracted from the two fractions, for each treatment and control. The miRNAs 
over-expression led to an increase of GRN mRNA presence in the sub-polysomal parts 
compared to the control. Indeed the experiments showed a trend toward a shift of GRN 
mRNA from the polysomal to the sub-polysomal compartment after the transfection with 
miRNAs compared to the empty control. These results indicate that the selected miRNAs 
could regulate the level of progranulin by affecting the translation efficiency of GRN mRNA 
(Figure 3.2.10b). 
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Figure 3.2.10a Polysomal Profile. Representative polysome profile obtained from KELLY cell 
line. The figure showed 40S and 60S- free small and large ribosomal subunits, 80S- 
monosomes and the sub-polysomal and polysomal fractions.* 
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Figure 3.2.10b Effect of miRNAs over-expression on GRN mRNA in polysomal and sub-
polysomal compartments. KELLY cell line was transfected with the over-expressing plasmid 
for all the selected miRNAs and the empty control. After 48h the mRNA-ribosomal 
complexes were separated through sucrose gradient centrifugation and RNA was extracted 
from the sub-polysomal and polysomal parts. Real Time PCR was performed for the 
quantification of GRN mRNA in the sub-polysomal and polysomal fractions. GRN mRNA 
expression was normalized against the housekeeping HPRTI transcript. Percentages of GRN 
transcript measured in the two fractions are calculated on the sum of 2−ΔCt values of GRN 
mRNA from polysomal and sub-polysomal compartments. Data derived from three 
biological experiments. (Mean SEM).* 
 
 
 
 
 
 
 
 
*This work was done in collaboration with Dr. Paola Zuccotti from laboratory of 
Translational Genomics in CIBIO. 
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CHAPTER FOUR: PROGRANULIN AND HYPOXIA* 
 
4.1 Introduction 
 
In CNS, normoxia constitutes the situation in which the level of O2 is considerably 
lower than the level of O2 present in the systemic circulation (Peers et al. 2009). Indeed, 
with an arterial O2 level of 90 mm Hg, it is reported that the cerebral cortex is functional at a 
pO2 below 30 mm Hg, with 50% functioning below 10 mm Hg (Sick et al. 1982; LaManna et 
al. 2007). However, the brain can undergo through relative hypoxia conditions due to 
pathological situations that could derive from different respiratory or cardiovascular 
diseases (Peers et al. 2007). Neurons are vulnerable to oxygen changes and the brain shows 
neural damage after few minutes of oxygen deprivation (Bazan et al. 2002). Increasing 
evidences indicated association between neurodegeneration and hypoxia. Indeed dementia 
represents a risk factor for the survival of stroke patients (Desmond et al. 2002a), while 
stroke patients are more prone to develop AD during the following years (Desmond et al. 
2002b). It was observed that in vivo hypoxia caused an increase levels of amyloid precursor 
protein (APP), that is the substrate for the amyloid β peptide (Aβ) aggregates classically 
present during Alzheimer’s disease pathology (Skoog et al. 2006). Moreover Aβ peptides 
induce the formation of reactive oxygen species (ROS) (Neve et al. 1998; Daniels et al. 
2001). Increased ROS expression is also associated with different neurodegenerative 
diseases such as Parkinson’s disease, or other disorders such as arthritis, stroke and 
atherosclerosis (Aliev et al. 2002). Furthermore infants that died from hypoxia showed 
neuronal degeneration in the hippocampus region with the presence of AD-type astrocytic 
changes (Nakamura et al. 1986). Therefore hypoxia seems not only an important factor for 
the generation and the progression of AD, but could be responsible for the pathogenesis of 
FTD (Martin et al. 2001). This hypothesis is supported by the facts that hypoxia in an acidic 
environment and ischemia caused astrocytes degeneration in vitro (Martin et al. 2001). In 
addition in FTD cases it was shown an inverse correlation between astrodegeneration and 
cerebral blood flow, indicating that mild ischemia could possibly contribute to the 
progression of FTD (Martin et al. 2001). In this scenario progranulin was reported as a stress 
response factor under hypoxia and acidosis conditions. A work demonstrated that 
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fibroblasts cultures exposed to hypoxia and acidosis showed an increased progranulin 
expression (Guerra et al. 2007). An additional study reported that hypoxic injury could 
significantly affect progranulin expression. HT22 mouse hippocampal cell line under hypoxic 
condition showed an increase of progranulin expression within a shorter period with a 
decrease of progranulin levels observed after 6 hours (Luo et al. 2014). Levels of GRN mRNA 
and progranulin protein expression were found significantly elevated following chronic 
hypoxia in neuroblastoma cell lines (Piscopo et al. 2010). This progranulin up-regulation 
seems to be important for the rescue from cell death induced by oxidative insults or 
glutamate-induced excitotoxicity (Xu et al. 2011). The chronic exposure of neurons to these 
neurotoxic mechanisms has been suggested as important factor contributing to 
neurodegeneration diseases with the progressive loss of cortical neurons (Fatokun et al. 
2008; Lau et al. 2010). Several studies demonstrated the neuroprotective role of 
progranulin (Xu et al. 2011; Martens et al. 2012; Zhou et al. 2015) that can stimulate the 
activation of the MEK/ERK/p90RSK and PI3K/Akt cell survival pathways after toxic insults (Xu 
et al. 2011). The absence of the neuroprotective activities observed in progranulin 
deficiency mice predisposes to an hyperactivation of microglia that contributes to increased 
neurons loss in response to oxidative injury (Martens et al. 2012). Indeed FTD patients that 
have a reduced expression of progranulin, showed microglia in an activate state (Ahmed et 
al. 2007). Therefore in condition of a reduced extracellular progranulin, like in a pathological 
FTD state, the neuroprotective signaling, induced by increased progranulin expression, will 
be less effective or absent with apoptotic or necrotic death. Even though neuroprotective 
function of progranulin was found more potent against the apoptotic death (Xu et al. 2011). 
It is reported that cells in low-oxygen conditions induce changes in a specific family of 
miRNAs, called hypoxamirs (Nallamshetty et al. 2013). An important factor that can mediate 
these modifications is the hypoxia inducible factor (HIF) (Semenza, 2012). HIF is an 
heterodimeric transcription factor, that is activated under hypoxic conditions and recruited 
to bind consensus hypoxia responsive elements (HREs) in the promoters of different genes 
(Nallamshetty et al. 2013), including promoter for different miRNA genes (Kulshreshtha et 
al. 2007). Some hypoxamirs promote the activity of HIF (Loscalzo, 2010), or are direct 
targets of HIF during hypoxia, such as miR-210, that is induced by hypoxia in a HIF-
dependent way and stabilizes HIF expression (Kelly et al. 2011). Other hypoxamirs induce 
adaptive actions to hypoxia in a way that is synergistic with the role played by HIF (Crosby et 
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al. 2009). However during hypoxic stress, other different transcriptional factors could have 
important role, such as NF-KB, p53 (Cummins et al. 2005). For these reasons hypoxamir 
biogenesis could be induced through an HIF-dependent or HIF-independent way.  
The present work intended to investigate the role played by miR-659-3p in the regulation of 
progranulin during oxidative stress. Previous analysis of our collaborators suggested that 
perinatal asphyxia causes a transient oxidative stress followed by an altered expression of 
different genes involved in antioxidant defenses, brain development and neuroprotection 
(Piscopo et al. 2008). As other reported, they observed that chronic hypoxia leads to an 
increased expression of GRN mRNA and progranulin protein in neuroblastoma cell lines 
(Piscopo et al. 2010). Therefore we wondered if the putative miRNAs implicated in the 
regulation of GRN 3’UTR could have a role in the upregulation of progranulin expression 
during hypoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This work is part of a collaborative project with the Department of Cell Biology and 
Neuroscience, Istituto Superiore di Sanità in Rome. For the complete project refer to the 
attached manuscript “Reduced miR-659-3p levels correlate with progranulin increase in 
hypoxic conditions: implications for frontotemporal dementia” submitted to the journal 
“Molecular and Cellular Neuroscience”. 
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4.2 Results 
 
4.2.1 Functional assays to validate miR-659-3p binding on the GRN 3’UTR 
 
In order to analyze the binding of miR-659-3p on GRN 3’UTR, HeLa cell line was co-
transfected with reporter plasmid containing the full length GRN 3’UTR downstream the 
firefly luciferase gene (pmiRGLO-GRN3’UTR) and the over-expressing plasmid for miR-659-
3p (pSiUx-miR659). The level of luciferase activity was compared to the level obtained with 
the transfection of an over-expressing vector for a non-targeting miRNA, representing the 
negative control (pSiUx-miR181a). The production of mature miRNAs derived from the over-
expressing plasmids was quantified by TaqMan Real Time PCR at 24h and 48h, as reported 
in the Figure 4.2.1a. The levels of miR-659-3p, were increased of 315 times at 24h and of 
123 times at 48h. Whereas the levels of miR-181a, that was already highly expressed in 
HeLa cell line at basal condition, were increased of 2,4 times at 24h and 2,4 times at 48h. 
 
 
Figure 4.2.1a pSiUx-miR-659 and pSiUx-miR-181a over-expression at 24h and 48h. miRNAs 
expression levels measured by qRT-PCR after 24h and 48h from transfection. Mean ± SEM of 
two biological replicates is shown (N=6, ***p < 0.001 vs. miRNAs basal expression levels). 
 
 77 
 
Co-transfection experiments with pmiRGLO-GRN’3’UTR and the over-expressing plasmids 
for miR-659-3p and miR-181a led to a significant level of luciferase down-regulation. In 
particular transfection of miR-659-3p caused a luciferase reduction of 33,9%, compared to 
miR-181a at 24h (Figure 4.2.1b A), whereas transfection with miR-659-3p at 48h produced a 
decreased luciferase activity of 30,7%, compared to the luciferase level measured with miR-
181a transfection (Figure 4.2.1b B). 
 
 
Figure 4.2.1b. Luciferase assays confirm the interaction between miR-659-3p and GRN 3′-UTR. GRN 3′-UTR 
was cloned downstream of the firefly luciferase gene in pmiRGLO vector and co-transfected with miR-659 and 
miR-181a-overexpressing plasmids in HeLa cells. Luciferase activity was assessed at 24h (A) and 48h (B) after 
transfection (* p < 0.05). 
 
4.2.2 Effect of miR-659-3p over-expression on progranulin protein, analyzed with ELISA 
and western blot 
 
The effect of miR-659-3p over-expression on the endogenous progranulin protein 
was investigated in HeLa cell line after 48h from the transfection. The levels of progranulin 
protein, measured after the transfection of miR-659-3p over-expressing plasmid, was 
compared to progranulin levels quantified after the transfection of the over-expressing 
plasmid for miR-181a, as represented in the Figure 4.2.2. This analysis was performed with 
two different techniques, ELISA (Figure 4.2.2 A) and western blot (Figure 4.2.2 B). In the 
ELISA assays miR-659-3p induced a progranulin reduction average of 25% compared to miR-
181a (Figure 4.2.2 A). Whereas in the western blot analysis miR-659-3p led a progranulin 
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down-regulation of 15% compared to the negative control, miR-181a (Figure 4.2.2 B). These 
figures were obtained from four and three biological replicates, respectively. 
 
 
Figure 4.2.2. Effect of miR-659-3p over-expression on progranulin protein in HeLa cell line. 
ELISA assay (A) for progranulin quantification in protein extracts from HeLa cells (N=4; ** p < 
0.01).Western blot analysis (B) for progranulin detection in protein extracts from HeLa cells 
(N=3; ** p < 0.01). Western Blot image is representative of three biological replicates. 
Expression of Western Blot was normalized on HPRT expression. 
 
4.2.3 Validation of the physical interaction between miR-659-3p and GRN mRNA 
 
In order to validate the effective interaction between miR-659-3p and GRN mRNA, miR-
CATCH experiments were perfomed as described previously. The pull down assay was done 
on SK-N-BE cell line at physiological condition. The eluted samples were analyzed with Real 
Time PCR for the quantification of GRN mRNA present on capture samples compared to 
specific scrambled controls. GAPDH expression was used as normalizator. The Figure 4.2.3 A 
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represents the fold enrichment calculated with the 2-∆∆Ct method. GRN mRNA was  23,73-
fold enriched, compared to scrambled controls. The eluted samples were also analyzed with 
TaqMan real time for the quantification of miR-659-3p present on the capture samples 
compared to controls, as reported in the Figure 4.2.3 B. MiR-659-3p showed a 311,5-fold 
enrichment, compared to the quantity of miRNA present on scrambled control samples, 
calculated with 2-∆Ct method. 
 
 
Figure 4.2.3. mRNA:miRNA isolation technique for GRN mRNA from SK-N-BE cell line. A 
capture anti-sense DNA oligonucleotide with a biotin modification at the 5’ end was 
designed to pull-down GRN mRNA. qRT-PCR showed enrichment of GRN mRNA (A) and of 
miR-659-3p (B) in samples captured with GRN mRNA-specific oligonucleotide compared to a 
scrambled oligonucleotide used as negative control. mRNA expression was normalized with 
GAPDH expression and the fold enrichment was calculated with 2−ΔΔCt method. miRNA fold 
enrichment was quantified with 2−ΔCt method. Mean ± SEM of three biological replicates is 
shown (N=9, *p < 0.05; ***p < 0.001 vs. scrambled ). 
 
4.2.4 GRN 3’UTR sequencing in HeLa and SK-N-BE cell lines 
 
GRN 3’UTR was characterized through sequencing in two different cell lines used: 
HeLa and SK-N-BE. Interestingly, the GRN 3’UTR sequence present in SK-N-BE cell line 
showed the presence of the SNP rs5848 found in FTLD patients by Rademakers and 
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colleagues (Rademakers et al. 2008). The common genetic variation (78 C>T) represents a 
genetic risk factor for FTD. In the study they reported a stronger binding of miR-659-3p in 
the presence of the T allele compared to the presence of the wild type C allele. In Figure 
4.2.4 are represented the chromatograms of the region containing the common genetic 
variant, for cell lines analyzed. SK-N-BE cell line showed an heterozygous presence of both 
alleles (TC) with a higher presence of the T allele (Figure 4.2.4 B). Whereas, GRN 3’UTR 
sequence derived from HeLa cell line showed the presence of wild type CC alleles (Figure 
4.2.4 A). 
 
 
Figure 4.2.4 GRN 3’UTR sequencing in HeLa and SK-N-BE cell line. Representation of 
chromatograms of GRN 3’UTR sequencing performed in HeLa and SK-N-BE cell lines. The 
images report the region of GRN 3’UTR characterized by the common genetic variant rs5848 
(78 C>T). HeLa cell line expresses wild type CC alleles (A), while SK-N-BE cell line shows 
heterozygous TC alleles, with the prevalence of the T allele (B). 
 
4.2.5 Negative correlation between miR-659-3p expression and GRN mRNA levels in SK-N-
BE cell line under hypoxic condition 
 
 SK-N-BE cell line was maintained in hypoxic condition for 24h. The glucose 
transporter GLUT1 was measured on the hypoxic SK-N-BE cell line, as marker of hypoxia. 
GLUT1 mRNA levels were found successfully up-regulated in the hypoxic samples compared 
to normoxic controls as reported in Figure 6 (Manuscript attached, Piscopo et al. 2015), 
demonstrating thus the correctly induced hypoxia condition. SK-N-BE hypoxic and normoxic 
samples were analyzed with TaqMan Real Time PCR for the quantification of miR-659-3p. 
Data were normalized with the expression of two small nucleolar RNAs, RNU44 and RNU48. 
These data were statistically investigated and correlated to the up-regulation of GRN mRNA 
expression observed on hypoxia samples compared to normoxic controls in Figure 6 
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(Manuscript attached, Piscopo et al. 2015). Figure 4.2.5 represents the negative correlation 
between miR-659-3p and GRN mRNA expression found on SK-N-BE hypoxic samples 
compared to controls (Spearman’s rank correlation coefficient = -0.96, p = 0.0005). 
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Figure 4.2.5 Negative correlation between GRN mRNA and miR-659-3p expression levels in 
SK-N-BE cell line. 
 
4.2.6 Negative correlation between GRN mRNA and miR-659-3p in vivo 
 
The correlation between GRN mRNA and miR-659-3p was analyzed in RNA samples 
derived from a rat model of global perinatal asphyxia. In a previous work it was 
demonstrated that 20 minutes of global asphyxia are necessary for the induction of 
significative brain oxidative stress (Calamandrei et al. 2004). The exposure conditions 
adopted in the present analysis were 0 and 20 minutes of asphyxia leading to a survival rate 
of 100% and 95%, respectively. qRT-PCR on GRN mRNA was performed in rat cortical 
samples at postnatal days (pnd) 1, 4 and 11. As reported in Figure 8 (Manuscript attached, 
Piscopo et al. 2015), 20 min of perinatal asphyxia was found to increase GRN mRNA levels 
compared to controls in all the analyzed pnd. The increase was significant at pnd1 and pnd4. 
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The same samples were analyzed with TaqMan Real Time PCR for the quantification of miR-
659-3p. As represented in Figure 4.2.6, there was a decrease  of miR-659-3p expression in 
rat cortical samples treated with perinatal asphyxia compared to controls, with a 
significative reduction at pnd4. Indeed pnd4 showed a strong up-regulation of GRN mRNA 
compared to non treated samples, indicating again a negative correlation between GRN 
transcript and miR-659-3p expression. 
 
 
Figure 4.2.6 miR-659 down-regulation in cortex of asphyctic newborn rats. Levels of miR-
659-3p measured by qRT-PCR at different time points in perinatal asphyctic newborn rats 
cortex and relative controls. Data, expressed as 2-∆Ct, are means±SEM. N=5 
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CHAPTER FIVE: IDENTIFICATION OF miRNAs INVOLVED IN THE 
POST-TRANSCRIPTIONAL REGULATION OF MAPT EXPRESSION 
 
5.1 Introduction 
 
The accumulation of tau protein is found and reported in a variety of different 
neurodegenerative disorders termed as tauopathies. These include the group of diseases 
collectively called as frontotemporal dementia (FTD), described previously (Wolfe, 2012). 
Tau is reported as the major component of the neurofibrillary tangles that accumulates in 
neurons in different type of tauopathies (Kosik et al. 1986, Wood and Mirra, 1986) and the 
presence of altered tau due to mutations, contributes to the process of neurodegeneration 
(Wolfe, 2009). In FTD, tau accumulations are usually found in the frontal and temporal 
lobes. The accumulations in these brain regions lead to socially inappropriate behavior and 
irrational choices (Lee et al. 2001). However, depending on the different type of FTD, tau 
aggregations can be present in other brain areas. Several experimental evidences suggested 
that a reduction of tau expression could represent a potential therapeutic strategy for the 
cure of tauopathies. Indeed knock out of tau in Alzheimer’s Disease transgenic mouse 
models led to an improved learning and memory compared to mice with wild-type tau 
(Roberson et al. 2007; Ittner et al. 2010). Moreover, hippocampal neurons cultures derived 
from homozygous tau knockout mice did not show axonal transport defects (Vossel et al. 
2010). Therefore, molecular approaches that lead to a reduction of tau expression, could 
represent possible therapeutic strategies for the cure of neurodegeneration caused by tau 
accumulations. A possible way to control gene expression is through the functions played by 
3’UTR regions. Indeed 3’UTRs are involved in mRNA 3’end formation and polyadenylation at 
the pre-mRNA level, while they have a role in mRNA stability or degradation, nuclear export 
and translational efficiency at the mRNA level (Chen et al. 2006). The action carried out by 
miRNAs on this important regulatory region, can lead to mRNA degradation or the block of 
translation, causing strong effects on the cell physiology. So far the role of MAPT 3’UTR in 
the regulation of tau expression was quite understudied. Only two works identified that 
miR-34 family controls tau expression through the presence of binding sites located on the 
MAPT 3’UTR region (Wu et al. 2013; Dickinson et al. 2013;). In particular Dickinson and 
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collaborators found that tau expression could be regulated by miR-34a (Dickinson et al. 
2013), whereas Wu and colleagues reported that miR-34c could down-regulate tau 
expression in gastric cancer cells (Wu et al. 2013). Even though miR-34a and miR-34c are 
encoded by different loci, they have the same seed, as members of the same family and 
they both bind on the same region on MAPT 3’UTR, regulating tau expression. Indeed LNA 
inhibition of endogenous miR-34 family led to an increase in tau expression (Dickinson et al. 
2013). It is reported that 3’UTR regions are more prone to evolution, containing a higher 
density of short insertion/deletion length variants, single nucleotide polymorphisms (SNPs) 
and repeat expansions (Imanishi et al. 2004; Missirlis et al. 2005). Interestingly MAPT gene is 
part of an ancient inversion of an extended region that led to two haplotype H1 and H2. 
Even though the aminoacids sequence is unchanged, H1 and H2 are defined by a series of 
different SNPs and a deletion in intron 9 (Baker et al. 1999; Pittman et al. 2006). Since the 
structure of tau is not altered, any pathogenic effects associated with a particular haplotype 
could be investigated on the action of SNPs present on important regulatory regions, such 
as the 3’UTRs. 
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5.2 Results 
 
5.2.1 MAPT mRNA as a direct target of putative microRNAs 
 
As reported for GRN 3’UTR, three different bioinformatics softwares (PITA, 
Targetscan and Targetprofiler) were used to predict the putative miRNAs that have binding 
sites located on MAPT 3’UTR. In order to increase the specificity, the results derived from 
these bioinformatics tools were integrated to obtain a global list of putative miRNAs. 
Hundreds of miRNAs were predicted from each database, however the same putative 
miRNAs that were identified for the regulation of GRN 3’UTR, showed potential binding sites 
on MAPT 3’UTR. This finding suggest a possible common mechanism of regulation played by 
miRNAs on these two different 3’UTR regions. Since MAPT 3’UTR is 4160 bp in length, the 
selected miRNAs (miR-608, miR-939-5p, miR-615-5p and miR-659-3p) showed multiple 
binding sites with good score in terms of free binding energy, site accessibility and seed 
type. In particular,the putative binding sites found for our selected miRNAs are: 13 for miR-
608, 16 for miR-939-5p, 7 for miR-615-5p-5p and 3 for miR-659-3p. In order to analyze the 
regulation played by these selected miRNAs, the MAPT 3’UTR was divided into eight 
different and partially overlapped fragments of 200 bp (MAPT 3’UTR I – VIII). The MAPT 
3’UTR fragment V was chosen for the analysis of 4 miR-608 binding sites and 1 miR-659-3p 
binding site, as reported by the Figure 5.2.1a. To analyze the level of sequence conservation, 
MAPT 3’UTR sequences derived from different species (mouse, rat and human) were aligned 
with ClustalW program. The 3’UTR showed a relevant level of conserved regions, as reported 
in the Figure 5.2.1b.  
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Figure 5.2.1a Scheme of the potential miRNAs binding sites on MAPT 3’UTR Fragment V. 
Schematic representation of putative miRNAs binding sites, present on MAPT 3’UTR 
Fragment V, according to the computational prediction of PITA, Targetscan and 
Targetprofiler. 
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Figure 5.2.1b Conservation analysis of MAPT 3’UTR among human, mouse and rat. 
Multiple alignment of MAPT 3’UTR sequences among human, mouse and rat species 
performed by ClustalW and graphically represented with Jalview. Black squares below the 
alignment and dark blue color on the sequences indicate the 100% conservation between 
human, mouse and rat. 
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5.2.2 MAPT 3’UTR Fragment V Analysis of SNPs Located on miRNAs Binding Sites  
 
In the present analysis twenty-two different SNPs or small insertion and deletion 
were identified in the Fragment V of MAPT 3’UTR, using dbSNPs database. Seven of which 
were located in putative miRNAs binding sites. RNAhybrid software was used to calculate 
the free binding energy (∆G) of miRNA-tagert interactions, in the presence of the common 
or variant sequence. As reported previously the difference between the free binding energy 
of the common and variant allele was calculated as variation (∆∆G), according to the 
method developed by Saba and colleagues (Saba et al. 2014). Based on the variation values 
(∆∆G), SNPs that increase miRNA binding have a positive variation (∆∆G>0 kcal/mol), SNPs 
that reduce miRNA binding have a negative variation (∆∆G<0 kcal/mol) and neutral SNPs 
that have no effect on miRNA binding have a variation equal to zero (∆∆G=0 kcal/mol) (Saba 
et al. 2014). As reported in the Figure 5.2.2 four SNPs caused an enhanced miRNA binding 
on Fragment V of MAPT 3’UTR, one is located on miR-659-3p binding site (Figure 5.2.2 B), 
two are located on the second binding of miR-608 (Figure 5.2.2 D and E) and the fourth one 
is present on the third binding of miR-608 (Figure 5.2.2 J). All the other SNPs overlapping 
miRNAs interaction regions induced a decreased miRNA binding. 
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Figure 5.2.2 SNPs overlapping miRNA binding sites analysis for Fragment V of MAPT 3’UTR 
region. Representation of the miRNA-MAPT mRNA functional characterization technique 
following the method reported by Saba and colleagues (Saba et al. 2014). (* The sequence 
used as wild type in the figures H, I and J derived from USCS Genome Browser database 
(http://genome.ucsc.edu/) and represents the variant with CA bases, without the insertion 
of T allele). 
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5.2.3 MicroRNA Capture Affinity Technology (miR-CATCH) 
 
 Due to the MAPT 3’UTR length (4160 bp), the process of computational miRNAs 
target recognition is challenging and complicated for the entire region. Moreover, as 
reported for GRN 3’UTR, the high false-positive rate, and the presence of multiple 
algorithms that lead to different outputs, increase the inconsistency of bioinformatic 
prediction. For all these reasons, the miR-CATCH approach was used to analyze the subset 
of miRNAs that are targeting MAPT transcripts and can be isolated in physiological 
conditions. The same neuroblastoma cell lines used for the GRN miR-CATCH was applied for 
the pull down of MAPT transcripts. Therefore KELLY cell line was used for the optimization 
of the miR-CATCH protocol and the validation of the isolation method of MAPT mRNAs. 
Subsequently, the miR-CATCH strategy was used to investigate the regulation played by 
miRNAs on MAPT mRNAs in the selected neuroblastoma cell lines: KELLY, SH-SY5Y and SK-N-
BE. 
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5.2.3.1 MAPT Biotinylated DNA Oligonucleotide Design 
 
The secondary structures of all the 6 MAPT isoforms reported to be present in adult 
brain were modeled using M-Fold web server. Two of the most thermodynamically stable 
structures for each MAPT isoforms were elaborated and analyzed with UGENE program. 
This software allows the identification of the most probable single strand regions present on 
these transcripts. One exposed single strand region localized between bases 852 and 871, 
according to the longest MAPT transcript, was used as a target sequence to design the 
MAPT DNA capture oligonucleotide biotinylated at the 5’end, as reported in the Figure 
5.2.3.1. This region of 20 bp, was analyzed with Basic Local Alignment Search Tool (BLAST), 
obtaining an exclusive 100% of total coverage to MAPT mRNA isoforms. However, BLAST 
showed a 17 bp similarity with the homo sapiens visual system homeobox 1 (VSX1) 
transcript variant 2 mRNA. An antisense DNA capture oligonucleotide biotinylated at the 
5’end was designed against the single strand region found on MAPT mRNAs sequences (5’-
GGG TGG TGT CTT TGG AGC GG -3’). Due to the complexity of the miR-CATCH protocol for 
all the six different isoforms of MAPT transcripts and the complicated identification of the 
single strand region for all the MAPT transcripts, the mismatch DNA oligonucleotide 
containing three different bases was not designed. However, for the validation of the MAPT 
mRNAs enrichment in biological triplicates, the DNA scrambled oligonucleotide biotinylated 
at the 5’ end (5’-ATA TAT TAG ATT GCG TAT AAT TAG G-3’), was used as specific control as 
reported previously for the GRN miR-CATCH experiments.  
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Figure 5.2.3.1 Design of MAPT mRNA Capture Oligonucleotide. Secondary structure of 
MAPT mRNA was elaborated with M-Fold. The exposed single strand region located 
between bases 852 and 871 of the transcript was used as target.* 
 
 
 
 
 
 
 
 
 
 
 
 
*Optimization of the miR-CATCH technique for the isolation of GRN and MAPT mRNAs was 
done in collaboration with Dr. Sebastian Vencken, at the laboratory of Respiratory Research 
at the Royal College of Surgeons in Ireland, Beaumont Hospital 
 98 
 
 
 
 
Table 5.2.3.1 Sequence and characteristics of the designed MAPT mRNAs Capture 
Oligonucleotide. 
 
SINGLE STRAND REGION :                                                 5’- CCGCTCCAAAGACACCACCC-3’ 
REVERSE AND COMPLEMENT SEQUENCE:                      5’- GGGTGGTGTCTTTGGAGCGG-3’ 
OLIGO SEQUENCE:                                                   Biotin 5’-GGG TGG TGT CTT TGG AGC GG -3’ 
LENGTH:                                                                                                              20 
GC CONTENT:                                                                                                   65% 
MELT TEMP:                                                                                                     74,9°C  
HAIRPINS TM:                                                                                                     19°C 
HOMO DIMER ANALYSIS:                                                                          ≥-3,61 Kcal/mole 
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5.2.3.2 Validation of MAPTmRNA:miRNA Isolation  
 
In order to validate the efficacy of MAPT transcripts isolation, the first experiment 
was performed with KELLY cell lysate, using MAPT capture oligonucleotide. Following the 
miR-CATCH protocol, the eluted samples were analyzed with Real Time PCR. Specific 
primers quantified the total amount of MAPT transcripts, due to the amplification of a 
product of 150 bp. Whereas GAPDH expression was used to normalize the MAPT transcripts 
quantification. Levels of MAPT mRNAs measured in the capture sample were compared to 
the levels obtained from the same cell lysates that did not undergo the capture procedure. 
Using the 2-∆∆Ct method there was an enrichment of 28,84 fold compared the total RNA 
extracted from the same lysate of KELLY cells, as reported in the Figure 5.2.3.2. Since MAPT 
capture oligonucleotide showed complementarity for the visual system homeobox 1 (VSX1) 
transcript variant 2 mRNA, specific primers were designed for the detection of this transcript 
in the capture sample. Real Time PCR demonstrated no enrichments for VSX1 transcript in 
the MAPT capture samples, compared to the total RNA (data not shown). This result ruled 
out the possibility to obtain an off target effect due to the presence of contaminant 
transcripts in the capture samples. 
 
 
Figure 5.2.3.2 Validation of the MAPT mRNAs isolation. Representation of the qRT-PCR 
data, showing the fold enrichment level (2-∆∆Ct) obtained with MAPT capture oligonucleotide 
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compared to the total RNA that did not undergo the miR-CATCH protocol. Expression of 
MAPT mRNAs was normalized against GAPDH expression.Representative data of one 
biological experiment and three technical replicates (Mean SD). 
 
5.2.3.3 MAPT mRNAs enrichment in KELLY, SH-SY5Y and SK-N-BE cell lines 
 
After the validation of miR-CATCH protocol with KELLY cell line, the isolation of 
MAPT transcripts was performed in biological triplicates for three different neuroblastoma 
cell lines: KELLY, SH-SY5Y and SK-N-BE. As negative controls, scrambled oligonucleotides 
biotinylated at the 5’end, were used for the miR-CATCH experiments. By Real time PCR, 
MAPT mRNAs expression was quantified, and normalized using GAPDH mRNA expression. 
The MAPT mRNAs quantity presents in the capture samples of each biological experiment 
was compared to that present in the scrambled controls using 2-∆∆Ct method. In particular 23 
fold enrichment of MAPT mRNAs was obtained in KELLY cell line, whereas 2,5 fold 
enrichment was found in SH-SY5Y cell line and 4 fold enrichment for SK-N-BE cell line, 
compared to scrambled control (Figure 5.2.3.3). 
 
 
Figure 5.2.3.3 MAPT mRNAs enrichment in different neuroblastoma cell lines. 
Representation of the fold enrichment (2-∆∆Ct) values of MAPT mRNAs compared to specific 
scrambled controls. Data were normalized with GAPDH expression. Mean ± SEM of three 
biological replicates is shown in the figure (** p<0,001; *** p<0,0001 vs. scrambled control). 
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5.2.3.4 Selected miRNAs enrichment on MAPT Capture Samples in KELLY, SH-SY5Y and SK-
N-BE cell lines 
 
The miR-CATCH MAPT samples were further analyzed for the presence of the 
putative miRNAs of interest (miR-659-3p, miR-939-5p, miR-608 and miR-615-5p). TaqMan 
Real Time PCR primers were used for the specific quantification of these miRNAs in the 
MAPT capture samples compared to the values measured on the scrambled controls, using 
the 2-∆Ct method. Figure 5.2.3.4.1 and Figure 5.2.3.4.2 represent the mean level of the 
specific miRNAs enrichment derived from biological triplicates for each different cell line. 
miR-659-3p shows an enrichment of 474,5 times in MAPT capture samples derived from 
KELLY cell line (Figure 5.2.3.4.1 A), 162620 times and 120319 times in MAPT capture 
samples derived from SH-SY5Y and SK-N-BE cell lines, respectively (Figure 5.2.3.4.2 A and 
B). MiR-939-5p was found highly enriched in all the three biological experiments performed 
in KELLY cell line (Figure 5.2.3.4.1 B), in SH-SY5Y and SK-NBE cell lines (Figure 5.2.3.4.2 A 
and B).MiR-608 and miR-615-5p were also quantified by TaqMan qRT-PCR in MAPT capture 
samples, however these miRNAs were not found enriched in all the cell lines analyzed, 
probably due to the lack of their basal expression in these neuroblastoma cell lines in 
physiological conditions (data not shown). The expression of miR-323 was used as negative 
control in KELLY cell line. miR-323 was not enriched in the capture samples compared to 
scrambled controls (Figure 5.2.3.4.1 C). 
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Figure 5.2.3.4.1 Selected miRNAs enrichment in KELLY cell line. Representation of miR-659-
3p A) and miR-939-5p B) significant enrichment in MAPT capture samples compared to 
scrambled controls. Panels C) represent the negative control miR-323, that shows no 
enrichment in the capture samples. miRNAs expression was represented as fold enrichment 
value (2-∆Ct).A) and B) Mean±SEM of three different biological experiments (*P<0,05; *** 
P<0,0001). C) Representative figures of two biological samples with three technical 
replicates. 
 
A 
B 
C 
C
D 
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Figure 5.2.3.4.2 Selected miRNAs enrichment in SH-SY5Y and SK-NBE cell lines. A) 
Representation of miR-659-3p and miR-939-5p enrichment found in MAPT capture samples 
compared to scrambled controls in SH-SY5Y samples. B) Graphs representing the 
enrichment of miR-659-3p and miR-939-5p compared to the scrambled controls in SK-NBE 
cell line. miRNAs expression was represented as fold enrichment value (2-∆Ct).Mean ± SEM of 
three different biological experiments (*** P < 0,0001). 
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5.2.4 Luciferase Assays using reporter vectors of the MAPT 3’UTR in HeLa cells 
 
The regulation of our miRNAs of interest was further investigated using luciferase 
reporter plasmid vectors and over-expressing plasmids for the putative miRNAs. The miR-
CATCH experiments showed strong enrichments of miR-659-3p and miR-939-5p in MAPT 
capture samples derived from all the analyzed neuroblastoma cell lines. However, according 
to the bioinformatic predictions, miR-939-5p could also bind the coding region of MAPT 
mRNAs. Luciferase assays were used to analyze miR-659-3p and miR-608 regulation on 
MAPT 3’UTR. These miRNAs were predicted to bind Fragment V of MAPT 3’UTR (Figure 
5.2.1a). Luciferase experiments were performed at 24h and 48h from the transfection day. 
The over-expressing plasmids for miR-608 and miR-659-3p were co-trasfected with 
luciferase reporter vectors containing: the full length MAPT 3’UTR (pmiRGLO-FullMAPT), 
MAPT 3’UTR Fragment V (pmiRGLO-MAPTV) and MAPT 3’UTR Fragment II (pmiRGLO-
MAPTII) that does not have any potential binding sites for miR-608 and one putative binding 
for miR-659-3p. The levels of luciferase activity measured in the presence of the miRNAs 
were compared to the levels obtained from samples transfected with the empty over-
expressing plasmid. After 24h there was a significant luciferase down-regulation using miR-
608 and miR-659-3p co-transfected with the full length MAPT 3’UTR and with the Fragment 
V. In particular a strong luciferase reduction, up to 50% and 46%, was obtained with the co-
transfection of Fragment V with miR-608 and miR-659-3p respectively, as reported by the 
Figure5.2.4 (A). The co-transfection using the full length MAPT 3’UTR produced a significant 
down-regulation of 30% with miR-608 and 22% with miR-659-3p, compared to the empty 
control. Whereas the co-transfection of Fragment II with the over-expressing plasmids for 
miR-608 and miR-659-3p did not show any luciferase down-regulation. At 48h there was a 
significant increase in the reduction of luciferase due to the over-expression of miR-659-3p 
with the presence of the full length MAPT 3’UTR, that reached the 49%, as represented in 
the Figure5.2.4 (B), while miR-608 caused a luciferase reduction of 36%. At 48h even the co-
transfection of Fragment V with miR-659-3p led to a significant down-regulation of 35%, 
while miR-608 produced a small and not significant decrease of 17% compared to the empty 
controls. At 48h there was a decrease of luciferase in the co-transfection of Fragment II, 
with a major effect played by the over-expression of miR-659 (up to a 30% decrease). 
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Indeed Fragment II contains only one putative binding site for miR-659. All these 
experiments derived from three or four biological replicates (Mean ± SEM). The experiments 
with fragment II at 48h were performed only two times and the observed luciferase 
reduction was not significant. Further repetitions would give more information about the 
regulation of these miRNAs on Fragment II and the dynamic of their reduction. 
 
 
Figure 5.2.4 Luciferase assays of reporter plasmid of MAPT 3’UTR and over-expressing 
vectors for miR-608 and miR-659-3p. A) Relative luciferase activity was measured in HeLa 
cells transiently co-transfected with pmiRGLO vector containing the full length MAPT 3’UTR 
or fragment II of MAPT 3’UTR or fragment V of MAPT 3’UTR and the over-expressing 
plasmids after 24h. Significant luciferase down-regulation in presence of miR-608 and miR-
 106 
 
659-3p compared to the empty control. Luciferase reduction was not observed with the co-
transfection of the fragment II of MAPT 3’UTR B) Relative luciferase activity analyzed at 48h 
using the same constructs. Significant luciferase down-regulation with miR-659-3p and the 
full length MAPT 3’UTR or fragment V of MAPT 3’UTR. Firefly luciferase activity was 
normalized with Renilla luciferase activity. Percentages of luciferase reduction, reported 
above the graph bars, are related to negative control, empty control vector. Mean  SEM of 
three biological replicates is shown in the figure. The 48h of fragment II of MAPT 3’UTR are 
representative of two biological replicate experiments (Mean ± SEM).(*p<0,05, ** 
P<0,001).* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This work was performed in collaboration with Dr.Margherita Grasso at the laboratory of 
RNA Biology and Biotechnology in CIBIO. 
 107 
 
5.2.5 Effect of Selected miRNAs Overexpression on Tau protein level in KELLY cell line 
 
In order to analyze the effect of miRNAs over-expression on tau protein, western 
blot analyses were performed after the over-expression of the putative miRNAs of interest. 
KELLY cell line was transfected with miR-615-5p, miR-939-5p, miR-659-3p, miR-608 over-
expressing plasmids, the empty control that does not contain the precursor region of any 
miRNAs (pSP-Empty). HPRT protein was detected with specific antibody and used to 
normalize tau expression in all the analyzed conditions. The expression of tau quantified in 
all the transfected samples was compared to the quantity observed in empty control 
transfection, representing the endogenous level of tau present in KELLY cell line at 
physiological condition. As represented in Figure 5.2.5 there was a down-regulation of tau 
level with the transfection of miR-659-3p and miR-608 compared to the control. In 
particular, transfection with miR-659-3p led to 87,5% of tau expression and transfection 
with miR-608 caused 84,1% of tau expression. Whereas transfection of miR-615-5p and miR-
939-5p did not reduce the level of tau protein compared to the empty control, there was a 
slightly increase of the protein maybe due to an indirect effect. 
 
 
Figure 5.2.5 Effect of miRNAs over-expression on tau. The over-expression of miR-659-3p 
and miR-608 that show binding sites located on the MAPT 3’UTR, down-regulated the 
expression of tau protein, compared to control sample represented by the transfection with 
the empty vector. Percentages of tau protein expression reported below the image are 
calculated with empty plasmid comparison. Data normalized with HPRT protein expression. 
Representative western blot of an experiment repeated three times. 
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5.2.6 Effect of Selected miRNAs Overexpression on MAPT mRNAs level in KELLY cell line 
 
The level of MAPT transcripts was quantified by Real Time PCR after the over-
expression of all the miRNAs of interest. KELLY cell line was transiently transfected with the 
over-expressing plasmid for putative miRNAs panel and the backbone empty plasmid, used 
for miRNA cloning, as negative control. RNA was extracted after 48h from the transfection 
day and used for MAPT mRNAs quantification using qRT-PCR. MAPT mRNAs expression level 
was normalized with two housekeeping genes: the hypoxanthine phosphoribosyltransferase 
I (HPRTI) and the succinate dehydrogenase complex subunit A (SDHA). The fold changes 
were calculated with the 2-∆∆Ct method, comparing the levels of MAPT mRNAs present in the 
samples transfected with miRNAs over-expressing plasmids, with the levels of MAPT mRNAs 
quantified in samples transfected with the negative control, the empty vector, as 
represented in the Figure 5.2.6. All the cells transfected with the putative miRNAs had a 
small and not significant or absent down-regulation of MAPT mRNAs level compared to 
negative control. 
 
 
Figure 5.2.6 Effect of miRNAs over-expression on the MAPT mRNAs level. KELLY cells were 
transfected with the putative miRNAs and the empty control. RNA was extracted after 48h 
and analyzed using Real Time PCR for the detection of MAPT mRNAs and two specific 
normalizators, SDHA and HPRTI mRNAs. Representation of the fold changes calculated with 
the 2-∆∆Ct method. Data derived from biological duplicate experiments (Mean ± SEM). 
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5.2.7 Effect of miRNAs Over-expression on MAPT mRNAs in polysomal and sub-polysomal 
compartments in KELLY cell line 
 
Since the over-expression of miR-659-3p and miR-608 reduced tau protein level, but 
did not alter and degrade MAPT mRNAs level, KELLY cell line was used for the polysomal 
analysis to verify whether miR-659-3p and miR-608 regulate the level of tau by affecting the 
translation efficiency of MAPT mRNAs. KELLY cell line was transfected with miRNAs over-
expressing vectors and empty controls, and after 48h, the mRNA-ribosomal complexes were 
separated through sucrose gradient centrifugation in polysomal and sub-polysomal 
fractions, containing the effectively translated transcripts and the untranslated mRNAs 
respectively. For each transfection condition, RNA was extracted from the polysomal and 
sub-polysomal compartments and used for Real Time PCR analysis, in order to quantify the 
MAPT mRNAs levels present in the polysomal and sub-polysomal parts. The expression of 
HPRTI mRNA was used as normalizator to calculate the 2-∆Ct values and results are reported 
in Figure 5.2.7. The relative distributions of MAPT mRNAs in the two compartments were 
indicated as percentages calculated on the sum of the transcripts extracted from the two 
fractions, for each treatment and control. After the transfection of all the miRNAs of interest 
there was an increase in the amount of MAPT mRNAs quantified on the sub-polysomal parts, 
compared to the empty control. Indeed the experiments showed a trend toward a shift of 
MAPT mRNAs from the polysomal to the sub-polysomal compartment after the transfection 
with miRNAs compared to the empty control. The major increase of MAPT mRNAs were 
measured in the polysomal parts derived from samples transfected with miR-615-5p, miR-
659-3p and miR-608. These results indicate that miR-659-3p and miR-608 could regulate the 
level of tau by affecting the translation efficiency of MAPT mRNAs. Whereas the effect of 
miR-615-5p over-expression on the translation of MAPT mRNAs could be potentially blocked 
by other cellular processes, since the expression of tau protein is not altered by miR-615-5p. 
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Figure 5.2.7Effect of miRNAs over-expression on MAPT mRNAs in polysomal and sub-
polysomal compartments. KELLY cell line was transfected with the over-expressing plasmid 
for all the selected miRNAs and the empty control. After 48h the mRNA-ribosomal 
complexes were separated through sucrose gradient centrifugation and RNA was extracted 
from the sub-polysomal and polysomal compartments. Real Time PCR was performed for 
the quantification of MAPT mRNAs in the sub-polysomal and polysomal fractions. MAPT 
mRNAs expression was normalized against the housekeeping HPRTI transcript. Percentages 
of MAPT transcripts measured in the two fractions were calculated on the sum of 2−ΔCt 
values of MAPT mRNAs from polysomal and sub-polysomal compartments. Data derived 
from three biological experiments. (Mean ± SEM).* 
 
 
 
 
 
 
 
 
*This work was done in collaboration with Dr. Paola Zuccotti from laboratory of 
Translational Genomics in CIBIO. 
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CHAPTER SIX: DISCUSSION AND FUTURE PROSPECTIVES 
 
6.1 PROGRANULIN AND HYPOXIA 
 
 Previous study by our collaborators identified an up-regulation of GRN mRNA and 
progranulin protein levels in SK-N-BE cell line exposed to chronic hypoxia (Piscopo et al. 
2010). The same hypoxic samples with the relative controls were analyzed during our 
collaboration, for the expression of miR-659-3p, showing a significant negative correlation 
between miR-659-3p and GRN mRNA expression. This opposite trend suggested a possible 
link of regulation. Indeed miR-659-3p was found to bind GRN 3’UTR as shown by luciferase 
assays performed at 24h and 48h. Moreover we showed that miR-659-3p over-expression 
down-regulates endogenous progranulin expression, as reported by ELISA assays and 
western blot analysis in HeLa cell line. Rademarker and colleagues demonstrated that a 
common genetic variant localized on GRN 3’UTR (rs5848), located at the predicted binding 
site for miR-659-3p, represents a risk factor for FTLD-TDP (Rademakers et al. 2008). They 
reported that in presence of the T variant allele there was a stronger binding of miR-659-3p, 
resulting in a major reduction of progranulin. Our results are additionally showing that miR-
659-3p could bind GRN 3’UTR even in presence of the wild type C-allele, regulating 
progranulin expression. Interestingly the sequencing of GRN 3’UTR performed in HeLa and 
SK-N-BE identified the presence of the variant T-allele in SK-N-BE cell line. Indeed SK-N-BE 
cell line expresses an heterozygous TC genotype, with a major prevalence of T-allele, while 
HeLa cell line carries the homozygous CC genotype. Following the pull-down experiments, 
GRN capture samples showed an high enrichment of miR-659-3p in SK-N-BE cell line. In 
order to investigate whether the putative correlation in oxidative stress condition takes 
place also in vivo, RNA extracted from a rat model of global perinatal asphyxia was used for 
the quantification of miR-659-3p. This model mimics an acute event of intra-uterine 
asphyxia around the time of birth (Bjelke et al. 1991). Neural and behavioral alterations 
have been identified in this model (Boksa et al. 1995; Chen et al. 1997a; Chen et al. 1997b; 
Dell’Anna et al. 1997) and a delayed cell death in frontal cortex, striatum and cerebellum 
was reported after eight days from the asphyxia induction (Dell’Anna et al. 1997; Van de 
Berg et al. 2002). Perinatal asphyxia is a major cause of brain damage in the newborn and 
could be responsible for different delayed neurologic disorders (Calamandrei et al. 2004). 
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Therefore the correlation between progranulin and miR-659-3p was investigated in vivo in a 
different scenario of oxidative stress, in which free radical generation blocks the anti-
oxidant defenses, playing a role in the neurodegeneration of different adult and infant brain 
diseases (Calamandrei et al. 2004). After 20 minutes of global intrauterine asphyxia there 
was an up-regulation of GRN mRNA, that was statistically significant at pnd1 and pnd4, with 
a major increase at pnd4 compared to controls. Interestingly samples in which progranulin 
was significantly up-regulated (pnd1 and pnd4), showed a reduction of miR-659-3p 
expression, that was significant at pnd4. Thus post natal day 4 demonstrated a significant 
negative correlation between miR-659-3p and GRN mRNA expression in a rat model of 
perinatal asphyxia. 
Some studies reported that chronic hypoxia condition can repress the level of proteins 
involved in miRNA biogenesis, such as Drosha and Dicer (Caruso et al. 2010; Ho et al. 2012). 
This finding could suggest that the down-regulation trend of miR-659-3p observed in 
hypoxia samples might be caused by a global reduction of protein involved in miRNAs 
production. However, in our analysis on SK-N-BE cell line under chronic hypoxia condition 
we screened additional miRNAs that did not show the same down-regulation pattern. These 
miRNAs were putative candidates for the regulation of GRN mRNA, but they reported an 
unaltered or up-regulated expression after hypoxia (data not shown). They were excluded 
from the study since their expression was not correlated with progranulin trend in chronic 
hypoxia experiments performed in neuroblastoma cell line and in perinatal asphyxia 
samples. Thus we can exclude the possibility that miR-659-3p expression could be 
influenced and down-regulated by Dicer reduction in hypoxic condition, even though Dicer 
and Drosha were not analyzed and investigated in this study. 
Progranulin has a role as inflammation antagonist (Tang et al. 2011) and this function, in the 
attenuation of the inflammatory response, seems to be important for the increase of 
neurons survival following CNS injury, caused by oxidative stress (Martens et al. 2012). 
Effectively up-regulation of progranulin expression induced by oxidative insults, activates 
survival pathways that lead to the rescue of cortical neurons from cell death (Xu et al. 2011). 
For this reason progranulin is considered a neuroprotection factor and its functional brain 
reduction causes a decreased neuronal protection with reduction of survival signaling, as 
observed in FTD patients (Martens et al. 2012; Xu et al. 2011). In this work we reported that 
miR-659-3p and progranulin expression are reverse regulated in hypoxic condition. 
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Interestingly it was demonstrated that hypoxia induces the production of several miRNAs 
implicated in the modulation of important cellular responses involving apoptosis and 
inflammation (Taganov et al. 2006; Zhang et al. 2012). It would be interesting to investigate 
if miR-659-3p could represent a negative regulator of this neuroprotection pathway and 
which are the additional miRNAs that instead lead to the up-regulation of progranulin and 
induction of survival responses. Several hypoxamirs promote HIF expression and activity, or 
represent transcriptional targets of HIF (Loscalzo et al. 2010; Semenza et al. 2012; Greer et 
al. 2012; Kelly et al. 2011). It would be of great use to analyze if miR-659-3p down-
regulation is linked with HIF hypoxic adaptation activity or with HIF-independent pathways 
that involved additional proteins, such as p53, mTOR or the endoplasmic reticulum stress 
related proteins. These findings will show the regulation pathways that should be activated 
in case of oxidative stress, in order to have progranulin neuroprotection function and 
preserve the neuronal activity. The regulative factors for the up-regulation of progranulin 
would be particularly important for the development of therapeutic strategies for the 
potential cure of neurodegenerations such as FTD. Further studies on this direction would 
also reveal important information for the potential cure of perinatal asphyxia. Indeed exist a 
narrow period of time between the insult and the development of CNS injury, during which 
therapeutic strategies could be effective (Lorek et al. 1994; Northington et al. 2001). Maybe 
during this period the neuroprotection role of progranulin could reduce brain damage or the 
risk of cognitive and attentional disorders during the development. 
 
 114 
 
 
6.2 IDENTIFICATION OF miRNAs INVOLVED IN THE POST-TRANSCRIPTIONAL REGULATION 
OF GRN EXPRESSION 
 
 In the last period accumulated evidences showed that complexity of higher 
eukaryotes is a highly regulated process which correlates with an increase in the size of non-
coding regions (Levine et al. 2003; Barrett et al. 2012). The untranslated regions and introns 
are the main regions involved in this highly regulated process that control gene expression. 
3’UTR regions regulate gene expression at multiple levels, such as the 3’end formation and 
polyadenylation or they influence mRNA stability, subcellular localization and translation 
efficiency (Conne et al. 2000, Mignone et al. 2002, Chabanon et al. 2004). The 3’UTR 
functions as binding region for numerous regulatory proteins and miRNAs to complete its 
regulative role (Barrett et al. 2012). 
In the present study, post-trascriptional regulation of different miRNAs acting on GRN 3’UTR 
was investigated using several techniques. A recent method, named miR-CATCH, developed 
by the laboratory of Catherine Greene and her co-workers, was applied for the analysis of 
miRNAs that can physiologically bind to GRN mRNA in different cell lines. This approach was 
used to complement the initial bioinformatic prediction performed to identify the putative 
miRNAs binding on GRN. The predictive outcome was the result of three computational 
programs, in order to increase the specificity of the prediction. However, it is estimated that 
bioinformatics softwares have a false-positive rate of 24-70% (Sethupathy et al. 2006) and 
different algorithms generate often heterogeneous lists that are barely overlapped. On the 
contrary miR-CATCH method has the advantage to identify miRNAs that could 
physiologically bind to the entire full length mRNA, including the 5’UTR and the coding 
regions. Indeed the isolation of an endogenous mRNA allows the identification of all the 
innate miRNAs and Argonaute proteins bind to its native conformation, reflecting a natural 
biological process (Hassan et al. 2013). The method was applied to different cell lines in 
order to compare the regulation played by our putative miRNAs of interest on GRN mRNA in 
different cell environment. Following the miR-CATCH experiments for the capture of GRN 
mRNA, only miR-659-3p showed a substantial and significant level of enrichment for all the 
cell lines analyzed, even though the fold enrichments were not similar. The difference could 
be caused by the heterogeneous level of GRN mRNA enrichment obtained with miR-CATCH 
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strategy, applied in the different cell lysate. This difference could probably reflect a varied 
endogenous quantity of GRN mRNA naturally present in the analyzed neuroblastoma cell 
lines. A disadvantage of miR-CATCH method was the possibility to isolate only miRNAs that 
are express at the endogenous level, for this reason miR-608 and miR-615-5p, that are 
absent or express in a minimal and hardly detectable quantity, were not found in the elute 
samples. Further improvements in the miR-CATCH protocol, should possibly focus on 
analyzing transfected cells. This will allow the isolation of targets or miRNAs expressed in 
lower levels at basal condition. The indicated modification could be of great help for a major 
use of the technique to different purposes. 
The activity of a miRNA in a particular cell type could be influenced by the target 
competition process (Hassan et al. 2013). This could in part explain why miR-939-5p was 
absent from the pull-down samples, although this miRNA was detectable in the analyzed 
cell lines. Although the bioinformatic screening appeared to be complex, the use of different 
softwares is fundamental for the subsequent analysis of miRNA recognition elements on 
GRN 3’UTR. MiR-939-5p was strongly predicted to target GRN mRNA, showing three 
putative binding sites located on GRN 3’UTR with good level of free binding energy (∆G). For 
this reason miR-939-5p was used to analyze the effect of its over-expression on GRN mRNA 
and progranulin, even though miR-939-5p was not found enriched in the capture samples. 
Similarly, the strong bindings predicted in silico for miR-608, miR-615-5p and miR-659-3p led 
to investigate their role on GRN mRNA and progranulin protein expression. Luciferase assays 
performed with GRN 3’UTR reporter plasmids, showed down-regulation of luciferase 
activity, upon the over-expression of the miRNAs of interest at 24h and 48h. The reduction 
of luciferase was significant upon the over-expression of miR-659-3p. Even though different 
level of luciferase down-regulation was obtained according to the different part of GRN 
3’UTR used for the assay, possibly indicating that the sequence and the length of the portion 
of GRN 3’UTR used, could influence the recognition process. To this matter it is reported 
that RNA regulatory elements function in a context of specific secondary structure (Chen et 
al. 2006). Therefore the differentiated pattern of luciferase reduction obtained could be 
attributed to the difference in secondary structures elicited by the different 3’UTR portions, 
containing the same miRNAs binding sites. Indeed the binding of a specific miRNA could be 
promoted and enhanced by a particular secondary structure. In case of the entire GRN 
3’UTR, miR-659-3p showed the best luciferase reduction at 24h and 48h. However at 48h 
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there was a considerable decrease of luciferase, upon the over-expression of miR-939-5p 
and miR-615-5p. The effect of miRNAs over-expression on the endogenous progranulin level 
was analyzed in KELLY cell line using western blot. All the over-expressed miRNAs caused a 
decrease of progranulin protein compared to control. In this experiment the major effect 
was observed with miR-939-5p and miR-659-3p. These findings demonstrated the role of 
the selected miRNAs on the regulation of GRN mRNA, showing a reduction in the translation 
of progranulin. Since in HeLa cell line miR-939-5p appeared to be expressed in a 
considerable level at physiological conditions, a miR-inhibitor was used to block the 
endogenous level of miR-939-5p. The block of miR-939-5p induced an up-regulation of 
progranulin expression, likely indicating a possible role of miR-939-5p in the control of 
progranulin expression. 
During the regulation of the target mRNA, miRNAs can have two main functions: 
degradation of the target mRNA, in case of a perfect complementarity binding and 
translational repression in the presence of an imperfect binding interaction (Krol et al. 
2010). In order to investigate the effect of putative miRNAs of interest on GRN, Real Time 
PCR reactions were performed to quantify the GRN mRNA level after the over-expression of 
the miRNAs of interest. However the over-expression of only miR-615-5p induced a 
significant down-regulation of GRN mRNA compared to control. These findings led us to the 
use of polysomes analysis, in order to verify whether the putative miRNAs of interest could 
regulate the level of progranulin by affecting the translation efficiency of GRN mRNA. 
Following the transfection of the selected miRNAs, there was an increase in the amount of 
GRN mRNA measured on the sub-polysomal compartments, indicating a translation 
repression of GRN mRNA induced by miRNAs. Reduction of translation efficiency of GRN 
mRNA was more prominent after the over-expression of miR-939-5p, miR-615-5p and miR-
659-3p. Therefore these data suggested that the selected miRNAs can regulate progranulin 
expression through a mechanism of translation repression. In these cell conditions the 
stronger effect of down-regulation was observed with miR-659-3p, miR-939-5p and miR-
615-5p. 
 117 
 
 
6.3 IDENTIFICATION OF miRNAs INVOLVED IN THE POST-TRANSCRIPTIONAL REGULATION 
OF MAPT EXPRESSION 
 
 Mir-CATCH method was applied for the isolation of all the different five isoforms of 
MAPT, obtaining good levels of fold enrichments in KELLY and SK-N-BE cell lines and a weak 
enrichment in SH-SY5Y cell line. However, the profiling of selected miRNAs showed high 
miR-659-3p and miR-939-5p enrichments in all the eluted samples compared to controls, 
indicating a possible mechanism of regulation. The bioinformatics prediction derived from 
three different softwares identified one particular binding site for miR-608 located on 
Fragment V of MAPT 3’UTR region. Luciferase assays were subsequently performed with the 
over-expression of miR-659-3p and miR-608. The logic behind choosing miR-608 and miR-
659-3p was due to the fact that miR-939-5p was also predicted to bind the coding region of 
MAPT mRNA, while miR-CATCH strategy results and bioinformatic predictions showed miR-
608 and miR-659-3p as good putative candidates for the regulation of MAPT 3’UTR. The 
over-expression of these miRNAs showed a significant luciferase down-regulation using the 
full length MAPT 3’UTR and the specific fragment V containing the putative binding sites. 
These results demonstrated an effective binding of miR-659-3p and miR-608 on MAPT 
3’UTR region. Initial bioinformatics prediction analysis derived from two softwares had 
previously identified putative binding sites for miR-615-5p and miR-939-5p on MAPT 
mRNAs. For this reason, in the following experiments, the usual panel of selected miRNAs 
(miR-659-3p, miR-608, miR-939-5p and miR-615-5p) was applied to investigate their role on 
the regulation of MAPT mRNAs and tau expression. Western blot experiment reported a 
down-regulation of tau protein upon the over-expression of miR-659-3p and miR-608, 
whereas miR-615-5p and miR-939-5p caused a tiny increase of tau expression. The function 
of miRNAs regulation on MAPT mRNA isoforms was analyzed with Real Time PCR in order to 
quantify the levels of MAPT mRNAs after over-expression of selected miRNAs. MAPT mRNAs 
levels were not down-regulated after miRNAs over-expression, indicating that miR-659-3p 
and miR-608 that affect the protein production, do not induce MAPT mRNAs degradation. 
Polysomal analysis was applied in order to understand the mechanism played by miR-659-
3p and miR-608 on the down-regulation of tau. The quantity of MAPT mRNAs found on the 
sub-polysomal compartments increased upon the over-expression of all the selected 
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miRNAs. The major shift of MAPT mRNAs from the polysomal to the sub-polysomal 
compartment was observed with the over-expression of miR-659, miR-608 and miR-615. 
However, the small increase of tau expression obtained with miR-615 and miR-939 does not 
correlate with the translational repression observed upon their over-expression. Since the 
over-expression induced by these miRNAs do not down-regulate tau protein expression, the 
translational repression of MAPT mRNAs could be caused by an indirect effect. Additional 
mechanisms could have a role in the regulation of MAPT mRNAs and tau expression played 
by miR-615 and miR-939. Further experiments and additional validations for these miRNAs 
would probably clarify their role on MAPT mRNAs regulation. However, the data indicated 
that miR-659 and miR-608 are potential regulators of tau expression, targeting MAPT 3’UTR 
and reducing the translational efficiency of MAPT mRNAs. 
 
6.4 FUTURE PERSPECTIVES 
 
 This study provides direct evidence and validation of the role of some miRNAs in the 
modulation of GRN and MAPT mRNAs and protein expression. However, additional analysis 
of miRNAs enriched in the capture samples derived from miR-CATCH experiments would 
reveal other potential regulators of GRN and MAPT mRNAs. With the use of miRCURY LNA 
Real Time PCR plates for miRNAs expression profiling in capture samples compared to 
scrambled controls, we would like to identify other miRNAs involved in GRN and MAPT 
regulation. 
Moreover, in order to correlate the regulation played by the selected miRNAs on GRN and 
MAPT, we plan to investigate the expression of these putative miRNAs on samples derived 
from post-mortem brains of FTD patients. Since only 20% of all FTLD-TDP cases have loss of 
function mutations in GRN (Baker et al. 2006; Cruts et al. 2006) and remaining patients 
present the same pathological manifestations often with a family history, other genetic 
factors could be involved in the regulation of progranulin level (Nicholson et al. 2011). One 
genetic factor was identified by Rademakers and co-workers in a study in which they 
demonstrated that a common genetic variant localized on GRN 3’UTR (rs5848) is a risk 
factor for FTLD-TDP (Rademakers et al. 2008). SNP rs5848 is located at the predicted miR-
659-3p binding site and, in presence of the T variant allele, there was a stronger miR-659-3p 
binding, resulting in a major reduction of progranulin. In agreement with these findings, 
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reduced progranulin levels were found in brain lysates of FTLD patients carrying two copies 
of rs5848 risk T-allele, compared to the levels observed in patients carrying two copies of 
the rs5848 C-allele (Rademakers et al. 2008). An additional study showed that rs5848 
polymorphism can significantly influence serum progranulin level, demonstrating lower 
level of serum progranulin in rs5848 TT carriers compared to the level measured in serum of 
CT and CC carriers (Hsiung et al. 2011). However another article reported no association of 
rs5848 with FTLD in three European cohorts (Rollinson et al. 2011). In the present study we 
suggested that additional common genetic variabilities observed on miRNAs binding sites 
found on GRN and MAPT 3’UTRs could alter the normal regulation of GRN and MAPT 
mRNAs, representing potential risk factors for FTD generation. In the SNPs analysis 
performed for GRN, six of the sixteen SNPs found on GRN 3’UTR region were located on 
putative miRNAs binding sites. According to the method developed by Saba and colleagues 
in 2014 (Saba et al. 2014), two SNPs identified on GRN 3’UTR caused an enhanced miRNA 
binding: one is located on the first miR-608 binding site, while the other one is the SNP 
rs5848 found by Rademarkers and coworkers. Except for one SNP that showed no effect, all 
the other 3 SNPs induced a decrease in miRNAs binding. Interestingly the miR-608 binding 
region located on Fragment V of MAPT 3’UTR could be affected by one SNP and two 
different events of small insertion or deletion (indel). Seven of the different variations 
identified on the Fragment V of MAPT 3’UTR showed an alteration of the free binding 
energy for the predicted miRNAs interactions. In particular four variations caused an 
increased miRNAs binding: one is located in miR-659-3p binding site, two are present in the 
second miR-608 binding site and the last is localized on the third miR-608 binding site. 
Whereas all the other variations caused a reduction in the predicted miRNAs binding to 
Fragment V of MAPT 3’UTR. It would be fascinating to analyze if these SNPs could be 
associated with FTD and represent possible risk factors for the development of 
neurodegeneration. Neurological diseases are indeed strongly influenced by natural genetic 
variability that exists in the population (Hulse and Cai, 2013; Lukiw, 2013). In this scenario, it 
should be considered not only the target region but also the miRNA gene variability. 
Evidence has shown that polymorphisms found on miRNA genes could interfere with their 
function, resulting in phenotypic variation and disease susceptibility (Zorc et al. 2012). A 
single variation may be enough to alter miRNA-mediate regulation and might induce altered 
fine tuning gene expression with unpredicted consequences.  
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Genetic association studies are necessary in both cases, in which the genetic variability 
affects miRNAs target regions or miRNAs encoding regions. These type of analysis would 
reveal if the variability can contribute to a disease state, playing a role as a risk factor in 
sporadic patients or modifying the pathological process in patients having causal mutations. 
Therefore further analysis related to the investigation of genetic factors involved in 
progranulin and tau regulation would be important for a better understanding of the 
pathology of FTD and other neurodegenerative disorders. 
In the present research project, the effect of two miRNAs suggests a possible common 
mechanism of regulation for progranulin and tau. Indeed the expression of miR-659-3p and 
miR-608 induces a down-regulation of progranulin and tau production, blocking the 
translational expression of GRN and MAPT mRNAs. These genes cause frontotemporal 
dementia through different mutations and trigger events. In addition the causal mutations 
of GRN and MAPT lead to opposite effects, showing reduced progranulin levels but 
increased tau expression in FTD patients. Possible common pathways of regulation would be 
important for the development of similar therapeutical strategies. Although the 
therapeutical approaches should be conducted in two different directions.  
The research of common regulations or pathways for progranulin and tau could potentially 
lead to the identification of additional key factors that are deregulated in all types of FTD 
pathology. These factors would be extremely important for the development of future 
therapeutical strategies and biomarkers for the early diagnosis of the disease state. 
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3. miRNA biogenesis and function 
4. Circulating miRNAs 
4.1 Alzheimer’s disease and circulating miRNAs 
4.2 Parkinson’s disease and circulating miRNAs 
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Production of: 
- Table 1 Alzheimer’s Disease and circulating miRNAs 
- Table 2 Parkinson’s Disease and circulating miRNAs 
- Table 3 Amyotrophic Lateral Sclerosis and circulating miRNAs 
 
 My contribution to the work “Reduced miR-659-3p levels correlate with progranulin 
increase in hypoxic conditions: implications for frontotemporal dementia.” 
(manuscript attached): 
 
- Bioinformatic prediction of miR-659 
- Cloning of GRN 3’UTR reporter plasmid (pmiRGLO-GRN3’UTR) 
- Cloning of miR-659 over-expressing plasmid (pSiUx-miR-659) 
- Transfection of miR-659-3p, miR-181a-5p and Empty vector in HeLa cell line 
- Real Time PCR for the validation of miR-659-3p and miR-181a-5p over-expression 
at 24h and 48h 
- Luciferase experiments at 24h and 48h 
- Protein analysis of endogenous progranulin after the over-expression of miR-
659-3p and miR-181a-5p through ELISA assays and western blot 
- Design of the GRN capture oligonucleotide and pull down assay of GRN mRNA in 
SK-N-BE cell line 
- Real Time PCR for GRN mRNA enrichment in capture samples compared to 
scrambled controls 
- Real Time PCR for miR-659-3p enrichment in capture samples compared to 
scrambled controls 
- Real Time PCR for the detection of miR-659-3p in all the hypoxic SK-N-BE samples 
compared to normoxic controls 
- Real Time PCR for the detection of miR-659-3p in all the asphyctic newborn rats 
samples compared to relative controls 
Results produced from the manuscript: 
- Figure 2 
- Figure 3 
- Figure 4 
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- Figure 5 
- Real Time data performed for all the hypoxic SK-N-BE samples and relative 
controls used for the statistical analysis reported in the Figure 7 
- Real Time data performed for all the samples reported in the Figure 8 B 
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A network of RNA and protein
interactions in Fronto Temporal
Dementia
Francesca Fontana 1†, Kavitha Siva 1† and Michela A. Denti 1, 2*
1 Laboratory of RNA Biology and Biotechnology, Centre for Integrative Biology, University of Trento, Trento, Italy, 2CNR,
Institute of Neuroscience, Padua, Italy
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by
degeneration of the fronto temporal lobes and abnormal protein inclusions. It exhibits
a broad clinicopathological spectrum and has been linked to mutations in seven different
genes. We will provide a picture, which connects the products of these genes, albeit
diverse in nature and function, in a network. Despite the paucity of information available
for some of these genes, we believe that RNA processing and post-transcriptional
regulation of gene expression might constitute a common theme in the network. Recent
studies have unraveled the role of mutations affecting the functions of RNA binding
proteins and regulation of microRNAs. This review will combine all the recent findings on
genes involved in the pathogenesis of FTD, highlighting the importance of a common
network of interactions in order to study and decipher the heterogeneous clinical
manifestations associated with FTD. This approach could be helpful for the research
of potential therapeutic strategies.
Keywords: FTD, TDP-43, FUS, progranulin, tau, CHMP2B. C9ORF72
Frontotemporal Dementia
Despite 90% of the human genome being transcribed to RNA, only 1.2% of genomic sequence is
protein-coding, indicating that a huge proportion of non-coding RNAs (ncRNAs) are likely to par-
ticipate in a number of physiological processes in cell types, including neurons (Lander et al., 2001;
Birney et al., 2007; Wilhelm et al., 2008; Clark et al., 2011). The transcribed precursors of messen-
ger RNAs (pre-mRNA) undergo splicing, such that the non-coding introns are removed and exons
are combined variably to produce an RNA that would code for protein (Pandit et al., 2008). The
pre-mRNAs undergoes alternative splicing producing mature messenger RNAs (mRNAs) which
are then expressed in specific tissues and cell types in different stages of development. These
mRNAs then associate with the ribosomal machinery to be translated into proteins in the cyto-
plasm. Non-coding RNAs (among which microRNAs and long non-coding RNAs), might regulate
the translation of specific mRNAs, thereby representing a post-transcriptional mechanism exerting
a fine-tuned control in the production of specific proteins.
microRNAs (miRNAs) are a group of small non-coding RNAs of 21–22 nt with important reg-
ulatory roles on the post-transcriptional expression of target mRNAs (Bartel, 2009; Ghildiyal and
Zamore, 2009). MiRNAs are generating from longer transcripts of different lengths called primary
transcripts (pri-miRNAs), usually transcribed by RNA polymerase II, from intragenic or intergenic
DNA regions (Lee et al., 2004; Garzon et al., 2010). The pri-miRNAs are processed in the nucleus by
the micro-processor complex, formed by an RNase III enzyme, Drosha, and its cofactor DiGeorge
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syndrome critical region in gene eight termed (DGCR8) (Lee
et al., 2003). The process lead to the production of small hairpin
structure of 70–100 nt called precursor miRNAs (pre-miRNAs).
Pre-miRNAs are exported to the cytoplasm through Exportin 5
(Kim, 2004), where they are further processed by an RNase III
nuclease, Dicer to produce RNA duplex (Bernstein et al., 2001;
Grishok et al., 2001; Hutvagner et al., 2001). One strand is loaded
on the RNA-Induced Silencing Complex (RISC) and associated
with Argonaute-2 (Ago2) to interact with the target mRNA. The
miRNA-RISC complex induces mRNA downregulation through
two different ways: mRNA cleavage in case of perfect com-
plementarity between miRNA and target mRNA or translation
inhibition if there is an imperfect binding (Wahid et al., 2010)
(Figure 1). In case of perfect complementarity, Ago2 is the pro-
tein involved in the cleavage of the target mRNA in humans
(Liu et al., 2004). However, in animals, translational repression
is the most frequent way of action for miRNAs (Huntzinger and
Izaurralde, 2011; Pasquinelli, 2012), although the exact process is
still unknown since is not clear if the repression occur at the ini-
tiation step or during the translation process (Wahid et al., 2010).
Even the mechanisms for target regulation played by miRNAs
are still unclear, the target mRNA could be repressed by the pro-
motion of deadenylation, sequestration of miRNAs and target by
stress granules and P-Bodies (Valencia-Sanchez et al., 2006), dis-
ruption of translation initiation or protein degradation caused by
RISC after translation (Tang et al., 2008).
FIGURE 1 | Representation of miRNA biogenesis.
The enormous content of non-coding RNA (ncRNA) in the
cell intrigues its role and function in the cells. LncRNAs are
defined as transcripts longer than 200 nucleotides and lacking
an appreciable open reading frame (usually less than 100 amino
acids). They may be transcribed by RNA polymerase II (RNA Pol
II) or RNAPol III, andmay undergo splicing or comprise of a sin-
gle exon. In contrast to small ncRNAs, lncRNAs tend to be poorly
conserved evolutionarily and regulate gene expression by diverse
mechanisms that are not entirely understood. As a functionally
diverse macromolecule, the biological roles of lncRNAs cannot
be determined solely from their nucleotide sequence, secondary
structures, or genomic locations (Ng et al., 2013).
Recent work has begun to elucidate the roles of some lncR-
NAs, such as architectural function in nuclear paraspeckles
(Sunwoo et al., 2009; Souquere et al., 2010), transcriptional
co-regulators (Feng et al., 2006; Bond et al., 2009), and as
endogenous competing RNAs (ceRNAs) (Cesana et al., 2011;
Tay et al., 2011). LncRNA expression is abundant in cells
of the CNS (Mehler and Mattick, 2007; Mercer et al., 2008)
and recent studies have suggested that lncRNAs play crucial
roles in spatial-temporal control of gene expression in brain
development (Mercer et al., 2008). They have also known to
be involved in brain development, neural differentiation and
maintenance, synaptic plasticity, cognitive function and mem-
ory, and in aging and neurodegenerative disorders (Wu et al.,
2013b).
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Though different mechanisms may play a role in causing
neurodegenerative disorders, recent studies show increasing evi-
dence of abnormalties in RNA processes, highlighting the pos-
sible putative role of RNA in neurodegeneration. An mRNA
gain-of-toxic-function has been proposed for some neurode-
generative diseases (Osborne and Thornton, 2006; O’Rourke
and Swanson, 2009; Todd and Paulson, 2010) whereas other
neurodegenerative disorders are driven through altered or lost
non-coding RNA, RNA splicing and RNA binding activities
(Gallo et al., 2005; Cooper et al., 2009; Lagier-Tourenne et al.,
2010).
Fronto temporal lobar degeneration (FTLD) is the most com-
mon cause of dementia after Alzheimer’s disease. The clinico-
pathological spectrum of FTLD includes frontal and temporal
variants of frontotemporal dementia (FTD), primary progressive
aphasia, semantic dementia, Cortico-basal degeneration (CBD),
progressive supranuclear palsy (PSP), progressive subcortical
gliosis (PSG) and FTD with motor neuron disease (FTD–MND)
(Bugiani, 2007). Moreover, despite Amyotrophic Lateral Sclero-
sis (ALS) and FTD being two different neurodegenerative dis-
orders, they often share genetic, neuropathological and clinical
characteristics; therefore they are considered part of the same
spectrum of diseases (Ling et al., 2013). Frontotemporal demen-
tia symptoms can also be present along with disabling muscle
weakness and osteolytic bone lesions, in IBMPFD1 (Inclusion
body myopathy with early-onset Paget disease with or without
Frontotemporal dementia 1).
It is estimated that one in seven people in the US might
develop a neurodegenerative disorder in their lifetime, with
dementia being one of the leading causes of death in US (Thies
and Bleiler, 2011). Though this broad spectrum of disorders has
been studied based on protein aggregation and research has been
focusing on protein functions and alterations, emerging avenues
in research unravels the role of RNA and RNA processing in
contributing to neurodegeneration (Belzil et al., 2013).
To date, FTD has been linked to mutations in seven different
genes (TARDBP, FUS,MAPT, GRN, VCP, CHMP2B, C9ORF72).
Findings that showed the presence of ubiquitinated protein
TDP-43 in sporadic cases of ALS with FTD further linked these
two diseases (Arai et al., 2006; Neumann et al., 2006). Following
these findings, mutations in the gene coding for the RNA bind-
ing protein TDP-43 were discovered in ALS cases (Kabashi et al.,
2008; Sreedharan et al., 2008; Van Deerlin et al., 2008) and FTD
cases (Borroni et al., 2009; Kovacs et al., 2009).
With the broadening knowledge on the impact of impaired
RNA binding proteins in mediating the disease process, muta-
tions in the fused in sarcoma/translocated in liposarcoma
(FUS/TLS) gene were found to account for an additional 5% of
familial ALS and few rare cases of FTD (Kwiatkowski et al., 2009;
Vance et al., 2009).
TDP-43 and FUS share similar structural and functional prop-
erties with a likely role in multiple steps of RNA processing
and they are both linked to RNA metabolism. The patholog-
ical accumulation of these proteins is observed in over 90%
ALS and 50% FTD patients. These studies also highlight that
errors in RNA processing might be enough to initiate the disease
process.
MAPT mutations were observed in several FTD families with
abnormally phosphorylated tau proteins being isolated from
neuroectoderm cells of patients. Mutations present in the C
terminal repeat domains lead to the inhability of abnormal
tau protein to bind microtubules, thus leading to its instability
and accumulation and causing neuronal degeneration (Bugiani,
2007). FTD with tau inclusions was characterized as a tauopathy
and dubbed FTLD-tau.
However, a different class of patients were found to have had
accumulated ubiquitin and ubiquitin-associated proteins (FTLD-
U). Co-localization of abnormal proteins with ubiquitin in the
nucleus and perikaryon of neuronal cells, indicated the involve-
ment of proteasome dysfunction in the pathology. Analysis of
significant genes on chromosome 17, close to the MAPT locus,
led to the discovery ofmutations inGRN (Baker et al., 2006; Cruts
et al., 2006). GRN is known to be involved in the cell cycle control
and motility.
Studies on an ALS/FTD-affected Scandinavian family (Morita
et al., 2006) and on IBMPFD1 families suggested the possible role
of mutations in chromosome 9 in FTD. The disorder was associ-
ated to mutations in VCP, encoding the valosin-containing pro-
tein essential for ubiquitin-mediated protein degradation (Watts
et al., 2004; Johnson et al., 2010).
Other FTLD mutations are located on chromosome 3 (FTD-
3), in the CHMP2B gene, which encodes for a protein involved
in degradation of surface receptor proteins and formation of
endocytic multivesicular bodies (Skibinski et al., 2005).
Another link between ALS and FTD are the large intronic hex-
anucleotide repeat expansions in the C9ORF72 gene located on
chromosome 9 found in ALS, FTD, or ALS/FTD cases (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al.,
2012).
This review will focus on the single genes known to have
implications in FTD and their altered functions in the diseased
state. The ultimate aim is to explorepossible functional connec-
tions between these seven diverse genes and describe a network in
which a possible common thread might be represented through
RNA mediated processes.
TARDBP (TDP 43)
Human TDP-43 was discovered in 1995 in a screen for tran-
scriptional repressors of the trans-active response (TAR) DNA
binding element of the HIV-1 virus, and thus the gene is named
TARDNA Binding Protein (TARDBP) (Ou et al., 1995). TARDBP
is composed of six exons and maps on chromosome 1p36.22.
The protein TARDBP produces is being labeled as TDP-43
due to its molecular weight of 43KDa (Neumann et al., 2006).
TARDBP is ubiquitously expressed in various human tissues
(Table 1) including brain and spinal cord (Wang et al., 2008a). To
date, 34 different TDP-43 mutations have been discovered in 131
different FTD and ALS families (Cruts et al., 2012). Pathogenic
mutations observed in TDP-43 are highlighted in Table 2.
Structure
TDP-43 is a 414 amino acids protein (Figure 2A) containing two
RNA recognition motifs (RRMs), a glycine-rich low sequence
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
TABLE 1 | Protein localisation of different genes associated to FTD.
Gene Genomic
location
Protein Tissue localization in the
brain
Cell type Subcellular localization
TARDBP Chromosome 1
p36.22
TDP-43 Cerebral cortex, hippocampus,
lateral ventricle, cerebellum
and spinal cord
Endothelial, neuronal, glial cells,
neuropil and cell in granular and
molecular layer, Purkinje cells
Nucleus and cytoplasm
FUS Chromosome 16
p11.2
FUS Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Endothelial, neuronal, glial cells,
neuropil and cell in granular and
molecular layer, Purkinje cells
Nucleus and cytoplasm
MAPT Chromosome 17
q21.3
Tau Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Neuronal, glial cells, neuropil and cell
in granular and molecular layer,
Purkinje cells
Cytoskeleton, cytoplasm, nucleus
and plasma membrane
GRN Chromosome 17
q21.31
Progranulin Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Neuronal, glial, endothelial cells and
cell in granular layer
Vesicles, endoplasmic reticulum,
golgi, extracellular space
VCP Chromosome 9
p13.3
VCP Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Endothelial, neuronal, neuropil, glial
cells and cell in granular and
molecular layer, Purkinje cells
Endoplasmic reticulum, nucleus,
cytoplasm
CHMP2B Chromosome 3
p11.2
CHMP2B Lateral ventricle Neuronal cells Cytosol, endosome, nucleus,
mitochondria
C9ORF72 Chromosome 9
p21.2
C9ORF72 Cerebral cortex, hippocampus
and lateral ventricle
Endothelial, neuropil, glial cells Cytoplasm, nucleus, cytoskeleton
The information provided are derived through integration of two different databases (http://www.genecards.org/ and http://www.proteinatlas.org/) and literature reported in the text.
TABLE 2 | List of mutations in TARDBP and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.6142C>T p.N12 Pathogenic Luquin et al., 2009
FTD g.9253C>T A90V Pathogenic Sreedharan et al., 2008
FTD/PSP g.14575A>G K263E Pathogenic Kovacs et al., 2009
ALS/FTD g.14588A>G N267S Pathogenic Corrado et al., 2009
FTD g.14671G>A G295S Pathogenic Benajiba et al., 2009
FTD g.14932G>A A382T Pathogenic Chiò et al., 2010
FTD, Frontotemporal Dementia; PSP, Progressive supranuclear palsy.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
complexity prion-like domain (Wang et al., 2013). A nuclear
localization signal motif (NLS) and a nuclear export signal motif
(NES) allow TDP-43 to shuttle between the nucleus and the
cytosol (Buratti and Baralle, 2001).
Localization and Function
Though TDP-43 expression is seen in the nucleus with low
cytosolic localization (Ayala et al., 2005), there is a significant
cytosolic TDP-43 expression especially in large motor neurons
where TDP-43 has an additional role in mRNA transport as a
neuronal activity responsive factor in dendrites thus promoting
dendritic branching (Wang et al., 2008a; Barmada et al., 2010;
Kabashi et al., 2010).
TDP-43 was found to be accumulated in cytoplasmic stress
granules due to oxidative stress (Colombrita et al., 2009).
Stress granules are aggregations, formed after cell insults such
as oxidative stress or heat shock that temporarily store non-
translating mRNAs, small ribosome subunits, RNA-binding pro-
teins and translation initiation factors (Buchan and Parker, 2009).
Formation of stress granules protects the cells, allowing a trans-
lational block and initiation of repair processes (Anderson and
Kedersha, 2008).
Upregulation of nuclear TDP-43 has also been shown to pro-
vide protection to primary neurons against glutamate induced
excitotoxicity (Zheng et al., 2012). These findings also sug-
gest that TDP-43 regulates synaptic plasticity by governing
the transport and splicing of synaptic mRNAs. In a recent
review, Belzil and co-authors postulate that altered TDP-43
could lead to impaired hippocampal plasticity and render
neurons more vulnerable to cellular stressors (Belzil et al.,
2013).
TDP-43 is highly conserved from human to C. elegans,
both in the RNA binding motifs and in the carboxy-terminal
portion (Ayala et al., 2005). In situ hybridization studies
showed that TDP-43 is expressed very early in the brain
and spinal cord of zebrafish (Shankaran et al., 2008) sug-
gesting that it plays an important role in nervous system
development.
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FIGURE 2 | (A) TAR DNA-binding protein 43 (TDP-43) contains two
RNA-recognition motifs (RRM1 and RRM2), a carboxy-terminal glycine-rich
domain, a bipartite nuclear localization signal (NLS), and a nuclear export
signal (NES). Mutations are mainly located in the glycine-rich domain. (B) The
network of interactions of TDP-43 with proteins and RNAs. Green arrows
indicate binding interactions or processes that result in activation or increased
expression. Red arrows indicate binding interactions or processes that result
in inhibition of activity or reduced expression. Black arrows indicate binding
interactions or processes whose result can be either positive or negative.
Dashed arrows indicated indirect processes. Symbols as in Legend.
lncRNAs, long non-coding RNAs; IGF-1, insulin-like growth factor 1; HDAC4,
histone deacetylase 4; NRXN1, neurexin 1; TDP-43, TAR DNA binding
protein; FUS, fused in sarcoma; GRN, progranulin; NEAT1, nuclear-enriched
autosomal transcript 1; NEAT2, nuclear-enriched autosomal transcript 1.
Implications of RNA in Pathogenesis
Many studies have linked TDP-43 to neurodegenerative dis-
orders, including ALS and FTLD (Neumann et al., 2006;
Lagier-Tourenne et al., 2010; Lee et al., 2012). Janssens and
Van Broeckhoven (2013) have highlighted the increasing evi-
dence of role of impaired RNA metabolism in TDP-43-driven
neurodegeneration.
TARDBP primary transcript undergoes alternative splicing to
produce eleven different mRNAs including the one encoding
TDP-43. Seven of these are shorter transcripts which are gener-
ated through the seven different splicing reactions within exon
6 of TARDBP pre-mRNA using a combination of four different
5′ donor sites and four different 3′ acceptor sites (Wang et al.,
2004a).
In few ALS cases a smaller TDP-43 isoform (∼28KDa) was
observed additionally to the 43 kDa isoform, lacking exon 3 and
a significant portion of exon 6-encoded amino acids (Strong et al.,
2007). This smaller isoform lacks the carboxy-terminal portion of
the protein and is thought to be associated with disease pathology
(Neumann et al., 2006).
Converging lines of evidence in research suggest that TDP-
43 regulates RNA in various ways (Figure 2B; Lee et al., 2012).
The RRM1 domain of TDP-43 is critical for its binding to single-
stranded RNA (Ou et al., 1995; Buratti and Baralle, 2001; Wang
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et al., 2004a; Ayala et al., 2005). TDP-43 preferentially binds
UG repeats, but is also found to be associated with non-UG
repeat sequences (Buratti and Baralle, 2001; Ayala et al., 2005;
Polymenidou et al., 2011; Tollervey et al., 2011).
Pathological TDP-43 aggregates are ubiquitinated and phos-
phorylated. Under normal conditions, these forms are not readily
detectable in brain tissues, thus making them disease-specific.
Over-expression of full-length TDP-43 in a variety of transgenic
animal models lead to the presence of phosphorylated TDP-43
aggregates similar to ALS and FTD cases (Wegorzewska et al.,
2009; Shan et al., 2010; Stallings et al., 2010; Wils et al., 2010; Xu
et al., 2010a). The phosphorylated form has a longer half-life than
the non-phosphorylated form thus leading to accumulation of
phosphorylated proteins. Despite the progress toward describing
the full spectrum of TDP-43 pathology in human neurodegen-
erative diseases, the fundamental question of whether TDP-43
dysfunction mediates neuro-degeneration through gain of toxic
function or a loss of normal function remains unanswered (Lee
et al., 2012).
Upon depletion of TDP-43 from adult mouse brain with anti-
sense oligonucleotides, levels of 601 mRNAs, including FUS,
GRN and other transcripts involved in neurodegeneration, were
altered, along with 965 varied splicing events. RNAs depleted by
the reduction of TDP-43 were coded by genes with long introns
(Polymenidou et al., 2011).
In-vivo searches for TDP-43 RNA targets in mouse
(Polymenidou et al., 2011), human brain (Tollervey et al.,
2011), rat cortical neurons (Sephton et al., 2011), a mouse
NSC-34 cell line (Colombrita et al., 2012), and a human neu-
roblastoma cell line (Xiao et al., 2011) revealed that there are
more than 6000 RNA targets which constitutes to about 30% of
total transcriptome. TDP-43 was found to preferentially bind to
introns (including deep intronic sites), 3′ untranslated regions
(UTRs), and non-coding RNAs (Polymenidou et al., 2011;
Tollervey et al., 2011), indicating a multifaceted role in RNA
maturation. TDP-43 can influence splice site selection by binding
to exon-intron junctions and intronic regions, mRNA stability
and transport by binding on 3′UTRs. A substantial amount of
mRNAs regulated by TDP-43 at splicing levels were involved
in neuronal development or in neurological diseases (Tollervey
et al., 2011). Additional data show that when TDP-43 is reduced
the levels of several other mRNAs increase. As the affected
mRNAs include more than 300 mRNAs without TDP-43 binding
sites, these observation point toward an indirect mechanism
(Polymenidou et al., 2011) of modulation.
i-CLIP experiments have also shown that TDP-43 binds to
long ncRNAs (lncRNAs), including nuclear-enriched autosomal
transcript 1 (NEAT1) and metastasis-associated lung adenocar-
cinoma transcript 1 (MALAT1, also called NEAT 2) (Tollervey
et al., 2011). Expression of both lncRNAs is elevated in FTD
patients with TDP-43 inclusions, thus correlating with their
increased association with TDP-43 (Tollervey et al., 2011).
The binding of TDP-43 to small (<200 base) ncRNAs and
miRNAs remains largely unexplored. However, the association of
TDP-43 with Droshamicroprocessor (Ling et al., 2010) and Dicer
complexes (Freibaum et al., 2011; Kawahara and Mieda-Sato,
2012) provides a suggestive role of TDP-43 involvement in
miRNA biogenesis. Indeed, let-7b miRNA is downregulated,
whereas miR-663 is upregulated upon reduction of TDP-43
(Buratti et al., 2010). Di Carlo and collegues demonstrated that
TDP-43 directly interacts with Drosha and controls its stability at
different levels. Moreover, TDP-43 is also involved in the Drosha
substrate recognition as in the regulation mediated by Drosha of
Neurogenin 2, an important andmaster gene in neurogenesis (Di
Carlo et al., 2013).
Fan et al. (2014) have performed CLIP-seq analysis to exam-
ine the small RNAs (pri-miRNAs, miRNAs, and piRNAs) bound
to TDP-43 and found that a novel miRNA (miR-NID1), which
is processed from the intron five of human neurexin 1 gene
(NRXN1), interacts with TDP-43 and represses expression of
NRXN1. Neurexins are cellular proteins that function as cell
adhesion molecules and receptors in the vertebrate nervous sys-
tem, involved in synaptic development including calcium sig-
naling, heterogeneous cell-to-cell adhesion and synaptogenesis
(Craig et al., 2006; Bottos et al., 2011) Disruptions or mutations
of NRXN1 have been reported to associate with autistic spectrum
disorder (ASD), mental retardation, and schizophrenia (Reichelt
et al., 2012).
Recent studies by King and colleagues identified a physical
interaction between TDP-43 and miR-1 family which is known
to be involved in smooth muscle gene repression in heart and
an opposing myogenic differentiation (King et al., 2014). TDP-
43 overexpression in skeletal muscle led to decrease of miR-1
and increased protein levels of the miR-1 family targets, IGF-1
and HDAC4. These results demonstrate that TDP-43 could influ-
ence miRNA regulation through a physical interaction by limit-
ing their bioavailability for RISC loading and offer a mechanism
by which mature miRNAs can be differentially regulated.
The expression of TDP-43 is tightly autoregulated through
a complex interplay between transcription, splicing, and 3′
end processing (Avendaño-Vázquez et al., 2012): TDP-43 over-
expression in humans and mice leads to activation of a 3′ UTR
intron which results in excision of proximal polyA site (PAS)
which in turn activates a cryptic PAS and prevents TDP-43
expression through a nuclear retention mechanism.
The above mentioned studies have highlighted that TDP-43 is
linked to various mRNAs and non-coding RNAs, in a neuronal
context wherein it mediates effects through splicing or interac-
tion with Drosha and Dicer complexes. It is also involved in its
autoregulation mediated at the RNA level.
Additionally, TDP 43 is known to interact with MATR3, a
DNA RNA binding protein. Their interaction was confirmed to
be RNA based. Mutations in this gene have been linked to cases
of ALS. The authors further report that the phenotype observed
in patients with MATR3 was a combination of those observed in
cases of ALS and myopathy. Clinical symptoms were similar to
patients with VCP mutations (Johnson et al., 2014).
FUS
FUS, (fused in sarcoma, also called TLS: translocated in liposar-
coma) belongs to the TET family of RNA binding proteins
involved in many different cellular processes (Bertolotti et al.,
1996; Law et al., 2006; Tan and Manley, 2009). FUS, located
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on chromosome 16 at locus p11.2, encodes a multifunctional
protein able to bind and interact with single stranded RNA and
double stranded DNA, participating in different aspects of RNA
metabolism (Shelkovnikova et al., 2014).
Structure
FUS is characterized by different domains (Figure 3A): a
N-terminal domain with transcriptional activating properties
mainly composed of glutamine, glycine, serine, and tyrosine
residues (Law et al., 2006), a glycine rich region, a RNA binding
domain, and a highly conserved C-terminus capable of binding
DNA, RNA and splicing factors (Law et al., 2006).
Localization and Function
FUS is mainly localized in the nucleus (Colombrita et al., 2009;
Van Blitterswijk and Landers, 2010; Kawahara and Mieda-Sato,
2012) but it is also actively implicated in other cellular processes
that occur in the cytoplasm such as mRNA transport, mRNA sta-
bility and translation (Buratti and Baralle, 2010; Colombrita et al.,
2011). Indeed FUS was reported to shuttle between the nucleus
and the cytoplasm, exporting to the cytoplasm spliced mRNAs in
ribonucleoprotein complexes (Zinszner et al., 1997). Particularly,
upon stimulation in hippocampal neurons FUS was reported
to accumulate in the spines of mature dendrites, where local
translation occurred (Fujii and Takumi, 2005). FUS immunore-
activity was also observed in dendritic spines in mature primary
cultures and in adult hippocampus in situ (Belly et al., 2005;
Table 1).
The C-terminal part of FUS encodes for a non-classic nuclear
localization signal (Figure 3A; Iko et al., 2004) that is necessary
for nuclear import, as it was demonstrated through the genera-
tion of deletion mutant lacking 13 amino acids in the C-terminal
part of FUS(Dormann et al., 2010).
Several papers reported that mutations and aberrations of FUS
are linked to the pathogenesis of frontotemporal degeneration
(FTD) as well as familial and sporadic ALS (Kwiatkowski et al.,
2009; Vance et al., 2009), as reported in Table 3. Moreover, FUS
accumulates in inclusions in the cytoplasm of autopsied spinal
cords and brains of sporadic and familial ALS and FTD. FUS
inclusions are not only observed in presence of FUS mutations,
as they were found in patients with different or unknown genetic
defects such as sporadic ALS, ALS/dementia or FTLD (with or
without progranulin mutations), FUS or TDP43mutation-linked
familial ALS, SOD1-negative familial ALS. These inclusions were
also positive for TDP43/ubiquitin and p62 (Deng et al., 2010).
ALS/FTD patients show mutations mainly in the Glycine
rich region and C-terminal part (Lagier-Tourenne et al., 2010).
The mechanism underlying the pathogenesis of FUS mutations
was related to FUS nucleus/cytoplasmic imbalance since ALS
mutations increase its localization in the cytoplasm, observed
through immunostaining of FUS in postmortem ALS brain sam-
ples (Kwiatkowski et al., 2009), or through the analysis in neu-
roblastoma cell lines of the subcellular localization of recombi-
nant mutant FUS fused either to green fluorescent protein (GFP)
(Kwiatkowski et al., 2009; Morlando et al., 2012), an N-terminal
hemagglutinin (HA) tag (Vance et al., 2009), a C-terminal V5-His
tag, or an N-terminal myc tag in HeLa (Ito et al., 2011).
Both the loss of FUS nuclear function and the potential gain of
toxic effect by FUS in the cytoplasm could explain pathogenesis
(Shelkovnikova et al., 2014).
Very few studies so far reported FTD cases associated with
FUSmutations. The first analysis of FUS in FTD patients showed
a novel missense mutation in the glycine-rich region of FUS, pre-
dicted to be pathogenic by in silico analysis (Van Langenhove
et al., 2010). Subsequently another study found novel missense
mutations in patients with familial ALS with features of fron-
totemporal dementia (FALS/FTD) and one with familial ALS
with parkinsonism and dementia (FALS/PD/DE) (Yan et al.,
2010). Recently, another study found two novel heterozygous
missense mutations in FUS in patients with behavioral variant
FTD (bvFTD), however the pathogenicity of these mutations
needs to be further investigated in other screening (Huey et al.,
2012).
FUS has been reported to co-localize with TDP-43 in nuclear
complexes (Kim et al., 2010b; Ling et al., 2010) and in larger
cytoplasmic complexes (Kim et al., 2010b). Purified FUS has
also been reported to interact with purified His-tagged TDP-
43 in vitro in an RNA-independent manner, associated to the
C-terminal region of TDP-43 (Kim et al., 2010b). These ubiq-
uitously expressed binding proteins seem to have similar and
complementary functions.
Only the mutant form of FUS was found in stress granules
in reponse to translational arrest (Bosco et al., 2010). FUS and
TDP-43 were observed to co-localize in cytoplasmic aggregations
of ALS/FTLD-affected neurons (Da Cruz and Cleveland, 2011).
Dormann and colleagues found stress granule markers such as
PABP-1 and eIF4G co-deposited with FUS inclusions in sections
of post-mortem brain and spinal cord tissue from familial ALS-
FUS and sporadic FTDLD-U. On the contrary, TDP inclusions
did not show any co-localization with stress granules proteins in
HeLa transiently transfected with the mutated form of FUS, after
heat shock for 1 h (Dormann et al., 2010). Another study reported
that ubiquitin-positive inclusions in frozen post-mortem tissue
from FTLD-TDP patients were not stained with anti-FUS anti-
bodies (Neumann et al., 2009b), therefore FUS and TDP-43 are
not always found in the same inclusions or aggregates.
The relation between FUS and TDP-43 is reported as a deli-
cate equilibrium, where small alteration on their relative quantity
and presence in nucleus/cytoplasm could very likely cause seri-
ous problem over a long period (Colombrita et al., 2012), which
might be an accumulation of events due to an alteration of their
targetome.
Implications of RNA in Pathogenesis
FUS is involved in pre-mRNA splicing (Figure 3B), by inter-
acting with splicing factors such as SRm160, PTB, and ser-
ine/arginine rich proteins (SR proteins) (Yang et al., 1998; Meiss-
ner et al., 2003). In addition the recent sequencing approaches
applied to clarify the function and identify the targets of FUS
reinforced its fundamental role in splicing (Colombrita et al.,
2012) by revealing its binding to intronic sequences or to splice
site acceptors.
Similarly to many other splicing factors, FUS can bind
the C-terminal domain of RNA polymerase II and prevent
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
FIGURE 3 | (A) Schematic representation of the functional domains in
FUS/TLS. FUS contains a N-terminal part enriched in glutamine, glycine,
serine and tyrosine residues (QGSY region), a glycine-rich region, a
nuclear export signal (NES), an RNA recognition motif (RRM), repeats of
arginine, glycine, glycine (RGG), a zinc finger motif (ZNF), and a
C-terminal nuclear localization signal (NLS). Most of the mutation are
localized in the glycine rich region and in the last 17 amino acids of the
NLS part. (B) The network of interactions of FUS with proteins and
RNAs. Green arrows indicate binding interactions or processes that result
in activation or increased expression. Red arrows indicate binding
interactions or processes that result in inhibition of activity or reduced
expression. Black arrows indicate binding interactions or processes
whose result can be either positive or negative. Dashed arrows indicated
indirect processes. Symbols as in Legend. lncRNAs, long non-coding
RNAs; IGF-1, insulin-like growth factor 1; HDAC4, histone deacetylase 4;
NRXN1, neurexin 1; TDP-43, TAR DNA binding protein; FUS, fused in
sarcoma; MAPT, microtubule-associated protein tau; NEAT1,
nuclear-enriched autosomal transcript 1; CCND1, G1/S-specific cyclin-D1;
CBP, CREB-binding protein; p300, Histone acetyltransferase p300; PolII
CTD, Carboxy-terminal Domain of the RNA polymerase II.
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TABLE 3 | List of mutations in FUS and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.4961A>G M254V Unclear Van Langenhove et al., 2010
bvFTD g.31183985C>T P106L Unclear Huey et al., 2012
ALS/FTD g.31185031G>A G206S Unclear Yan et al., 2010
FALS/PD/DE g.31191418C>T R521C Unclear Yan et al., 2010
ALS/FTD g.31191419G>A R521H Pathogenic Broustal et al., 2010
ALS, Amyotrophic lateral sclerosis; FTD, Frontotemporal Dementia; bv FTD, behavioral variant Frontotemporal Dementia; FALS, Familial Amyotrophic lateral sclerosis; PD, Parkinson’s
disease; DE, Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
the premature hyperphosphorylation of Ser2 in the C-terminal
domain of RNA polymerase II. Moreover the lack of FUS leads to
an accumulation of RNA polymerase II at the transcription start
site with a shift toward abundance of mRNA isoforms with early
polyadenylation (Schwartz et al., 2012).
FUS can bind to the promoter antisense strand transcript of
some genes such as Ptprn2, Xrn1, Gak, or Glt1d1 and this interac-
tion downregulates the transcription of the coding sense strand,
but this effect seems to be specific for some genes enriched with
GO terms connected to the reproductive process(Ishigaki et al.,
2012).
As FUS was shown to regulate RNA polymerase II at many
more gene promoters than the genes reported for splicing defects,
its role on transcription could be a separated function in addi-
tion to the regulation on splicing (Schwartz et al., 2012). How-
ever, a small proportion of FUS target regions is localized in
exonic sequences and in the 3′UTRs (Hoell et al., 2011), suggest-
ing another potential role, such as the transport of mRNAs or
the control of mRNA stability and translation (Fujii et al., 2005;
Fujii and Takumi, 2005). A model was suggested, in which FUS
is released from actin filaments, when cytoskeletal organization
collapses, becoming free to be linked to the mRNA that is trans-
ported to the local translational machinery in the spines (Fujii
and Takumi, 2005).
Recent techniques, like HITS-CLIP or RIP-CHIP were also
used to identify FUS binding motif, but all the studies lead to the
common assumption that FUS binds to specific secondary struc-
tures on its RNA targets and a primary sequences analysis is not
sufficient (Colombrita et al., 2012; Ishigaki et al., 2012).
Interestingly, silencing of FUS was reported to alter splicing
events in genes, such as MAPT, that have an important neu-
ronal function (Ishigaki et al., 2012). This finding leads an unex-
pected connection between these two genes, both involved in the
pathogenesis of FTD. In particular, FUS was shown to help the
skipping of MAPT exon 10 in primary cortical neurons (Ishi-
gaki et al., 2012). The alternative splicing of MAPT exon 10 is
known to have a causative role in FTD as discussed later (MAPT
paragraph).
FUS is also involved inmicroRNA biogenesis (Morlando et al.,
2012), specifically interacting with pri-miRNAs and Drosha, and
helping the recruitment of Drosha for the correct miRNA pro-
cessing in neuronal cells. Several miRNAs like miR-9, miR-
132, and miR-125b whose biogenesis is controlled by FUSare
important for neuronal functions, neuronal differentiation, and
synaptogenesis (Morlando et al., 2012). Additionally miR-9 and
miR-132 have also been shown to control neurite extension and
branching through downregulation of Foxp2 (Forkhead box pro-
tein P2) (Clovis et al., 2012) Moreover this role of FUS seems
to be prominent in neuronal cells compared to non-neuronal
cells, such as HeLa cells, in which the proportion of miRNAs
affected by FUS knockdown was lower. Indeed the mutations
known to induce a cytoplasmic delocalization of FUS would
impede its nuclear role as pri-miRNA processor. Though the
balance of nuclear and cytoplasmic FUS seems necessary, the
sole role of nuclear FUS should not be neglected and further
investigations would be needed to clarify its biological func-
tion within this cell compartment. Recently, the same labora-
tory demonstrated the presence of a regulatory loop in which
FUS can enhance the expression of miR-141 and miR-200a,
which in turn regulate FUS, through a binding on its 3′UTR.
This pathway seems to be affected in the presence of one
mutation found in two ALS patients (Dini Modigliani et al.,
2014).
FUS is also reported to bind lncRNAs. The binding to
lncRNA CCND1 induces an allosteric change in FUS, thus in
turn permits its interaction with CBP/p300. As FUS represses
CBP/p300-mediated transcription by inhibiting their histone
acetyltransferase (HAT) functions (Wang et al., 2008a), in the
presence of ncRNA CCDN1, CBP/p300-mediated transcription
is repressed.
The nuclear-enriched abundant transcript 1 (NEAT1) pro-
duces two types of lncRNAs from the same promoter NEAT1_1
and NEAT1_2 (Nishimoto et al., 2013). FUS was shown to
bind NEAT1_2, known to assemble and organize the core pro-
teins of paraspeckles (Wang et al., 2008a; Hoell et al., 2011;
Lagier-Tourenne et al., 2012), which represent a storage for
the rapid release of RNAs during stress condition or a nuclear
retention of long hyperedited transcripts (Prasanth et al., 2005;
Chen and Carmichael, 2009). According to observations and data
obtained from cultured cells, transgenic mice and human post-
mortem tissue, paraspeckles represents an important protective
cell mechanism during stress conditions (Nakagawa et al., 2011;
Nakagawa and Hirose, 2012; Shelkovnikova et al., 2014).
Paraspeckels are present in almost all the cultured cells (Fox
and Lamond, 2010), but in normal tissues are found only in cells
that contain high levels of NEAT1_2 RNA and coherently, in
neurons where NEAT1 is express at low levels, paraspeckles are
not observed (Nakagawa et al., 2011).
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The presence of FUS in paraspeckles was confirmed in differ-
ent cell lines by three studies (Naganuma et al., 2012; Nishimoto
et al., 2013; Shelkovnikova et al., 2014) Moreover, NEAT1 was
shown through PAR-CLIP to be a target of both WT and mutant
FUS (Hoell et al., 2011).
Paraspeckles are found in spinal motoneurons of patients at
early stage of ALS. The possibility that aging induces an increase
in the level of NEAT1_2 was ruled out due to the fact that
human control cases were older that ALS cases of an average of
10 years. However, the process that induces an up-regulation
of NEAT1_2 lncRNA during the early phases of ALS is still
unknown (Nishimoto et al., 2013). Overall FUS seems to play a
key role on the regulation of RNA at different levels, acting on
transcription, splicing, transport, and stability of mRNA with a
particular function in microRNA biogenesis and interaction with
non-coding RNAs.
MAPT (Tau)
MAPT (microtubule associated protein) encodes for protein Tau
and is located on chromosome 17q21.3. The gene, which is
150 kb-long, contains 16 exons, out of which 11 are expressed in
CNS (Wolfe, 2012).
Structure
The protein consists of a projection domain, including an acidic
and a proline-rich region, which interacts with cytoskeletal ele-
ments (Figure 4A). The N-terminal part is involved in sig-
nal transduction pathways by interacting with proteins such as
PLC-γ and Src-kinases. The C-terminal part, referred to as the
microtubule binding domain, regulates the rate of microtubules
polymerization and is involved in binding with functional pro-
teins such as protein phosphatase 2A (PP2A) or presenilin 1
(PS1) (Luna-Muñoz et al., 2013).
Localization and Function
Tau is a microtubule-associated protein which is found in abun-
dance in the axons of Central nervous system (CNS) and Periph-
eral nervous system (PNS) (Binder et al., 1985; Couchie et al.,
1992; Table 1). It is also observed in astrocytes and oligoden-
drocytes in the CNS. The tau pre-mRNA undergoes alternative
splicing at exons 2, 3, and 10 to give six different possible iso-
forms. Inclusion of exon 10 generates 4-repeat or 4R tau, while
exclusion forms 3-repeat or 3R tau. In neurons this ratio is con-
trolled throughout development, emphasizing the importance of
this balance for neuronal functions.
Implications of RNA in Pathogenesis
In FTD populations, MAPT mutation frequency ranges from 8
to 50%. To date, 44 different MAPT mutations, either mis-sense
or splice mutations or both, have been discovered in 138 dif-
ferent families (Cruts et al., 2012). The list of pathogenic muta-
tions observed inMAPT are reported in Table 4). Most missense
mutations alter ability of tau to bind to microtubules, thus lead-
ing to the formation of inclusion in neurons and glia, called
neurofibrillary tangles (NFT) (Lee et al., 2005).
About half of the mutations inMAPT, however, are associated
with alteration of splicing of exon 10 and increase the ratio of 4R
to 3R. The mutations near exon 10 5′splice site enhance inclusion
of exon 10 either by altering the linear cis-splicing elements or by
FIGURE 4 | (A) Schematic representation of the functional domains of the
largest tau isoform (441 amino acids 2N4R isoform). The N-terminal
projection domain, including an acidic and a proline-rich region, interacts
with cytoskeletal elements. The N-terminal part is also involved in signal
transduction pathways by interacting with proteins such as PLC-γ and
Src-kinases. The C-terminal part, also known as the microtubule-binding
domain, regulates the rate of microtubules polymerization and is involved in
binding with proteins such as protein phosphatase 2A (PP2A) or presenilin
1(PS1). (B) Schematic representation of the progranulin structure encoded
by the major human transcript containing all the 13 exons. The lettered
boxes on the progranulin scheme represent the individual granulin domains
containing cystein-rich motifs.
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TABLE 4 | List of mutations in MAPT and their characteristic phenotypes.
Subtypes of dementia Mutation Change in amino acid Type References
FTD g.75756G>A R5H Pathogenic Hayashi et al., 2002
FTD g.110018A>C K592T Pathogenic Rizzini et al., 2000
FTD g.110026A>G I595V Pathogenic Grover et al., 2003
FTD g.110044C>G L601V Pathogenic Kobayashi et al., 2003
FTD g.110063G>T G607V Pathogenic Schenk, 1959
FTD g.110065G>A G608R Pathogenic Van der Zee et al., 2006
FTD g.123725T>G N614K Pathogenic Wszolek et al., 1992
FTD g.123729_123731delAAG DeltaK616 (alias 1K280;1K281) Unclear Rizzu et al., 1999
FTD g.123740T>C L619 Pathogenic D’Souza et al., 1999
FTD g.123774A>C N631H Pathogenic Iseki et al., 2001
FTD g.123776T>C N631 Pathogenic Brown et al., 1996
FTD g.123789C>A P636T Pathogenic Lladó et al., 2007
FTD g.123789C>T P636S Pathogenic Bugiani et al., 1999
FTD g.123790C>T P636L Pathogenic Hutton et al., 1998
FTD g.123802G>A S640N Pathogenic Iijima et al., 1999
FTD g.123802G>T S640I Pathogenic Kovacs et al., 2008
FTD g.123803T>C S640 Pathogenic Spillantini and Goedert, 2000
FTD/PSP g.123806G>A Intronic Pathogenic Spillantini et al., 1997
FTD g.123814T>C Intronic Pathogenic Miyamoto et al., 2001
FTD g.123815C>T Intronic Pathogenic Takamatsu et al., 1998
FTD g.123816A>G Intronic Pathogenic Hutton et al., 1998
FTD g.123817C>T Intronic Pathogenic Lynch et al., 1994
FTD g.123819C>T Intronic Pathogenic Lanska et al., 1994
FTD g.123822C>G Intronic Pathogenic Stanford et al., 2003
FTD g.127672T>G L650R Pathogenic Rosso et al., 2003
FTD g.127673G>A L315 Pathogenic (Bird, 2005, Personal
Communication)
FTD g.127678A>T K652M Pathogenic Zarranz et al., 2005
FTD/PD/MND g.127687C>T S655F Pathogenic Rosso et al., 2002
FTD g.132033G>A G670S Pathogenic Spina et al., 2007
FTD g.132034G>T G670V Pathogenic Neumann et al., 2005
FTD g.137420G>A G389R Pathogenic Pickering-Brown et al., 2000
FTD g.137420G>C G389R Pathogenic Murrell et al., 1999
FTD g.137471C>T R741W Pathogenic Dickson, 1997
FTD g.137525C>A Q424K Pathogenic (Brice, 2005, Personal
Communication)
FTD g.137535C>T T762M Pathogenic Giaccone et al., 2004
bvFTD c.163G>A G55R Pathogenic Iyer et al., 2013
FTD c.363T>C V363A Pathogenic Rossi et al., 2014
FTD c.363C>A V363I Pathogenic Rossi et al., 2014
FTD c.454G>A A152T Pathogenic Kara et al., 2012
FTD c.530A>T D177V Unclear Kim et al., 2014
FTD c.853A > C S285R Pathogenic Ogaki et al., 2013
FTD c.892 A>G K298E Pathogenic Iovino et al., 2014
FTD c.1090C>T P364S Pathogenic Rossi et al., 2012
FTD c.1096G>A G366R Pathogenic Rossi et al., 2012
FTD c.1228A>C N410H Pathogenic Kouri et al., 2014
FTD c.1381-74G > A Intronic Pathogenic Kim et al., 2010a
FTD c.1908G > A P636P Pathogenic Kim et al., 2010a
FTD c.1815G > A P605P Pathogenic Kim et al., 2010a
FTD c.1828-47C > A Intronic Pathogenic Kim et al., 2010a
FTD c.2002+90G > A Intronic Pathogenic Kim et al., 2010a
(Continued)
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TABLE 4 | Continued
Subtypes of dementia Mutation Change in amino acid Type References
FTD c.2092G>A V363I Pathogenic Bessi et al., 2010
FTD IVS10+4A>C Intronic Pathogenic Anfossi et al., 2011
FTD IVS9-15T>C Intronic Pathogenic Anfossi et al., 2011
FTD g.132037A>G Q336R Pathogenic Pickering-Brown et al., 2004
FTD, Frontotemporal Dementia; bv FTD, behavioral variant frontotemporal Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
destabilizing a stem-loop structure at the exon-intron junction
(D’Souza et al., 1999; Grover et al., 1999; Spillantini and Goedert,
2013). This stem-loop arises as a result of the self complementar-
ity among bases in this region and has a putative role in masking
the 5′ splice site Mutations that disrupt the stem-loop structure
make the 5′ splice site accesible to splicing factors, leading to
inclusion of exon 10 (Wolfe, 2012).
Though mutations lead to alteration of splicing at the mRNA
level, their primary effect becomes pathogenic through changes
in the protein level in about half of the cases (Goedert and Jakes,
2005).
The human MAPT 3′UTR, as well as that of rodents, con-
tains two Polyadenylation Signals (PAS) in tandem and can
undergo alternative polyadenylation (APA) to produce tran-
scripts of approximately 2 or 6 kb, namely the short and long
transcript variants (Poorkaj et al., 2001). Dickson and colleagues
investigated the role of human MAPT 3′-UTR in regulating tau
expression (Dickson et al., 2013). They observed that the two
MAPT 3′UTR variants are differentially regulated and influence
both mRNA stability and protein expression levels. The same
authors have reported that miR-34a can bind the human MAPT
3′-UTR long form and reduce tau levels, whereas inhibition of
endogenous miR-34 family members leads to increased tau lev-
els, leading to a hypothesis that up-regulation of miR-34 observed
during neuronal differentiation could be a compensatory mech-
anism to decrease the expression of tau aggregates. Recent work
(Wu et al., 2013a) also confirms the finding that MAPT is reg-
ulated by miRNA 34c-5p and miRNA 34c-3p, which bind to its
3′UTR.
Additionally, work by Zovoilis and colleagues have suggested
that miR-34c could be a marker for the onset of cognitive distur-
bances linked to Alzheimers disease and they also indicate that
targeting miR-34c could thus be a suitable therapy (Zovoilis et al.,
2011).
Studies also reported that miR-34 regulates apoptosis by
blocking the SIRT1 gene (Hermeking, 2010) and astrocytic apop-
tosis has been observed as an early event in FTLD conditions
(Broe et al., 2004). These findings suggest that miRNAs might be
involved in FTD through apoptotic mechanisms.
Tau is known to spread through synaptic and non-synaptic
mechanisms (Medina and Avila, 2014) and its accumulation is
thought to be mediated through spreading of the protein from
cell to cell. Tau has been reported to be secreted unconvention-
ally in naked form (Chai et al., 2012) or associated to exosomes
(Saman et al., 2012) and/or other membrane vesicles (Simón
et al., 2012). Thismethod of elimination of tau has been suggested
as a response mechanism to inhibit tau secretion and toxicity.
Recent reports have suggested that tau is released into culture
medium from neuroblastoma cells, tau-expressing non-neuronal
cells, induced pluripotent stem cell-derived human neurons, and
mouse primary neurons (Kim et al., 2010a; Shi et al., 2012).
This has also been observed in the brain interstitial fluid of both
wild-type and P301S tau-expressing mice in micro-dialysis stud-
ies (Yamada et al., 2011). Clinico-pathological studies underline
the tau pathology progression from entorhinal cortex through
the hippocampus and into limbic system (Arriagada et al., 1992).
Recent in vivo studies in tauopathy transgenic mouse models
have also highlighted the spreading of tau pathology through a
trans-synaptic mechanism in anatomically connected neuronal
networks (De Calignon et al., 2012; Liu et al., 2012). Apart from
these, intracerebral inoculation of synthetic tau fibrils induced
NFT (Neuro fibrillary tangles) like inclusions that propagated
from injected sites to other connected regions of brain (Iba et al.,
2013).
Current hypotheses also include that pathological progression
of improperly folded of tau could be transferred between neu-
ronal cells via a prion-like seeding mechanism which might lead
to neurodegeneration.
Themajor implication observed uponmutations which lead to
splice defects highlights the relevance of regulation at RNA level
which decides the fate of onset of neurodegeneration. The regu-
lation of MAPT mediated through miRNAs further indicates the
role of non-coding RNAs in determining tau protein levels.
GRN (Progranulin)
GRN is located on the long arm of chromosome 17 at the locus
q21.31 which is present at a distance of 1.7 Mb from MAPT
(Baker et al., 2006; Cruts et al., 2006). GRN encodes for a 593 aa
precursor protein of 68.5 kDa called progranulin.
Structure
Progranulin can be N-glycosylated at five potential sites and
secreted as a mature protein of 88 kDa (Chen-Plotkin et al., 2010;
Songsrirote et al., 2010). The protein is formed by 7.5 cysteine-
rich granulin domains, separated through linker sequences that
contain disulfide bridges (He and Bateman, 2003), as represented
in Figure 4B. This characteristic structure can be cleaved at the
intra-linker spacer sequences to produce seven non-identical
granulins that contain cysteine-rich motifs. Different proteases
can cleave progranulin, such as matrix metalloproteinase-14
(Butler et al., 2008), elastase (Zhu et al., 2002), proteinase 3, and
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neutrophil elastase (NE) at the pericellular microenvironment of
the neutrophil cell surface (Kessenbrock et al., 2008). The full-
length progranulin, once secreted, is protected from cleavage by
the high-density lipoprotein (HDL)/Apolipoprotein A-I complex
(Okura et al., 2010) and the secretory leukocyte protease inhibitor
(SLPI) (Zhu et al., 2002).
Localization and Function
Progranulin is present in many tissues, is highly expressed in
immune system cells (Daniel et al., 2000) and in a medium level
in the brain (Bhandari et al., 1996; Ahmed et al., 2007), where
it is highly expressed in specific populations of neuronal cells,
such as cortical neurons, and granule cells of the hippocampus
(Daniel et al., 2000; Table 1). The subcellular location of pro-
granulin seems to be the endoplasmic reticulum (ER) and Golgi,
where it is particular abundant in mouse cortical neurons and
mouse microglia (Almeida et al., 2011). Progranulin is implicated
in a wide range of biological processes such as embryogenesis
(Díaz-Cueto et al., 2000; Daniel et al., 2003; Bateman and Ben-
nett, 2009), cell survival and cell growth (Plowman et al., 1992; He
and Bateman, 1999), inflammation and wound repair (Zhu et al.,
2002; He et al., 2003; Kessenbrock et al., 2008; Yin et al., 2010),
transcriptional repression (Hoque et al., 2003, 2010) and several
reports suggest its role in neuronal development (Van Damme
et al., 2008). Interestingly, progranulin and the proteolytically
cleaved granulins can have coherent functions, such as in the reg-
ulation of neurite outgrowth (Van Damme et al., 2008), or they
can have contrasting roles, such as in inflammation processes (He
and Bateman, 2003).
To date, 69 different GRN mutations have been discovered
in 231 families (Cruts et al., 2012). A list of detailed pathogenic
mutations are reported inTable 5. TheGRNmutations frequency
range from 1 to 11.7% in FTD patients, but the frequency rises
to 12–25% in familial FTD (Cruts et al., 2006; Gass et al., 2006;
Huey et al., 2006; Bronner et al., 2007; Borroni et al., 2008). There
are different types of GRN mutations, the majority are classified
as non-sense, frameshift, and splice site mutations that cause a
premature stop codons (Baker et al., 2006; Cruts et al., 2006).
However, the pathogenic variants include also missense muta-
tions with a partial decrease of progranulin and a loss of its
function (Mukherjee et al., 2006, 2008; Shankaran et al., 2008;
Wang et al., 2010). Silent and intronic mutation with unknown
pathology can also occur. Generally the pathogenic GRN muta-
tions lead to a decreased GRN expression due to a non-sense-
mediated mRNA decay, resulting in a GRN haploinsufficiency
inherited in an autosomal dominant manner (Baker et al., 2006;
Cruts et al., 2006; Gass et al., 2006; Cruts and Van Broeckhoven,
2008).
Indeed progranulin levels, measured in either the serum
or cerebrospinal fluid (CSF) of patients with GRN mutations
are ∼30–50% of normal (Van Damme et al., 2008). More-
over, a decreased progranulin level can be also detected in
plasma of GRN mutations patients (Finch et al., 2009) and a
reduced GRN mRNA level can be observed in patient whole
blood samples through microarray experiments (Coppola et al.,
2008). In contrast an increased level of GRN mRNA was
observed in the frontal cortex from post-mortem brain samples
of FTD patients with GRN mutations, as compared to FTD
patients without GRN mutations (Chen-Plotkin et al., 2010).
The higher level of GRN transcripts could be due to the robust
microglia infiltrations, observed in the brain tissues of GRN
mutation patients. Indeed microglia shows high level of GRN
expression.
Implications of RNA in Pathogenesis
Most of the patients with FTLD-U show GRN mutations with
presence of TDP-43 ubiquitin positive inclusions, hence bear-
ing the term FTLD-TDP (Mackenzie et al., 2006, 2010; Sam-
pathu et al., 2006). The relation between TDP-43 and pro-
granulin is not fully understood, however several recent stud-
ies indicate that TDP-43 controls the expression of progranulin
by binding to GRN mRNA. On a study in which TDP-43 tar-
gets were identified through a RIP-chip analysis, it is shown
that TDP-43 has a post-transcriptional regulation on GRN and
VEGFA (Vascular endothelial growth factor A) (Colombrita et al.,
2012).
As previously mentioned, TDP-43 was shown to specifically
bind GRN 3′UTR controlling GRN mRNA stability and the
final quantity of progranulin protein (Polymenidou et al., 2011;
Colombrita et al., 2012). Moreover a knock-down of TDP-43 in
mice showed an increase in the amount of GRN mRNA level
(Polymenidou et al., 2011; Colombrita et al., 2012). Depletion
of TDP-43 also led to altered splicing of sortilin, the putative
progranulin receptor (Polymenidou et al., 2011). The relation
between GRN and TDP-43 was also demonstrated in vitro: cells
that were treated with siRNA against GRN for 72 h, showed a
caspase-dependent cleavage of TDP-43 into fragments (Zhang
et al., 2007); whereas primary neuronal cultures upon knowck-
down of GRN showed a re-localization of TDP-43 in the cyto-
plasm (Guo et al., 2010).
Through genetic association analysis, a common genetic vari-
ation localized on the 3′UTR of GRN (rs5848) was shown to
represent a genetic risk factor for FTD (Rademakers et al., 2008).
Progranulin levels in brain extracts from rs5848 TT homozy-
gous FTD patients were lower than in CC carriers, as observed
through western blot analyses, ELISA, and immunohistochem-
istry. A stronger binding of miR-659 in the 3′UTR of GRN was
shown in the presence of the rs5848 T variant, and might explain
the reduced progranulin levels.
It is reported that miR-107 is downregulated in presence of
Alzheimer’s disease at early stage (Wang et al., 2008b). Another
study demonstrated through a RIP-Chip analysis performed in
human H4 neuroglioma cells that the open reading frame of
GRN mRNA contains many recognizing sequences elements
for miR-107 (Wang et al., 2010), showing implications of miR-
107 deregulation in neurodegenerative diseases. In particular
miR-107 regulation of GRN seems to be relevant to glucose
metabolism in cultured H4 neuroglioma cells. Previous analy-
sis identified miR-107 as one of the microRNAs that increase
their expression with glucose supplementation in cell culture
medium (Tang et al., 2009). Wang and colleagues reported that
glucose metabolic pathway may recruit miR-107 to regulate
GRN expression. Another microRNAs that was found signifi-
cantly down-regulated in brains of Alzheimer’s disease patients
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TABLE 5 | List of mutations in GRN and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD delGRN[DR184] Complete gene deletion Pathogenic Gijselinck et al., 2008
FTD c.-7-20C>T INTRON Suggesting Pathogenic Kim et al., 2010a
FTD c.349+ 34C > T INTRON Suggesting Pathogenic Kim et al., 2010a
FTD IVS6+5_8delGTGA N/A Unclear Marcon et al., 2011; Skoglund et al., 2011
FTD c.1138C>G Q380E Unclear Kim et al., 2014
FTD g.2988_2989delCA P439_R440fsX6 Pathogenic Gabryelewicz et al., 2010
FTD g.5215A>T Complete protein degradation Pathogenic Le Ber et al., 2007
FTD g.5217G>C Complete protein degradation Pathogenic Cruts et al., 2006
FTD g.5913A>G INTRON Pathogenic Mukherjee et al., 2008
FTD/PD g.8948_12532del Complete protein deletion Pathogenic Rovelet-Lecrux et al., 2008
FTD g.9044T>C Predicted failed translation Pathogenic Baker et al., 2006
FTD g.9045G>A Predicted failed translation Pathogenic Cruts et al., 2006
FTD/MND g.9055G>C V5L Unclear Lopez de Munain et al., 2008
FTD g.9061T>C W7R Unclear Le Ber et al., 2007
FTD/PPA g.9068C>A A9D Pathogenic Mukherjee et al., 2006
FTD g.9132_9133insCTGC C31LfsX35 Pathogenic Baker et al., 2006
FTD/PPA g.9144delC G35EfsX19 Pathogenic Gass et al., 2006
FTD g.9181G>A Failed translation initiation Pathogenic Gass et al., 2006
FTD/AD g.9319delA T52HfsX2 Pathogenic Gass et al., 2006
FTD g.9399_9400delAG G79DfsX39 Pathogenic Gass et al., 2006
FTD g.9408delC S82VfsX174 Pathogenic Bronner et al., 2007
FTD g.9429G>A E88 Unclear Gass et al., 2006
FTD g.9593T>C C105R Unclear Gass et al., 2006
FTD g.10129C>T Q125X Pathogenic Baker et al., 2006
FTD g.10134 C>G C126W Unclear Bernardi et al., 2012
FTD g.10136_10137delCT P127RfsX2 Pathogenic Cruts et al., 2006
FTD g.10144_10147delCAGT Q130SfsX125 Pathogenic Baker et al., 2006
FTD g.10319G>A A155WfsX56 Pathogenic Gass et al., 2006
FTD/PPA g.10645_10646delCA S226WfsX28 Pathogenic Gass et al., 2006
FTD g.10668C>A P233Q Unclear Bronner et al., 2007
FTD g.10678C>T N236 Unclear Gass et al., 2006
FTD g.10679G>C V200GfsX18 Pathogenic Gass et al., 2006
FTD g.10965_10966delTG C253X Pathogenic Gass et al., 2006
FTD g.11002 G>C A266P Unclear Bernardi et al., 2012
FTD g.11041_11042insCTGA A237WfsX4 Pathogenic Cruts et al., 2006
FTD/CBS g.11240G>C V279GfsX5 Pathogenic Gass et al., 2006
FTD g.11266G>C E287D Unclear Gass et al., 2006
FTD g.11315_11316insTG W304LfsX58 Pathogenic Gass et al., 2006
FTD g.11316G>A W304X Pathogenic Gass et al., 2006
FTD g.11339G>A V279GfsX5 Pathogenic Baker et al., 2006
FTD/CBS g.11639delC T382SfsX30 Pathogenic Baker et al., 2006
FTD g.11651G>A W386X Pathogenic Baker et al., 2006
FTD g.11944_11945delGT V411SfsX2 Pathogenic Bronner et al., 2007
FTD g.11965C>T R418X Pathogenic Baker et al., 2006
FTD g.12054C>T H447 Unclear Bronner et al., 2007
FTD g.12108_12109insC C466LfsX46 Pathogenic Gass et al., 2006
FTD g.12115C>T Q468X Pathogenic Baker et al., 2006
FTD g.12227C>T C474 Unclear Gass et al., 2006
FTD g.12282C>T R493X Pathogenic Huey et al., 2006
FTD g.12428G>C W541C Unclear Bronner et al., 2007
AD, Alzheimers disease; CBS, Corticobasal syndrome; FTD, Frontotemporal Dementia; PPA, Primary progressive aphasia; MND, Motor neuron disease; PD, Parkinsons disease.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
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is miR-29b, that beloged to the miR-29a/b-1 cluster (Hébert et al.,
2008). Interestingly progranulin can also be regulated bymiR-29b
through a binding in the 3′UTR of GRNmRNA (Jiao et al., 2010).
It would be useful to know if these microRNAs deregulation
can contribute to the pathogenesis of dementia. So far different
microRNAs seem to be important for the control of progranulin
along with the role played by TDP-43 on the stability of GRN
mRNA and its expression.
VCP
The VCP (Valosin-containging protein) gene is located on chro-
mosome 9p13.3. It also called p97 or CDC48, consists of 17
coding exons.
Structure
The VCP protein is composed of four domains vital for its proper
functioning, namely the N, D1 D2 and C-terminal domains
(Figure 5B; DeLaBarre et al., 2006; Pye et al., 2007). The VCP
N domain is encoded by exons 1, 2, 3, 4 and 5, while the D1
and D2 domains are encoded by exons 6, 7, 8, 9, 10 and 12, 13,
14, respectively. There are two linker domains in the protein: the
N-D1 linker and the flexible D1-D2 linker.
VCP is a member of theAAA-ATPase gene superfamily
(ATPase Associated with diverse cellular Activities) (Woodman,
2003; Wang et al., 2004b), and is one of the most abundant
cytosolic proteins (Table 1) conserved throughout in mammals.
The complete protein contains 806 amino acids. The N domain
of VCP is responsible for the cofactor and ubiquitin binding
FIGURE 5 | (A) Schematic representation of the CHMP2B which contains an
acidic negatively charged C-terminal domain and a basic positively charged
N-terminal domain, a predicted coiled-coil structure (14-51 aa) and a
conserved Snf7 domain (16-178 aa). The autoinhibitory structure formed in
the cytosol due to the C- and N- terminal part interactions is reverted through
the binding of VSP4 on the VPS4 binding domain (VPS4 BD), localized on
the C-terminal part. (B) Schematic representation of the six functional
domains of the VCP protein: the N-terminal domain, the weak ATPase
domain (D1), the major ATPase domain (D2), the N-D1 linker domain, the
flexible D1–D2 linker domain and the C-terminal domain. (C) Overview of the
genomic structure of the C9ORF72 gene, with white boxes representing the
coding exons and gray boxes representing the non-coding exons. The
position of the hexanucleotide repeat (GGGGCC), the start codon (ATG), and
the stop codon (TAA) are indicated in the scheme.
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FIGURE 6 | A possible network of interactions between proteins and
RNAs, at the basis of FrontoTemporal Dementia. Green arrows indicate
binding interactions or processes that result in activation or increased
expression. Red arrows indicate binding interactions or processes that result
in inhibition of activity or reduced expression. Black arrows indicate binding
interactions or processes whose result can be either positive or negative.
Purple arrows indicate binding interactions or processes which are
hypotetical. Symbols as in Legend. lncRNAs, long non-coding RNA; TDP-43,
TAR DNA binding protein; FUS, Fused in Sarcoma; GRN, progranulin; MAPT,
Microtubule-Associated Protein Tau; VCP, Valosin Containing Protein;
C9ORF72. CHMP2B, Charged multivesicular body protein 2b; Rab7,
Ras-related protein 7.
function (Wang et al., 2004b). While the D1 domain mediates
oligomerization-independent nucleotide binding, the D2 domain
confers most of the ATPase activity (Wang et al., 2004b).
Localization and Function
This protein functions as a molecular chaperone in various dis-
tinct cellular processes including ubiquitin-dependent protein
degradation, stress responses, programmed cell death, nuclear
envelope reconstruction, and Golgi and endoplasmic reticulum
(ER) assembly (Guinto et al., 2007).
VCP is known to be involved in protein aggregation/quality
control of mitochondria and cell proliferation (Hayashi, 2013)
and is vital for retro-translocation of misfolded proteins from
Endoplasmic reticulum to cytoplasm (Kimonis et al., 2008).
Mutation and depletion studies of VCP have provided evidence
of accumulation of poly-ubiquitinated proteins (Dai and Li,
2001). Mutations in this gene may suggest the disruption of nor-
mal protein degradation pathway in the disease. This could be
facilitated through the disruption of binding between the VCP
and protein adaptors.
The expression of mutant VCP in myoblastic cell lines is
associated with increased ubiquitin conjugated proteins (Weihl
et al., 2006). Studies on overexpression of mutant VCP protein
in transgenic mice implicated an age-dependent muscle weak-
ness and Ubiquitin-positive inclusions and accumulation of high
molecular weight protein aggregates (Weihl et al., 2007).
VCP functions as a homohexamer (Zhang et al., 2000; Rouiller
et al., 2002) by binding to multiple proteins associated with
Ubiquitin proteasome system (UPS). The VCP complex binds
to polyubiquitin chains and unbounds ubiquitinated proteins
from their binding partners thereby facilitating transport to
the UPS.
Implications of RNA in Pathogenesis
To date, 18 different VCP mutations have been discovered in
48 different families, which include FTLD that is associated
with ALS, inclusion body myopathy, and Paget disease (Cruts
et al., 2012). Table 6 high-lights the list of pathogenic mutations
observed so far. The association of inclusion body myopathy and
FTD was established by Kovach et al. (2001).
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TABLE 6 | List of mutations in VCP and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
IBMPFD g.284G>A R92H Unclear Kaleem et al., 2007
IBMPFD g.410C>T P137L Pathogenic Stojkovic et al., 2009
IBMPFD g.4438C>T R93C Pathogenic Guyant-Maréchal et al., 2006
IBMPFD g.4444C>G R95G Pathogenic Watts et al., 2004
IBMPFD g.4444C>T R95C Pathogenic Kimonis et al., 2008
IBMPFD g.6990C>T R155C Pathogenic Watts et al., 2004
IBMPFD g.6991G>A R155H Pathogenic Watts et al., 2004
IBMPFD g.6991G>T R155L Unclear Kumar et al., 2010
IBMPFD g.6991G>C R155P Pathogenic Watts et al., 2004
IBMPFD g.6990C>A R155S Pathogenic Stojkovic et al., 2009; Vesa et al., 2009
IBMPFD g.6996G>C G157R Pathogenic Stojkovic et al., 2009; Djamshidian et al., 2009
IBMPFD g.7002C>T R159C Pathogenic Bersano et al., 2009
IBMPFD g.7003G>A R159H Pathogenic Haubenberger et al., 2005
IBMPFD g.7099G>A R191Q Pathogenic Watts et al., 2004
IBMPFD g.8085T>G L198W Pathogenic Watts et al., 2007
IBMPFD g.8187C>A A232E Pathogenic Watts et al., 2004
IBMPFD g.9349A>G T262A Pathogenic Spina et al., 2008
IBMPFD g.10742A>C N387H Pathogenic Watts et al., 2007
IBMPFD g.11295G>C A439P Pathogenic Shi et al., 2012
IBMPFD g.11295G>T A439S Pathogenic Stojkovic et al., 2009
IBMPFD, Inclusion body myopathy with Paget’s disease of the bone and frontotemporal dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
A recent work by Jacquin et al. (2013) has showed R155H (464
G>A) mutation of the VCP gene in a French family, led to the
Inclusion body myopathy with Paget’s disease of the bone and
frontotemporal dementia (IBMPFD), with a psychiatric onset of
FTD.
The expression of IMBPFD-associated VCP mutations in
skeletal muscle cells reduced UNC-45 (a molecular chaperone
involved in myosin assembly) degradation that is linked to severe
myofibril disorganization in myotubules. This study suggests a
possible mechanism for the selective vulnerability of skeletal
muscle in IBMPFD; however, the implication for the pathogen-
esis of FTD still remains unknown. Studies on a VCP-mutant
transgenic mouse have shown TDP-43 and ubiquitin positive
accumulations (Custer et al., 2010) suggesting a possible interplay
between these proteins. IBMPFD is known to have TDP-43 aggre-
gation with VCP mutations (Nalbandian et al., 2011). Ju et al.
(2009) have established a link between VCP and autophagosomes
wherein the loss of VCP leads to accumulation of autophago-
somes, thus establishing a possible cause of aggregation of pro-
teins such as TDP-43.
VCP has been detected in a few inclusions of neurodegenera-
tive diseases such as senile plaques in Alzheimer’s disease, Lewy
bodies in Parkinson’s disease, neuronal intranuclear inclusions in
CAG/polyglutamine diseases and ubiquitin-positive inclusions in
ALS (Hirabayashi et al., 2001; Mizuno et al., 2003; Ishigaki et al.,
2004).
Bartolome and colleagues have performed analyses in fibrob-
lasts derived from patients with three different pathogenic VCP
mutations, VCP-deficient cells, mouse cortical primary neurons
and astrocytes, to conclude that reduction of VCP led to
uncoupling of mitochondria and increased oxygen consumption
and a subsequent decrease in ATP of cells leading to cellular
toxicity and neuronal death (Bartolome et al., 2013).
VCP has been recently involved in clearance of mRNP gran-
ules (Buchan et al., 2013), thereby unraveling a new mechanism
in clearance of RNPs from the cell. This might indicate why VCP
mutations lead to accumulation of stress granule constituents or
cytoplasmic inclusions. mRNP granules assemble to form stress
granules as a consequence of their aggregation (Erickson and
Lykke-Andersen, 2011). Wang et al. (2015) have shown a direct
interaction between VCP and FUS. VCP being a key regulator of
protein degradation, DNA interaction, and mitochondrial activ-
ity, its direct interaction with FUS is intriguing. Although there
is no evidence which shows a direct interaction or implication
of VCP mutations on RNA, its association with TDP-43 and
FUS, both of which are RNA binding proteins may suggest their
unraveled interactions in RNA metabolism.
CHMP2B
CHMP2B (Charged multivesicular body protein) is encoded by a
gene located on chromosome 3 and is a component of the endo-
somal sorting complex required for transport-III (ESCRT-III
complex).
Structure
CHMP2B is a protein of 213 amino acids, with an acid C-
terminal domain and basic N-terminal domain (Figure 5A), and
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a predicted coiled-coil structure (Skibinski et al., 2005). The
negatively charged C-terminal domain interacts with the pos-
itively charged N-terminal part, creating a closed and autoin-
hibitory structure in the cytosol (Whitley et al., 2003; Shim et al.,
2007). CHMP2B requires therefore an activation process per-
formed by VPS4, which binds to its C-terminal domain. Indeed
the C-terminal part of CHMP2B contains a binding domain
for VPS4. VPS4 is a member of theAAA-ATPase family and
it has a role in catalyzing the dissociation of ESCRT com-
plexes from endosomes (Katzmann et al., 2002). The ATPase
activity of VPS4 is important for endosomal sorting (Katz-
mann et al., 2002; Obita et al., 2007). Mutations localized in the
VSP4-binding region impair the function of CHMP2B, prevent-
ing the formation of protrusions from the cell (Bodon et al.,
2011).
Localization and Function
Northern-Blot analysis demonstrated that CHMP2B is expressed
in all the major parts of the brain, including the temporal and
frontal lobes (Table 1). Moreover through in situ hybridization
of mouse brain, an enhanced expression of CHMP2B in the
hippocampus, frontal and temporal lobes, and cerebellum was
shown (Skibinski et al., 2005). The endosomal-sorting complex
required for transport (ESCRT) is a protein complex involved
in the endocytosed protein trafficking from endosome to lyso-
somes, playing an important role for sorting of proteins and
for their efficient lysosomal degradation (Urwin et al., 2010).
Moreover ESCRT complexes have a relevant role at the plasma
membrane, during cytokinesis (Carlton and Martin-Serrano,
2007; Elia and Sougrat, 2011), budding of some enveloped
viruses (Usami et al., 2009; Martin-Serrano and Neil, 2011),
autophagy and transcriptional regulation (Roxrud et al., 2010;
Schmidt and Teis, 2012). Endosomal trafficking is a key pro-
cess for the internalization and transport of neuronal growth
factors, secreted growth factors, signaling molecules (Bronf-
man et al., 2007). A dysfunction in this process could lead to
an altered cell-signaling and aberrant communication between
cells.
Implications of RNA in Pathogenesis
In particular ESCRT dysfunction is associated with neurode-
generation, indeed mutation in CHMP2B have been reported
in frontotemporal dementia linked to chromosome 3 (FTD-3)
(Urwin et al., 2010). FTD-3 has an onset of 48–67 years and is an
autosomal dominant dementia with TDP-43 negative FTLD-U,
ubiquitin positive inclusions (Urwin et al., 2010).
As reported in Table 7, several missense mutations are con-
nected with FTD-3 (Skibinski et al., 2005), with familial or spo-
radic cases of ALS (Parkinson et al., 2006; Urwin et al., 2010),
familial frontotemporal lobar degeneration (FTLD) (Ghanim
et al., 2010) or CBD (Van der Zee et al., 2008), however only few
studies analyzed their pathogenic features in cultured neurons.
A point mutation has been identified in the 5′ acceptor site
of exon 6, causing the production of two abnormal transcripts:
CHMP2Bintron5 with retention of intron 5 and CHMP2B110 that
has a 10 bp deletion and a sequence frameshift due to the use
of a criptic splice site in exon 6 (Skibinski et al., 2005). Both
proteins lack 36 amino acids in the C-terminal part with the sub-
sequent absence of VPS4-binding domain and an accumulation
of CHMP2B on the endosomal membrane (Skibinski et al., 2005;
Urwin et al., 2010). This accumulation suggests that the binding
of mutated proteins to the endosomes prevents the recruitment
of the correct proteins necessary for the fusion with lysosomes
(Metcalf and Isaacs, 2010; Urwin et al., 2010). Indeed large and
abnormal endosomal structures are observed in post-mortem
brain tissues, in patient fibroblast cultures and in case of over-
expression of CHMP2B mutant in PC12 and human neuroblas-
toma cell lines (Skibinski et al., 2005; Van der Zee et al., 2008;
Urwin et al., 2010). Moreover CHMP2B seems to act through a
gain of function mechanism in the presence of mutations, since
only the transgenic mice expressing CHMP2Bintron5 show simi-
lar neuropathology features observed in FTD-3 patients, whereas
the knockoutmice with the inactivation of CHMP2B do not show
any pathological characteristics (Ghazi-Noori et al., 2012).
Another non-sense mutation replaces a glutamine residue
with a stop codon, creating a more severe C-terminal truncation
(Van der Zee et al., 2008).
TABLE 7 | List of mutations in CHMP2B and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.13227A>G I29V Unclear Cannon et al., 2006
FTD g.18376C>A T104N Unclear Cox et al., 2010
FTD g.25885A>G N143S Unclear Van der Zee et al., 2007
FTD g.25899G>T D148Y Pathogenic Skibinski et al., 2005
FTD g.25950C>T Q165X Pathogenic Van der Zee et al., 2007
FTD g.26189G>C p.M178VfsX2/p.M178LfsX30 Pathogenic Skibinski et al., 2005
FTD g.26214C>T R186X Unclear Momeni et al., 2006
FTD g.26218G>A S187N Unclear Ferrari et al., 2010
FTD g.26276A>C Q206H Pathogenic Parkinson et al., 2006
FTD c.581C>T S194L Unclear Ghanim et al., 2010
FTD, Frontotemporal Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
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Since CHMP2B is involved in the endosomal trafficking of sig-
nal molecules, it could be interesting and possibly relevant for the
pathology to check if an altered endosomal process can affect the
function of other proteins involved in FTLD, such as progranulin,
as is it also suggested by Urwin et al. (2010).
C9ORF72
Structure
Large expansions of the non-coding GGGGCC repeat in
C9ORF72 (Chromosome 9 open reading frame 72) were recently
demonstrated to cause ALS and FTD (DeJesus-Hernandez et al.,
2011; Renton et al., 2011). Indeed 20–80% of familial and
5–15% of sporadic ALS and FTD in North American and
European patients show this hexanucleotide expansion with
a range of 700–1600 repeats, whereas the normal population
carries less than 30 repeats (DeJesus-Hernandez et al., 2011;
Renton et al., 2011; Smith et al., 2012). Pathogenic mutations
reported in C9ORF72 are listed in Table 8. C9ORF72 is local-
ized on chromosome 9 and is composed of 12 exons, with two
alternate non-coding first exons (Figure 5C, exon 1a and 1b)
(DeJesus-Hernandez et al., 2011). Specifically, the polymorphic
hexanucleotides repeat was identified between the two alterna-
tively spliced non-coding exons, through a sequencing approach
(DeJesus-Hernandez et al., 2011).
Depending on alternative transcription initiation, the
GGGGCC repeat can be located on the promoter of transcrip-
tional variant 1 or in the intron 1 of transcriptional variants 2
and 3. Variant 2 results from splicing of exons 1a and exons 2–5
whereas variant 3 is composed of exon 1a and exons 2–11.
Localization and Function
Expression array data showed wild type C9ORF72 RNA present
in different CNS tissues, including spinal cord and higher expres-
sion in the cerebellum (Renton et al., 2011; Table 1).
The protein encoded by C9ORF72 is still uncharacterized and
with unknown function even if it is well-conserved across species
(DeJesus-Hernandez et al., 2011).
Recently, Farg et al. (2014) demonstrated for the first time
that the endogenous C9ORF72 protein has a function in the
regulation of intracellular trafficking processes in the endoso-
mal and autophagy-lysosomal compartments in neuronal cell
lines. Therefore, they reported the normal cellular function of
C9ORF72 that is essential to understand its role in FTD/ALS.
In particular, they found co-localization in neuronal cell
lines and primary cortical neurons of C9ORF72 with four Rab
proteins, which are involved in endosomal trafficking. In motor
neurons, they found 70% of colocalization with Rab7, which is a
fundamental protein implicated in the biogenesis of lysosomes,
the transport of endosomes and the maturation of autophago-
somes (Gutierrez et al., 2004). A similar mechanism of interac-
tion and recruitment of Rab7 was also described for CHMP2B by
Urwin and collaborators. In CHMP2B mutant cells, an impaired
recruitment of Rab7 onto endosomes was observed with a
decreased fusion with lysosomes and a delayed degradation
(Urwin et al., 2010).
C9ORF72 protein was also found to colocalize with lysosomes,
ubiquilin-2 and autophagosomes, involved in autophagy (Farg
et al., 2014). Interestingly, the ability of C9ORF72 to interact
with hnRNPs and induce not yet characterized nuclear aggregates
and stress granules, could link the C9ORF72 protein with RNA
metabolism processes (Farg et al., 2014).
Implications of RNA in Pathogenesis
Immunocytochemistry analysis on human fibloblasts and mouse
motor neuron NSC-34 cell line revealed a predominant nuclear
localization of C9ORF72 protein (Renton et al., 2011). Immuno-
histochemical analysis showed C9ORF72 expression in neurons
and in FTD- and ALS-affected regions with a predominant cyto-
plasmic staining and a synaptic localization, but the quantitative
mRNA analysis demonstrated that the repeat expansion reduces
C9ORF72 transcript variant 1 expression in lymphoblast cell
lines of expanded repeats carriers and in frontal cortex samples
from unrelated FTLD-TDP patients carrying expanded repeats
(DeJesus-Hernandez et al., 2011). The hexanucleotide repeti-
tions present in the C9ORF72 transcript can form G-tetrad units,
called G-quartets, where G bases are rearranged in a cyclic pat-
tern with eight hydrogen bonds (Fratta et al., 2012). The pres-
ence of RNA G-quadruplexes has been found in different organ-
isms and has been observed in vitro and in vivo (Kikin et al.,
2008; Xu et al., 2010b). Transcripts are enriched in RNA G-
quadruplexes structures in the 5′UTR, 3′UTR and in the first
exon (Eddy and Maizels, 2008; Huppert et al., 2008). Recently
a molecular mechanism was described by which the DNA and
RNA G-quadruplexes in C9ORF72 create structures that pro-
mote the formation of RNA/DNA hybrids (R-loops) (Haeusler
et al., 2014). The pathological mechanism involvingC9ORF72
gene or its function are not clear, even if several studies showed
a decrease in the mRNA levels of some C9ORF72 variants in
ALS, which suggests a loss-of-function mechanism (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012;
Mori et al., 2013b). Moreover, the aberrant transcripts containing
TABLE 8 | List of mutations in C9ORF72 and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD/ALS g.5321GGGGCC(?) G4C2 hexanucleotide repeat expansion Pathogenic DeJesus-Hernandez et al., 2011
FTD g.11942A>T T66S Pathogenic Van der Zee et al., 2013
TD, Frontotemporal Dementia; ALS, Amyotrophic lateral sclerosis.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
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the hexanucleotide repeats can accumulate and form structures
in the nucleus called RNA foci, which may produce neurodegen-
eration through a toxic effect (DeJesus-Hernandez et al., 2011).
These transcripts can be aberrantly expressed through repeat-
associated non-ATG (RAN) translation (Mori et al., 2013b).
Several groups reported that the RAN translation of the hex-
anucleotide repeats produces poly(GP), poly(GA) and poly(GR)
proteins, since this type of translation, without an initiation
codon, can have all the possible reading frames (Ash et al., 2013;
Mori et al., 2013b) and RNA can be also bidirectionally tran-
scribed (Gendron et al., 2013). These RAN proteins can form
inclusions in neurons and are considered a hallmark of the dis-
ease (Ash et al., 2013; Mori et al., 2013b). The neuronal inclu-
sions can be detected through antibodies that recognize putative
GGGGCC repeat RAN-translated peptides, therefore this type of
immunoreactivity can be use as a potential biomarker for the
disease (Ash et al., 2013).
It is also reported that RNA focimay sequester important RNA
binding proteins, causing an alteration inside the cell and a sub-
sequent dysfunction of RNA targets, in a process similar to the
formation of RNA foci in myotonic dystrophy type 1 (DM1) (Lee
et al., 2013; Mori et al., 2013a; Reddy et al., 2013; Xu et al., 2013).
Specifically, one study demonstrated that hnRNP-H is seques-
trated by RNA foci, reducing its available amount and its splicing
efficiency on different target transcripts (Lee et al., 2013). A recent
paper by Gendron et al. (2013) contains detailed descriptions of
the proteins found to be sequestered on RNA foci in in vitro
studies.
The presence of both sense and antisense RNA foci in fron-
totemporal dementia with the presence of C9ORF72 repeats
(C9FTLD), was demonstrated in patients, specifically in the
frontal cortex, motor cortex, hippocampus, cerebellum, and
spinal cord (Gendron et al., 2013; Lagier-Tourenne et al., 2013;
Mizielinska et al., 2013; Zu et al., 2013). RNA foci were identified
in neurons and with lower frequency in astrocytes, microglia, and
oligodendrocytes; the highest concentration of foci was found in
the frontal cortex region, compared to cerebellum and hippocam-
pus (Mizielinska et al., 2013). However, another work reported
that foci are localized with higher frequency in the cerebellum
(Lee et al., 2013). Despite this inconsistency, the major part of
RNA foci is localized at the very edge of the nucleus, but the
explanation for this localization is still unknown (Mizielinska
et al., 2013). The cellular toxicity associated with the longer hex-
anucleotide repeats and the presence of RNA foci was demon-
strated using neuroblastoma cells and zebrafish embryos (Lee
et al., 2013). One patient, who was homozygous for the C9ORF72
hexanucleotide repeats, showed a higher proportion of sense and
antisence foci with an early onset of FTD and severe pathological
characteristics, compared to the heterozygous case (Mizielinska
et al., 2013). A recent study found a mechanism for the disease in
which the DNA and RNA–DNA structures formed in the repeat
regions, alter the RNA transcription, with a result of transcrip-
tional pausing and abortion. The accumulation of abortive tran-
scripts with hexanucleotides repeats, creates G-quadruplexes,
and hairpins structures with a binding of essential proteins,
leading to nuclear stress, and further defects (Haeusler et al.,
2014).
TDP-43 and FUS, two FTD related proteins previously
decribed, are structurally related to the hnRNPs that are found
to bind C9ORF72 RNA foci (Lee et al., 2013; Mori et al., 2013b),
however FUS and TDP-43 do not colocalize with C9ORF72
RNA foci in cells, patient motor neuron cultures or in spinal
motor neurons from patients (Lagier-Tourenne et al., 2013; Lee
et al., 2013; Sareen et al., 2013). Since TDP-43 is capable to bind
through its C-terminal region the hnRNP proteins (Buratti et al.,
2005), the accumulation of these ribonucleoprotein on the RNA
foci could indirectly influence TDP-43 function, creating a pos-
sible link of interaction between these two factors involved in
FTD and ALS (Gendron et al., 2013). Indeed most of the cases
with C9ORF72 expansion show TDP-43 inclusions (FTLD-TDP)
(DeJesus-Hernandez et al., 2011; Lagier-Tourenne et al., 2013;
Mackenzie et al., 2014) with some exception, such as a case in
UK with C9ORF72 repeats with FTLD-tau pathology (Snowden
et al., 2012). It was reported that the plasma and CSF level of
phosphorylated TDP-43 is significantly higher in patients with
FTD carrying C9ORF72 expansion or GRN mutations compared
to other FTD patients or healthy controls (Suárez-Calvet et al.,
2014). This finding creates another possible link of interaction
or regulation between TDP-43 and C9ORF72 that needs further
analysis.
Discussion
In this review we describe the different genes involved in FTD,
focusing on their possible interactions, in order to identify a com-
mon network of their combined regulations. We created this
network focusing on the RNA aspect, an emerging and crucial
molecule that plays critical and fundamental functions in the
cells. Recently, research has increased its focus onthe role of RNA
in neurodegeneration (Renoux and Todd, 2012). We believe that
the RNA mediated regulation plays a key role in the unique
integration of all the known genes involved in FTD.
In this picture (Figure 6) FUS and TDP-43 RNA binding pro-
teins are at the core of the network, since they often are associated
factors that share similar features, with sometimes different but
complementary roles (Colombrita et al., 2012). They interact with
RNA in three main roles: as RNA binding proteins participating
on the different aspects of mRNA processing (Bosco et al., 2010;
Colombrita et al., 2011), as regulators of microRNAs processing,
and as regulators of lncRNAs. FUS and TDP-43 were both found
in aggregates in ALS/FTLD affected neurons (Da Cruz and Cleve-
land, 2011), nuclear complexes and in cytoplasmic RNPs (Kim
et al., 2010b). TDP-43 appears to be the main regulator of this
network, being able to interact with FUS pre-mRNA and regu-
late its splicing, and auto-regulate its own pre-mRNA, causing a
reduction of its own expression (Polymenidou et al., 2011).
TDP-43 can also bind GRN pre-mRNA, negatively controlling
its splicing and, accordingly, knock-down of TDP-43 was shown
to increase the amount of GRN mRNA level (Polymenidou et al.,
2011; Colombrita et al., 2012). In the presence ofGRN mutations,
TDP-43 regulation can be altered, causing the formation of inclu-
sions containing TDP-43 (Mackenzie et al., 2006, 2010; Sampathu
et al., 2006). Though TDP-43 aggregation is a typical hallmark
of many other neurodegenerative disorders, such as Alzheimer’s
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disease, Guam Parkinsonism dementia complex, and Lewy body
disease (Dickson, 2008), its impact on FTD in influencing the
regulation of the network should not be underestimated.
On the other side, FUS acts as a splicing regulator of MAPT
mRNA, indeed it was demonstrated that silencing of FUS alters
the splicing of MAPT. In particular, FUS helps the skipping of
exon 10 in primary cortical neurons (Ishigaki et al., 2012). The
presence and the absence of exon 10 inMAPT gene has a funda-
mental role in the regulation of a delicate balance in the ratio of 4
or 3 repeats that can lead to FTD.
For the recently identified C9ORF72 gene, large expansions
of the non-coding GGGGCC repeat correlate with pathogene-
sis, making an RNA gain-of functionmechanism possible. Indeed
the aberrant C9ORF72 transcripts accumulate in nuclear RNA
foci and sequester several RNA-binding proteins, including some
splicing factors. However, other possible pathogenetic mecha-
nisms are under scrutiny for C9ORF72, including impaired tran-
scription of the expanded gene or repeat-associated non-ATG
(RAN) translation of expanded transcripts.
In this scenario, two FTD genes code for proteins that fit in the
picture not for their relation to RNA, but for their role in protein
degradation.
VCP, taking part in the ubiquitin-proteasome pathway and
protein turnover (Zhang et al., 2000; Rouiller et al., 2002),
could be involved in the degradation of protein inclusions
present in different forms of FTD. TDP-43 inclusions were
found in the presence of a VCP mutation (Neumann et al.,
2009a). A direct interaction between VCP and FUS has been
observed suggesting a possible convergence in their functions
(Wang et al., 2015).
CHMP2B regulates protein trafficking between endosomes
and lysosomes and is involved in the protein degradation path-
way through lysosomes (Urwin et al., 2010). Therefore, CHMP2B
could be relevant for the internalization and transport of neu-
ronal growth factors or signaling molecules such as progranulin.
Recently, a function for the C9ORF72 protein was uncov-
ered, in the regulation of intracellular trafficking processes in
the endosomal and autophagy-lysosomal compartments (Farg
et al., 2014), providing an additional link to VCP and CHMP2B
proteins.
During the preparation of this review a recent study per-
formed by Van der Zee and colleagues have demonstrated ananal-
ysis on a European cohort of 1808 FTLD patients revealing muta-
tionsin SQSTM1 (Sequestosome 1) or p62. The p62 protein is
a stress-responsiveubiquitin-binding protein, which is shown to
have a role in degradation ofpolyubiquitinated proteins via the
proteasome pathway or autophagicprocesses (Van der Zee et al.,
2014). This gene was known to be associated with ALS and found
as a rare mutation with a frequency of 1–3% in both ALS and
FTLD cases. This further intrigued its possible role in pathogenic-
ity with a common patho-mechanism. p62 is present in neuronal
and glial ubiquitin-positive inclusions in different tauopathies
and synucleinopathies (Van der Zee et al., 2014). The meta-
analysis performed by Van der Zee and colleagues revealed that
rare mutations clustering in the UBA domain of SQSTM1 may
influence disease susceptibility by doubling the risk for FTLD.
Further, histopathology analysis of autopsied brain of SQSTM1
mutation carriers demonstrated a widespread of neuronal and
glial phospho-TDP-43 pathology. Therefore, this study opens up
another target gene SQSTM1, which is known to have impli-
cations in FTLD/ALS and additionally associated with TDP-43.
Despite further work being needed, to unravel and confirm the
details of the proposed network, we foresee that the construc-
tion of a picture of the interactions between proteins and RNAs
at the basis of the FTD pathology will be of invaluable impor-
tance, not only to comprehend the pathogenetic mechanisms but
also to develop new and more effective therapeutical approaches.
Through the network analysis proposed in this review, it can be
foreseen that more genes can be linked to FTD and their roles
will possibly fall in to two main categories: regulation of gene
expression through RNA or protein degradation. Additionally it
could be predicted that novel genes related to FTD in future will
be possibly a part of the proposed network.
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1. Introduction 
Neurodegenerative diseases include a range of debilitating conditions of the central nervous 
system characterized by the progressive loss of neural tissues. More than 600 disorders 
afflict the nervous system, as hereditary or sporadic conditions that progressively cause 
neurodegeneration.  
The main neurodegenerative diseases are: 
Alzheimer’s disease (AD) and other dementias (FTD); 
Parkinson’s disease (PD) and PD-related disorders; 
Huntington’s Disease (HD); 
Amyotrophic Lateral Sclerosis (ALS). 
These diseases are multifactorial debilitating disorders of the nervous system accounting for 
a significant and increasing proportion of mortality in the world. All these 
neurodegenerative diseases are characterized by loss and death of neurons in specific brain 
areas and by different clinical manifestations.  
Alzheimer disease (AD) is the most common cause of dementia. It is characterized by 
cortical atrophy and loss of neurons in the parietal and temporal lobes. It is a progressive 
neurodegenerative disorder characterized by memory impairment with executive 
dysfunction, motor problems, and/or language difficulties. AD is caused by mutations in 
three highly penetrant genes: Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1) and 
Presenilin 2 (PSEN2) (Levy-Lahad et al., 1995) and one susceptibility gene (APOE) 
(Strittmatter et al., 1993). 
Frontotemporal dementia (FTD) is characterized by atrophy of the brain that predominantly 
affects the frontal and temporal lobes, and is often used as a synonym for Fronto-Temporal 
Lobar Degeneration (FTLD). It results in progressive behavioral changes and language 
dysfunction, but motor and cognitive impairment may be present as well. Mutations in five 
genes have been linked to FTLD: Microtubule-Associated Protein Tau (MAPT) (Hutton et al., 
1998), Progranulin (GRN) (Baker et al., 2006), Chromosome 9 open reading frame 72 
(C9orf72) (Renton et al., 2011), Valosin-Containing Protein (VCP) (Watts et al., 2004) and 
Charged Multivesicular Body Protein 2B (CHMP2B) (Skibinski et al., 2005). Moreover, there 
are other two subtypes of FTLD called FTLD-TDP43, characterized by tau-negative inclusions 
containing aggregates of TDP-43 (TAR DNA binding protein 43) (Neumann et al., 2006), and 
FTLD-FUS, showing inclusions of FUS (Fused in Sarcoma) protein co-localized with ubiquitin-
immunoreactive inclusions (Neumann et al., 2009). 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder leading to 
loss of dopamine-producing brain cells and a progressive deterioration of motor function. It 
is characterized by symptoms such as tremor, stiffness, slowness, impaired balance, anxiety, 
depression, and dementia. With regard to PD, late-onset forms of disease show mutations 
in α-Synuclein (SNCA) (Polymeropoulos et al., 1996, 1997) and Leucine-Rich Repeat Kinase2 
(LRRK2) (Funayama et al., 2002) genes, whereas early-onset forms of disease show Parkin 
(PARK2) (Kitada et al., 1998), PTEN Induced Putative Kinase1 (PINK1) (Valente et al., 2001), 
oncogene DJ1 (DJ1) (Bonifati et al., 2003; Van Duijn et al., 2001) mutations. 
Huntington disease (HD) is an autosomal dominant disorder associated with degeneration of 
the striatum. It is a genetic, progressive disorder characterized by the gradual development 
of involuntary muscle movements (chorea) and deterioration of cognitive processes and 
memory (dementia). Mutations in the Huntingtin (HTT) gene cause HD (MacDonald, 1993). 
Amyotrophic Lateral Sclerosis (ALS) is a progressive degenerative disorder affecting upper 
and lower motor neurons. Loss of motor neurons results in progressive loss of voluntary 
muscle movement, which in turn leads to muscle atrophy. Motor impairment may 
eventually affect respiratory systems but cognitive functions usually remain intact. ALS is 
caused by different mutations, such as mutations in Superoxide Dismutase 1 (SOD1) (Rosen 
et al., 1993), in the genes coding for TDP-43 (TARDBP) (Sreedharan et al., 2008), FUS/TLS 
(Sapp et al., 2003) and Ubiquilin2 (UBQLN2) (Kaye and Shows, 2000). Moreover, mutations 
in CHMP2B (Parkinson et al., 2006), VCP (Johnson J.O. et al., 2010), and C9ORF72 (DeJesus-
Hernandez et al., 2011; Renton et al., 2011) have also been implicated in ALS. 
Although these are distinct pathologies in which neurodegeneration predominantly affects 
specific neuronal populations (dopaminergic neurons in PD, striatal medium spiny neurons 
in HD, motor neurons in ALS, and cortical and hippocampal neurons in AD), there are 
converging lines of investigation showing a clinical, pathological and genetic overlap. Some 
examples are the aggregation and deposition of misfolded proteins, dysfunction of RNA 
metabolism and processing and protein homeostasis.  
The accumulation of insoluble aggregates and deposition of misfolded proteins vary from 
disease to disease, such as amyloid plaques mainly constituted by β-Amyloid protein (A) 
(Glenner and Wong, 1984) and neurofibrillary tangles composed of aggregates of 
hyperphosphorylated Tau protein (Grundke-Iqbal et al., 1986) in AD, Lewy bodies formed by 
α-Synuclein (Spillantini et al., 1997) in PD, intranuclear deposits of a polyglutamine-rich 
version of Huntingtin protein (DiFiglia et al., 1997) in HD, aggregates mainly composed of 
Superoxide Dismutase (Bruijn et al., 1998) in ALS.  
RNA processing is a very important step in cellular physiology in general, and in neuronal 
function in particular. RNA binding proteins (RBPs) and miRNAs, acting on mRNAs, add a 
level of gene expression regulation in the cell. Dysregulation of RBPs and miRNAs in neurons 
can affect RNA metabolism and, as a consequence, can lead to neuronal dysfunction and 
neurodegeneration. 
One example of this complex regulation network comes from mislocalization of TDP-43 and 
FUS/TLS, observed in a large number of disorders (mainly in ALS and FTLD, but also in AD, 
HD and PD). All together these specific kinds of neurodegenerative diseases are called TDP-
43 and FUS/TLS proteinopathies. TDP-43 and FUS/TLS are both structurally close to the 
family of heterogeneous ribonucleoproteins (hnRNPs) and act as regulators of multiple 
levels of RNA processing including transcription, splicing, transport, translation, nucleo-
cytoplasmic shuttling, formation of stress granules and miRNA processing.  
TDP-43 inclusions are found in ALS patients with TARDBP mutation but not in forms caused 
by SOD1 mutations (Mackenzie et al., 2007), in sporadic FTLD as well as familial FTLD cases 
with mutations in GRN gene, in VCP gene and in rare cases with TARDP mutations (Cairns et 
al., 2007; Neumann et al., 2007). TDP-43 inclusions have also been reported in Alzheimer 
(Uryu et al., 2008) and Parkinson patients (Hasegawa et al., 2007) and, in some instances, 
these inclusions co-exist with Tau or -Synuclein aggregates. 
FUS/TLS inclusions are less well defined but they were found in ALS and FTLD patients and in 
association with another kind of inclusions found in postmortem analysis of patients with 
different polyQ diseases (such as HD) (Doi et al., 2008). 
Another example of defects in RNA metabolism comes from hexanucleotide (GGGCCC) 
expansion in C9ORF72 gene (between alternative exons 1a and 1b) accounting for some ALS 
and FTD patients. There are at least three mechanisms of action of expanded 
hexanucleotide repeat in the C9ORF72 gene: haploinsufficiency due to reduced expression 
of the allele containing the repeat expansion; RNA toxicity due to the production of a 
mutant RNA containing the repeat that may sequester RNA binding proteins; protein toxicity 
due to the expression of a mutant protein containing the repeat expansion (La Spada and 
Taylor, 2010).  
Other factors implicated in neurodegeneration are mitochondrial dysfunctions (shape, size, 
fission-fusion, distribution, movement), oxidative stress, and/or environmental factors. 
Oxidative stress can be caused by an imbalance in the redox state of the cell, or by 
overproduction of reactive oxygen species, or by dysfunction of the antioxidant systems. A 
link has been demonstrated also between several environmental factors strongly associated 
with age, including pesticides, metals, head injuries, lifestyles and dietary habits and an 
increased disease risk. 
Overall, these findings show that several common multifactorial processes contributing to 
neuronal death and leading to functional impairments are shared by many 
neurodegenerative diseases, making a diagnosis extremely complex. 
Neurons of the central nervous system cannot regenerate after cell death and, as a 
consequence, once a neurodegenerative disease has manifested, significant neuronal loss 
and damage are already present. Therefore, it is clear the importance to establish an early 
diagnosis to maximize the effectiveness of disease-modifying therapies. In recent years large 
efforts have been made to identify disease neuropathological, biochemical, and genetic 
biomarkers to try to establish a diagnosis in the earlier stages. The finding that some related 
neurodegenerative diseases share common mechanisms suggests that these disorders may 
have similar targets for the development of diagnostic and therapeutic agents. Moreover 
the fact that the current diagnosis is based on the patient’s cognitive functions increases the 
need to investigate for common or similar non-invasive diagnostic methods, able to identify 
the disease at an early stage. Robust biomarkers would be valuable not only for the initial 
diagnosis, but also to classify various subtypes of the disease, to monitor responses to 
therapeutic agents and to track disease progression. 
 
2. Biomarkers in Neurodegenerative diseases 
Neurodegenerative disorders are different nervous system diseases characterized by the 
progressive loss of neuronal cells and tissues, without a possible regeneration process after 
the damage occurs (Rachakonda et al., 2004). The group is formed by hundreds of 
neurological diseases that show different symptoms, such as cognitive dysfunction or 
altered behavior (Krystal et al., 2014). The standard methodologies failed in the attempt to 
clarify and investigate on the pathological causes, due to the complex nature of 
neurodegenerative diseases that involves many different pathway and targets (Han et al., 
2014). In the recent years there was an increasing application of sequencing and genomic 
approaches for the study of neurodegenerative disorders (McCarroll et al., 2014) that lead 
to the discovery of novel risk genes and peripheral biomarkers useful for the investigation 
disease mechanisms. Although genetic studies represent a key method to identify genetic 
risk factors through DNA sequencing and investigate the heritability process of a disease 
state, their function of risk assessment is clearly different from biomarkers roles (Gonzalez-
Cuyar et al., 2011). Biomarkers are biological substances measured in vivo and used to 
indicate the onset or the presence of a specific disease (Rachakonda et al., 2004). The 
hypothetical biomarker changes are thought to begin 10-20 years before the clinical onset 
of a disease event. However, this timing could be influenced by the type of disorder 
considered, the analysis applied and the age of the subjects (Langbaum et al., 2013; 
Knickmeyer et al., 2014). According to this perspective the possibility to identify disease 
specific biomarkers at an early stage would lead to an early and maybe more effective 
treatment for the patients. Moreover, specific and reliable biomarkers could be applied to 
follow and quantify disease progression and investigate on the possible reactions to 
treatments, in order to achieve a better therapy (Rachakonda et al., 2004; Gonzalez-Cuyar 
et al., 2011). Biomarkers could also help in specific diagnosis, in discriminating similar 
diseases or in identifying combinations of diseases, which is enormously important for the 
assembling of subjects for clinical trials (Gonzalez-Cuyar et al., 2011). Body fluids, such as 
plasma, serum, urine and cerebrospinal fluid (CSF) represent a useful reservoir of 
information of what is happening in the body. In particular CSF that is closely linked with the 
brain, could reflect neuro-pathological features of brain disorders (Ghidoni et al., 2011). 
Biomarkers that can be measured in different biological fluids can fall in two categories: 
proteins or microRNAs. Compared to proteins, microRNAs show many advantages such as a 
tissue- or cell type- specific expression, lower cost and shorter time required for the 
development of an assays and the presence of an amplifiable signal (Chevillet et al., 2014). 
 
3. miRNA biogenesis and function 
microRNAs (miRNAs) are a group of small non-coding RNAs with important regulatory roles 
on the post-transcriptional expression of target mRNAs (Bartel, 2009; Ghildiyal and Zamore, 
2009), found in animals, plants, green algae and viruses (Griffiths-Jones et al., 2008). 
Specifically miRNAs are 21-22 nt-long single-stranded RNA molecules, firstly discovered by 
Lee et al. (1993), generating from longer transcripts of different lengths (pri-miRNA), usually 
transcribed by RNA polymerase II, from intragenic or intergenic DNA regions (Lee et al., 
2004; Garzon et al., 2010). microRNAs can perform their function when they are loaded on 
the RNA-Induced Silencing Complex (RISC) and associates with Argonaute-2 (Ago2; Meister 
et al., 2004 a and b). The miRNA-RISC complex interacts with the target mRNAs, through a 
binding between the seed region of the miRNA, localized on its 5’ end between nucleotides 
2 to 8 (Bartel, 2009). However a significant fraction of non-canonical interactions, that 
involve non-seed base pairing can occur between the miRNA-RISC complex and the target 
mRNA (Helwak et al., 2013). The RISC complex induces mRNA degradation if there is a 
perfect complementarity between the sequences of the miRNA and its target mRNA, while 
the interaction leads to translation inhibition in case of imperfect binding (Bartel, 2009). 
Frequently miRNAs recognized bind to sequences in the 3’untranslated region (UTR) of 
target mRNAs, but also the coding region and the 5’UTR of a mRNA could be involved in the 
interaction with miRNAs (Rigoutsos, 2009; Ørom et al., 2008). 
miRNAs modulate through their binding the transcriptome of cells (Guo et al., 2010). This 
process of post-transcriptional regulation seem to be complex and difficult to be fully 
understood, since one single miRNA could potentially target hundreds of different mRNAs 
and one single mRNA could be controlled by many different miRNAs. Moreover miRNAs 
themselves can be regulated post-transcriptionally as suggested by Farajollahi and Maas 
(Farajollahi and Maas, 2010), creating an increasingly intricate network of regulation. 
The assumption that miRNAs dysregulation has the potential to lead to neurodegeneration 
derived from different experiments in which knockout of Dicer, with consequent disruption 
of miRNAs biogenesis causes neurodegenerative phenotypes. Specifically, deletion of Dicer 
was performed in mouse cerebellar neurons (Schaefer et al., 2007), in midbrain dopamine 
neurons (Kim et al., 2007), in striatal, retinal, spinal and cortical neurons (Cuellar et al., 
2008; Damiani et al., 2008; Davis et al., 2008; Haramati et al., 2010) and in glial cells (Tao et 
al., 2011; Shin et al., 2009; Wu et al., 2012). Several studies showed that the DGCR8 
haploinsufficiency leads to a decreased production of miRNAs, with neuronal alteration as 
result (Stark et al., 2008; Fénelon et al., 2011; Schofield et al., 2011). Hébert and colleagues 
found an altered phosphorylation pattern of tau after the deletion of Dicer, suggesting the 
presence of miRNAs’ control on specific aspects of the neurodegeneration process (Hébert 
et al., 2010). 
Microarray analyses demonstrated a specific brain expression of different miRNAs (Lim et 
al., 2005; Manakov et al., 2009), which is particularly relevant during brain development 
(Miska et al., 2004; Kapsimali et al., 2007), whereas sequencing data lead to the 
development of a mammalian miRNAs expression atlas in different cell types (Landgraf et al. 
2007). Recent studies showed an interesting correlation between the expression pattern of 
miRNAs in brains of different primates and human development (Somel et al., 2010 and 
2011; Hu et al., 2011) suggesting that changes in miRNAs profiles induced significant 
differences at mRNA and protein levels between human and other primates’ brain. 
Therefore, not only the global loss of miRNAs can cause neurodegeneration, but in some 
cases a specific alteration of a single miRNA pattern in the brain could be linked to a 
particular disease. 
 
4. Circulating miRNA 
RNA was considered for a long time to be unstable in the blood, due to the nuclease activity 
observed in human plasma (Kamm et al., 1972). However this concept changed rapidly with 
the observation of circulating and stable cell-free miRNAs in healthy individuals and 
different types of cancer patients (Mitchell et al., 2008; Asaga et al., 2011; Hu et al., 2010; 
Schwarzenbach et al., 2011). Subsequently many circulating miRNAs that can be used as 
possible biomarkers were also described for different neurodegenerative disorders (Table 1-
3). However, it is not clear yet if all the reported miRNAs are directly released from cells 
linked with the disease or a product of aspecific secondary response. 
The observation of the rapid degradation of purified or synthetic miRNAs compared with 
the ones found in the plasma (Mitchell et al., 2008) lead to the hypothesis of a packaging 
system to protect them from RNase degradation. Exosomes, which are membrane vesicles 
of 50-100 nm diameter found in many body fluids (Weber et al., 2010), were shown to 
contain proteins, mRNAs and miRNAs derived from the originating cell (Valadi et al., 2007). 
Moreover, microvesicles (secreted vesiscles of 1-10 µm diameter), were found to contain 
miRNAs associated with invasion and migration in prostate cancer (Morello et al., 2013). 
Several studies observed in vitro the cellular uptake of exosomes and other vesicles, 
indicating the miRNAs-containing exosomes as a possible way of communication between 
cells (Skog et al., 2008; Stoorvogel, 2012; Montecalvo et al., 2012; Kharaziha et al., 2012). In 
case of RNA transfer, the target cells’ gene expression and protein translation would be 
modified, as a result (Pant et al., 2012). The origin of extracellular vesicles from 
multivesicular bodies indicates that they could have an important role for the clearance of 
toxins or altered proteins by the lysosomal pathway (Candelario and Steindler, 2014). Many 
neurodegenerative disorders, such as AD and PD, present lysosomal dysfunctions. 
Moreover, different proteins that lead to aggregation and accumulation in 
neurodegenerative disorders have been found secreted through extracellular vesiscles, such 
as TDP-43 (Nonaka et al., 2013), Aβ (Rajendran et al., 2006), tau (Saman et al., 2012) and α-
synuclein (Emmanouilidou et al., 2010). Different studies found a large part of miRNAs 
which is not associated with lipid vesicles but can be affected by protease digestion (Arroyo 
et al., 2011; Turchinovich et al., 2011). Therefore miRNAs could circulate in biofluids also in 
association with different proteins, such as Ago2 (Arroyo et al., 2011) or nucleophosmin 
(Wang K et al., 2010) and the high-density lipoprotein (Vickers et al., 2011). 
 
Different methods are used for the isolation, quantification and profiling of miRNAs. Total 
RNA extraction and isolation, guaranteeing recovery of miRNAs, is possible through 
commercially available column filtration protocols, or by using ‘Tri-reagents’ (acid phenol in 
combination with guanidinium-thiocyanate and chloroform). miRNAs quantification and 
profiling is obtained with different techniques: Next Generation Sequencing (NGS), 
Microarray and Real-Time PCR. Next generation sequencing (NGS) is rapidly evolving for its 
multiplexing capacities and provides accurate and sensitive miRNAs measurements. NGS 
gives the possibility to discover novel miRNAs, in contrast to microarray and qRT-PCR 
methods, detecting only already known miRNAs. However, NGS is labor-consuming in 
sample preparation and data analysis and very expensive. Another technique used for 
miRNA profiling is represented by microarray, showing often problems of cross-
hybridisation between members of miRNA families and discrepancies in comparing results 
obtained with different microarray platforms. A common strategy is to validate the 
microarray data by qRT-PCR, to warrantee high sensitivity and specificity. Moreover, 
multiwell plate-based qRT-PCR assays could substitute microarrays in the high-throughput 
profiling of miRNAs. qRT-PCR is presently the most easily performed and cost-effective 
method when there is a need to measure the levels of a restricted number of miRNA as 
biomarkers. An important step during qRT-PCR analysis is the choice of a suitable 
normalization method, constituted by one or more stably expressed genes (called 
housekeeping or endogenous genes). This step is required to remove variations and 
increase the accuracy of miRNAs quantification. Ribosomal RNAs (rRNAs), U6 snRNA or a 
combination of different miRNAs have been used as reference genes in miRNA profiling. 
Finally, two approaches are frequently used for the selection of promising circulating miRNA 
as disease biomarkers. The first is based on an initial screening of miRNAs with subsequent 
validation of potential biomarkers by qRT-PCR. This kind of approach gives the possibility to 
study a new mechanism not previously associated with the disease. The limitations are 
linked to sensitivity and variability depending on the platforms used to profile miRNAs. The 
second approach is based on the analysis of miRNAs already associated with the disease, 
but it has the limitations of the potential involvement of the same miRNA in non-related 
diseases and of a lack of correlation between the expression of the specific miRNA in the 
affected organ and the relative expression of the same miRNA in plasma or CSF. This latter 
issue is specifically important in neurodegenerative diseases, in which the isolation of the 
nervous system from the rest of the body, by the blood-brain barrier, makes it difficult for 
the dysregulation of a miRNA in the brain to be reflected in body fluids. 
 
4.1 Alzheimer’s disease and circulating miRNAs  
Alzheimer’s disease (AD) is the most prevalent cause of dementia in the elderly (Blennow et 
al., 2006) and shows the typical accumulation of two modified proteins: the amyloid β (Aβ) 
peptide, derived from the amyloid precursor protein (APP), can accumulate in diffuse or 
neuritic plaques (O’Brien and Wong, 2011) whereas the microtubule associated protein tau 
accumulates in structures called neurofibrillary tangles (NFTs). The accumulation of these 
proteins leads to toxic effects and inflammatory responses, contributing to the disruption of 
the neuronal network important for the cognitive functions (Gascon and Gao, 2012). 
 
Dosage of proteins associated with AD in CSF is already reported as a neurochemical way for 
the diagnosis of AD (Blennow et al., 2009; Marksteiner et al., 2007). Specifically one of the 
most common peptides derived from the cleavage of APP, the 42-amminoacids-long Aβ42, 
was found decreased in CSF of AD patients (Galasko et al., 2010). Similarly, elevated levels of 
total and phosphorylated tau in the CSF are AD biomarkers (Blennow et al., 2009; 
Marksteiner et al., 2007; Fagan et al., 2007). Regarding the altered expression of miRNAs in 
AD tissues and their pathogenic role, a study identified miR-107 to be decreased during AD 
(Wang W.X. et al., 2008), through a miRNA expression profiling in cortex from control and 
AD patients. The mRNA of BACE1, the protease involved in the cleavage of APP was 
predicted as target of miR-107 and the miRNA’s role was confirmed by expression studies. 
mRNA profiling showed that BACE1 mRNA levels tented to increase as miR-107 decreased 
during the progression of AD, indicating how this microRNA could be involved in the 
pathological process of Alzheimer’s disease (Wang W.X. et al., 2008). Regulation and control 
of BACE1 by another cluster of miRNAs (miR-29a/b-1) was further investigated by Hébert et 
al. (Hébert et al., 2008). Moreover, a study demonstrated up-regulated levels of miR-9 and 
miR-128 in AD hippocampus (Lukiw et al., 2007) and another work found increased levels of 
miR-9, miR-125b and miR-146a in the temporal lobe neocortex of affected AD individuals 
(Sethi et al., 2009), suggesting that miRNAs pattern can be altered in sporadic AD.  
The recent research demonstrated that miRNAs are not only aberrantly expressed in AD or 
involved in the regulation of the main pathological processes, but also that their altered 
presence in different body fluids could be diagnostic of AD (Table 1). The first study that 
investigated peripheral miRNAs expression in Alzheimer condition was performed in 2007 
(Schipper et al., 2007). The authors identified an increased level of miRNAs in blood 
mononuclear cells (BMC) of patients with sporadic AD using a microarray containing 462 
human miRNAs. In particular miR-34a and miR-181b were significantly increased in AD 
individuals, as validated through qPCR (Schipper et al., 2007). In 2012 a decreased level of 
some circulating miRs measured through SYBR Green qRT-PCR in the blood serum of AD 
patients was suggested as a non-invasive diagnostic method for Alzheimer’s disease 
(Geekiyanage et al., 2012). Around the same year another work used plasma miRNAs 
quantified through TaqMan miRNA qRT-PCR assay to detect mild cognitive impairment 
(MCI), that represents an intermediate state between normal aging and AD or other types of 
dementia (Sheinerman et al., 2012). This group demonstrated that ratio of plasma levels of 
miR-132 and miR-134 families paired with miR-491-5p and miR-370 differentiate MCI 
subjects from controls, with high sensitivity and specificity (Sheinerman et al., 2012). In 
particular they identified two sets of paired biomarkers ratio: the miR-132 family (miR-
128/miR-491-5p, miR-132/miR-491-5p and miR-874/miR-491-5p) and the miR-134 family 
(miR-134/miR-370, miR-323-3p/miR-370 and miR-382/miR-370). Subsequently Leidinger 
and co-workers identified in the blood of AD patients a signature of 12 miRNAs that can be 
useful for the diagnosis. They applied next-generation sequencing to select a panel of 12 
miRNAs that were further used through RT-qPCR in larger cohort of samples, differentiating 
with high accuracy and specificity between AD and controls or between AD patients and 
individuals suffering of other neurological diseases  (Leidinger et al., 2013). The signature 
contains 7 up-regulated miRNAs in AD (brain-miR-112, brain-miR-161, hsa-let-7d-3p, hsa-
miR-5010-3p, hsa-miR-26a-5p, hsa-miR-1285-5p and hsa-miR-151a-3p) and 5 down-
regulated miRNAs in AD patients (hsa-miR-103a, hsa-miR-107, hsa-miR532-5p, hsa-miR-26b-
5p and hsa-miR-let-7f-5p) (Leidinger et al., 2013). A different signature of 7 miRNAs (miR-let-
7d-5p, miR-let-7g-5p, miR-15b-5p, miR-142-3p, miR-191-5p, miR-301a-3p and miR-545-3p) 
was identified in the plasma to distinguish AD patients from normal subjects with a good 
accuracy (Kumar et al., 2013). Another work that evaluated the possibility to use miRNAs 
expressed in human brain and biofluids as biomarkers of AD, was performed by Bekris and 
collaborators, in which miR-15a level was shown to positively correlate with neuritic plaque 
score (Bekris et al., 2013). In particular a higher plasma miR-15a level was suggested to be a 
feasible marker of high neuritic plaque in hippocampus (Bekris et al., 2013). Bhatnagar and 
collaborators studied through TaqMan array and validated with qRT-PCR, miRNAs circulating 
in plasma and blood mononuclear cells (PBMC) of AD patients, identifying miR-34c as a 
biomarker to individuate sporadic AD subjects, since its level is significantly increased in 
plasma samples of patients (Bhatnagar et al., 2014). During the last year one work showed 
an altered expression of 6 miRNAs (miR-98-5p, miR-885-5p, miR-483-3p, miR-342-3p, miR-
191-5p, miR-let-7d-5p) in serum of AD patients compare to controls, with high specificity 
and sensitivity for miR-342-3p (Tan et al. 2014). More recently Galimberti and colleagues 
correlated altered miRNAs expression between serum and CSF of AD patients campare to 
healthy individuals, finding downregulation of 3 miRNAs (miR-125b, miR-23a and miR-26b) 
in serum derived from 22 AD patients. Downregulation of miR-125b and miR-26b was also 
observed and confirmed in CSF from AD individuals (Galimberti et al. 2014). The function of 
miR-125b was also recently validated in vivo, indeed injection of miR-125b into 
hippocampus in mice induces tau phosphorylation and learning impairment (Banzhaf-
Strathmann et al. 2014). 
The first time in which CSF was used to identify possible biomarkers for the diagnosis of AD 
was in the 2008, Cogswell and coworkers discovered that miRNAs can be detected in this 
fluid and their expression is altered in the presence of AD pathology. In particular they 
found altered miRNAs related to immune cell differentiation and innate immunity (Cogswell 
et al., 2008). Significant increases in the levels of miR-9, miR-125b, miR-146a and miR-155 
was found in CSF and in extracellular fluid (ECF) derived from short post-mortem interval 
brain tissue of AD patients (Alexandrov et al., 2012). Some of these miRNAs are known to be 
over-express in brain of patients and associated with the spreading of inflammatory 
neurodegeneration (Alexandrov et al., 2012). Another candidate biomarker for AD is miR-
27a-3p, which was found reduced in the CSF of patients compare to control subjects in a 
pilot study (Sala Frigerio et al., 2013). The decrease in the level of miR-27a-3p is combined 
with high CSF tau levels and low CSF β-amyloid levels (Sala Frigerio et al., 2013). 
As already reported (Cogswell et al., 2008) CSF- and ECF-derived from AD patients contain 
abundant levels of proinflammatory miR, in particular miR-146a and miR-155 (Lukiw et al., 
2012). These two miRNAs were suggested to be involved in the spreading process of 
Alzheimer’s disease, since human neuronal-glial cocultures secrete these miRNAs upon 
cytokine tumor necrosis factor-α (TNF-α) and Aβ42-peptide stress; in addition it was 
observed that a conditioned medium containing miR-146a and miR-155 induces 
inflammatory gene expression and downregulation of complement factor H (CFH). This 
regulator is involved in inflammatory degeneration in Alzheimer’s disease and other 
disorders (Lukiw et al., 2012). A similar function was proposed for miR-let-7, that was found 
up-regulated in the CSF of AD subjects. They demonstrated that extracellular introduction of 
let-7b in the CSF of mice induces neurodegeneration through the RNA-sensing Toll-like 
receptor (TLR) 7 (Lehmann et al., 2012). miR-146a was also identified in plasma and CSF of 
AD patients in another recently study with other candidates miRNAs (Kiko et al., 2014). 
However its level was analysed through qRT-PCR and found significantly dowregulated in AD 
patients compared to controls in apparently contrast with previous reports (Alexabdrov et 
al., 2012; Lukiw et al. 2012).  
 
4.2 Parkinson’s disease and circulating miRNAs  
Approximately 1% of the population over the age of 55 is affected by Parkinson’s disease 
(PD). This neurodegenerative disorder is characterized by the degeneration of dopaminergic 
neurons of the substantia nigra that leads to rigidity, tremors and slowed movements. 
Another pathological feature is the presence of inclusions primarily composed of α-
synuclein, called Lewy bodies. These inclusions are cytoplasmic and show a characteristic 
pattern in the brain. One of the biochemical markers used to recognize the onset of PD is 
the loss of the dopamine transporter (DAT) or the identification of α-synuclein protein in the 
Lewy bodies (Duyckaerts et al., 2003). Ruling out the analysis of protein involved in the 
pathology in the brain, an increased level of oxidative stress markers in blood of PD patients, 
such as superoxide radicals and the coenzyme Q10 redox ratio were suggested as potential 
biomarker for Parkinson’s disease (Michell et al., 2004). It was also shown that the 
proinflammatory factor tumor necrosis factor (TNF-α) is 3-4 fold higher in CSF of PD patients 
compared to controls (Le et al., 1999). Decreased levels of α-synuclein concentration in CSF 
of PD patients have been found by different laboratories (Mollenhauer et al., 2011; Shi et 
al., 2011). In addition some groups investigated as biomarker of PD, the CSF level of a 
multifunctional redox-sensitive protein, important for mitochondrial function, called DJ-1 
(Waragai et al., 2006; Hong et al., 2010). However the studies highlighted the necessity of 
controlling blood contamination of CSF, age during the analysis (Hong et al. 2010) and the 
clear need of an improved laboratory test with higher performance (Shi et al. 2011). So far 
none of these potential biomarker seems to be sufficiently robust and specific to be useful 
as a real diagnostic biomarker in clinical practice.  
 
Regarding the presence of circulating miRNAs in the body fluids of PD patients (Table 2), the 
first study that investigate blood samples was performed by Margis and collaborators in the 
2011 (Margis et al., 2011). They found through qRT-PCR analysis three differential expressed 
miRNAs: miR-1, miR-22-5p and miR-29 that could be used to distinguish between not-
treated PD patients and normal controls individuals; whereas miR-16-2-3p, miR-26a-2-3p 
and miR-30a are differentially expressed between treated and untreated PD patients 
(Margis et al., 2011). In the same year another study found using miRCURY LNA microarrays, 
18 miRNAs with an altered expression in the peripheral blood mononuclear cells (PBMCs) of 
PD subjects, and predicted that target genes of these miRNAs were involved in PD's 
pathological pathways (Martins et al. 2011). More recently a study identified through RNA-
Seq, 16 miRNAs differentially expressed in blood leukocytes of PD patients compared to 
healthy control volunteers (Soreq et al., 2013). Eleven miRNAs were modified after deep-
brain stimulation (DBS) treatment, whereas five were changed inversely to the disease-
induced changes (Soreq et al., 2013). Investigation and analysis of miRNAs expression in 
plasma of PD patients was also performed by Khoo and coworkers (Khoo et al., 2012). Using 
microarrays and TaqMan qRT-PCR validation, they identified four miRNAs: miR-1826, miR-
450b-3p, miR626 and miR-505, whose levels can be used in combination to obtain the 
highest predictive biomarker performance to individuate the presence of the disorder (Khoo 
et al., 2012). Another work that analyzed plasma from PD patients and normal controls 
through TaqMan miRNA qRT-PCR, identified miR-331-5p as a possible PD biomarker (Cardo 
et al., 2013). Recently a study investigated circulating miRNAs in serum of PD or multiple 
system atrophy (MSA) patients compared to healthy controls to distinguish individuals that 
are affected by these two different pathologies with overlapping features (Vallelunga et al., 
2014). Specifically, through array analysis and qRT-PCR validation, the authors identified 4 
miRNAs that are downregulated and five miRNAs that are upregulated in PD serum versus 
control subjects (Vallelunga et al., 2014). miRNAs profiling of serum derived from idiopathic 
Parkinson’s disease (IPD), PD patients carriers the LRRK2 G2019S mutation and controls was 
also performed through real time PCR- based TaqMan MicroRNA arrays, finding 
downregulation of miR-29a, miR-29c, miR-19a and miR-19b in patients compare to healthy 
individuals (Botta-Orfila et al. 2014). So far there are no studies reporting miRNA biomarkers 
for PD in patients' CSF. 
 
4.3 Amyotrophic lateral sclerosis and circulating miRNAs 
As already mentioned, ALS is caused by mutations in SOD1, in RNA-binding proteins as TDP-
43 and FUS/TLS, in CHMP2B, VCP, and C9ORF72. Some miRNAs are emerging as important 
contributors to ALS pathogenesis. 
The involvement of TDP-43 and FUS/TLS in miRNAs biogenesis, has been uncovered, as 
these proteins directly bind key components of the miRNA processing pathway. Drosha is 
able to form two distinct protein complexes, a "more canonical" complex with DGCR8 and a 
larger complex, including TDP-43 and FUS, with limited pri-miRNA processing activity 
(Gregory et al., 2004). In addition, TDP-43 was shown to directly bind Dicer, Ago2, subsets of 
pri-miRNAs in the nucleus and pre-miRNAs in the cytoplasm (Kawahara and Mieda-Sato, 
2012). In vitro depletion of TDP-43 and FUS proteins leads to a reduction of specific subsets 
of miRNAs implicated in neuromuscular development, neuronal function and survival 
(Buratti et al., 2010; Kawahara and Mieda-Sato, 2012; Morlando et al., 2012). 
To determine if miRNAs are essential to motor neuron survival, Haramati's group in 2010 
used Dicer knockdown mice. They demonstrated that the heavy neurofilament subunit is a 
target of miR-9, already reported to be down-regulated in a genetic model of Spinal 
Muscular Atrophy (SMA) (Haramati et al., 2010). It has been shown that SMA and ALS are 
motor neuron diseases linked by a common molecular pathway: FUS, mutated in ALS, 
interacts with SMN, deficient in SMA (Yamazaki et al., 2012). Moreover, in a recent study, a 
miR-9 reduction was found in human neurons derived from Induced Pluripotent Stem Cells 
(iPSCs) from patients with the pathogenic TARDBP M337V mutation, suggesting that miR-9 
down-regulation could be a common pathogenic event in FTD/ALS (Zhang et al., 2013). In a 
recent study alteration in ALS of some miRNAs directly targeting neurofilament light chain 
mRNA (NEFL) has been shown. Among these dys-regulated miRNAs, there are miR-146a* 
(up-regulated) and miR-524-5p and miR-582-3p (down-regulated) in spinal cord (SC) from 
sporadic ALS (sALS) patients (Campos-Melo et al., 2013). In addition, a group of 80 putative 
novel miRNAs from control and sporadic ALS (sALS) spinal cords has been characterized. 
Among them, 24 have miRNA response elements (MREs) within the NEFL mRNA 3'UTR and 2 
of them, miR-b1336 and miR-b2403, are down-regulated in ALS spinal cord (Ishtiaq et al., 
2014). 
Changes in miRNAs have also been seen in peripheral ALS tissues. The muscle-specific miR-
206 is up-regulated in lower limbs of SOD1-G93A mice (Williams et al., 2009) and in a mouse 
model with miR-206 deletion, acceleration of disease progression was observed, suggesting 
that the high amount of miR-206 in SOD1-G93A mice may have a compensatory effect to 
reduce degeneration in ALS. A similar increase in miR-206 was also observed in ALS patients' 
muscle tissue (Russell et al., 2012). In the same work the authors found that skeletal muscle 
mitochondrial dysfunction in ALS patients is associated with an increase in some miRNAs 
(miR-23a, 29b, 206 and 455) and with a reduction in peroxisome proliferator-activated 
receptor γ coactivator-1α (PGC-1α) signaling pathways (Russell et al., 2012). 
 
In another work, high expression of miR-29a was observed in brain and spinal cord of SOD1 
(G93A) mice, a model for familial ALS. These results provide a first evidence for the possible 
therapeutic utility of modulation of miR-29a function in ALS (Nolan et al., 2014). In a very 
recent study, miR-141 and miR-200a are found to be linked with FUS by a feed-forward 
regulatory in which FUS up-regulates miR-141/200a, which in turn regulate FUS protein 
synthesis. Moreover, Zeb1, a miR-141/200a target and at the same time a transcriptional 
repressor of these two miRNAs, is part of the circuitry and reinforces it (Dini Modigliani et 
al., 2014). 
 
A small number of studies recently investigated miRNAs as ALS biomarkers in CSF and in 
blood (Table 3). A first study was performed on leukocytes from sALS patients with respect 
to healthy controls. The study reported a profile of 8 miRNAs significantly up- or down-
regulated in sALS patients (De Felice et al., 2012). Another study performed the analysis on 
sorted CD14+ CD16– monocytes from ALS patients, which are monocytes activated and 
recruited to the spinal cord in case of inflammation correlated with neuronal loss. This study 
showed a miRNAs profile constituting an inflammatory signature that could be useful as 
biomarker for disease stage or progression (Butovsky et al., 2012). The populations of 
deregulated miRNAs found in leucocytes (De Felice et al., 2012) and monocytes (Butovsky et 
al., 2012) are not overlapping and comparable, although the two analyses were performed 
with the same technical approach, TaqMan miRNA assay-based quantitative RT-PCR (qRT-
PCR).  
Recently, other two miRNAs emerged as possible candidates as ALS biomarkers in biofluids. 
In the first, miRNA alterations were studied in plasma of SOD1-G93A mice, and subsequently 
in the serum of human ALS patients (Toivonen et al., 2014). miR-206 was increased in 
plasma of symptomatic animals and in ALS patients, showing to be a promising candidate 
biomarker for this motor neuron disease (Toivonen et al., 2014). In the second study, up-
regulation of miR-338-3p in blood leukocytes as well in cerebrospinal fluid, serum, and 
spinal cord from sALS patients was detected (De Felice et al., 2014). 
 
4.4 Huntington's disease and circulating miRNAs  
The causal mutation of HD is an expanded repetition of the CAG trinucleotide in the first 
exon of the gene encoding huntingtin (HTT). HTT associates with Ago2 in P-bodies, and HTT 
knockdown has an effect on gene silencing mediated by miRNAs as demonstrated by 
Luciferase assay in which HTT kd abrogates let-7b silencing effect (Savas et al., 2008). 
miRNAs were implicated in HD pathogenesis. The repressor element 1 silencing 
transcription (REST) factor, a transcriptional repressor acting to silence neuronal gene 
expression in non-neuronal cells, is elevated in HD neurons, and this up-regulation gives as 
result a repression of key neuronal genes (Zuccato et al., 2007; Johnson R. et al., 2010). REST 
and its cofactor coREST have target sites for miR-9 and miR-9*, respectively (Packer et al., 
2008), and these two miRNAs, together with miR-7, miR-124, miR-132, and other miRNAs 
result to be down-regulated in HD patients (Johnson R. et al., 2008; Martí et al., 2010). 
There are also deregulated miRNAs not under REST control, suggesting that miRNA 
dysregulation is extensive in HD (Jin et al., 2012; Sinha et al., 2010). In cellular models of HD, 
miR-146a, miR-125b, and miR-150 are down-regulated in the presence of mutant HTT 
protein (Sinha et al., 2010). Interestingly, miR-146a, miR-150, and miR-125b target HTT and 
were also predicted to interact with the TATA binding protein (TBP) mRNA. This protein is 
known to be recruited into mutant HTT aggregates (Sinha et al., 2010 and 2011). In the 
cortex of mutant HTT mouse models at early stages of disease miR-200 family is altered, 
compromising genes involved in neuronal plasticity and survival (Jin et al., 2012). 
With regard to biofluids, it has been demonstrated that miR-34b is up-regulated in response 
to mutant HTT in human plasma, suggesting a possible role for miR-34b as a biomarker for 
HD (Gaughwin et al., 2011). 
 
4.5 Other diseases 
Some miRNAs were linked to FTD through different mechanisms. For example, miR-29b and 
miR-107 regulate progranulin levels (Jiao et al., 2010; Wang W.X. et al., 2010). These 
miRNAs might decrease progranulin levels and, since it has been demonstrated that 
progranulin haploinsufficiency can cause FTD, might be a risk factor for this disease. 
Moreover, a genetic polymorphism (rs5848) in PGRN 3'UTR, associated with a higher risk of 
FTD, affects miR-659 binding site resulting in a more efficient binding and, as a 
consequence, in decreased progranulin levels (Rademakers et al., 2008). Finally, several 
miRNAs were found deregulated in FTD with TDP-43 pathology (Kocerha et al., 2011). 
Unfortunately, no studies were performed about circulating miRNA in plasma or serum from 
patients with FTD, suggesting that the study of circulating miRNA in plasma/serum for 
diagnosis of this kind of disorder needs more detailed investigations. 
 
5. Therapy 
The advantages in the use of miRNAs are that these very small RNAs have the ideal 
biomarker characteristics: ease of detection, extreme specificity and remarkable stability. 
The use of miRNA as therapeutic agents for neurodegenerative diseases is an important 
opportunity but also a challenging topic for several reasons. Each miRNA can regulate 
numerous target of the same pathway and so they could be a promising tool in which low 
dose of the top miRNA would be enough to induce a focused change in the entire pathway. 
However, these same features also present great challenges. There are still many notions to 
be elucidated, such as all the functional targets for each miRNA in specific cell types or the 
hierarchic order of miRNA regulation in a specific pathway and, obviously, the delivery of 
therapeutics miRNAs into the brain due to the blood-brain barrier. 
There are different miRNA-based therapeutic strategies in vivo. miRNA mimics are small 
RNA molecules very similar to miRNA precursors and could be used to potentiate the miRNA 
post-transcriptional regulation role in some disease conditions in which one miRNA is down-
regulated. On the other hand, it would be possible to block over-expressed miRNAs in other 
kind of diseases by injecting a complementary RNA sequence (anti-miRNA) that binds to and 
inactivates the target miRNAs. A different experimental strategy to inhibit miRNA function 
could be mediated by synthetic sponge mRNA, containing complementary binding sites for a 
miRNA of interest. 
In the first strategy of miRNA-based therapeutics some challenges are its potential off-target 
effects and the possibility to saturate the endogenous miRNA processing machinery and to 
interfere with the normal functions of the cell. Another big challenge for this approach is the 
delivery of the miRNA to the right cells in the body. It has been shown that exosomes, 
endogenous nanovesicles transporting RNAs and proteins, can deliver siRNA to the brain of 
mice when injected intravenously (Alvarez-Erviti et al., 2011). This finding paves the way for 
a possible therapeutic approach mediated by exosomes opening the possibility to load 
miRNAs into the exosomes and to target them to the brain following systemic delivery. This 
approach has great potential but it will have to be explored further. In the second strategy 
locked nucleic acids (LNAs), a class of bicyclic conformational analogs of RNA, exhibiting high 
binding affinity to complementary RNA target molecules and high stability in vivo (Fluiter et 
al., 2003; Hutvágner et al., 2004) are used to enhance the specificity and to reduce the 
amount of anti-miRNA molecules. However, those "antagomirs" cannot cross the blood-
brain barrier, but can enter into brain cells only if injected directly into the brain (Kuhn et al., 
2010).  
Finally, the sponge technology has some advantages in its experimental settings. For 
example many miRNAs have the same seed sequence but are encoded by multiple distant 
loci and, therefore, sponges provide a way to sequestrate at the same time different 
miRNAs having the same seed sequence. However also this technology needs further 
investigations to be a therapeutically viable strategy. 
In conclusion, despite many scientific questions still open and a need of further 
investigations, the analysis of miRNA as biomarkers for neurodegenerative pathologies 
could be helpful to develop minimally invasive screening tests and to find diagnostic, 
prognostic and therapeutic tool for these diseases.  
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Table 1.Alzheimer’s Disease and circulating miRNAs 
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miR-34a, 
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Upregulation miRNA profiling 
Microarray 
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NEC:16 
Taqman® 
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PCR 
Schipper et al. 
2007 
Blood 
serum 
miR-137, 
miR-181c, 
miR-9, miR-
29a/b 
Downregulation 
candidate 
miRNAs 
SYBR qRT-
PCR AD:7 
MCI/Early 
AD:7 CT:7 
  
Geekiyanage 
et al. 2012 
Plasma 
miR-132 
family, miR-
134 family, 
miR-491-5p, 
miR-370 
Ratio of miRNAs 
paired 
candidate 
miRNAs 
Taqman® 
miRNA qRT-
PCR MCI:10 
CT:10 
TaqMan® 
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MCI: 20 
AD: 20 
CT: 20 
CY: 20 
Sheinerman 
et al. 2012 
Blood 
12-miRNA 
signature: 
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miR-161, let-
7d-3p, 
miR-5010-3p, 
hsa-miR-26a-
5p, 
hsa-miR-
1285-5p, and 
hsa-miR-
151a-3p  
Upregulation miRNA profiling 
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Generation 
Sequencing 
AD: 48 
CT: 22 
SYBR qRT-PCR 
AD: 94 
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MS: 16 
PD: 9 
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BD: 15 
Schiz: 14 
CT: 21 
Leidinger et 
al. 2013 
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Leidinger et 
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7-miRNA 
signature: 
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hsa-miR-15b-
5p, 
hsa-miR-142-
3p, 
hsamiR-191-
5p, 
hsa-miR-
301a-3p and 
hsa-miR-545-
3p 
  miRNA profiling 
Nanostring 
AD:11 MCI:9 
CT:20 
Taqman® 
miRNA qRT-
PCR AD:20 
CT:17 
Kumar et al. 
2013 
Plasma 
miR-15a 
associated 
with amyloid 
plaque score 
in 
hippocampus 
region 
Downregulation 
Candidate 
miRNAs 
Microarray qRT-PCR 
Bekris et al. 
2013 
cell free 
Plasma or 
PBMC 
miR-34c Upregulation 
Candidate 
miRNAs 
Taqman® 
miRNA qRT-
PCR AD:110 
CT:123 
  
Bhatnagar et 
al. 2014 
Plasma 
miR-34a, 
miR-146a 
Downregulation 
Candidate 
miRNAs 
qRT-PCR   
Kiko et al. 
2014 
Serum 
miR-98-5p, 
miR-885-5p, 
miR-483-3p, 
miR-342-3p, 
miR-191-5p, 
miR.191-5p, 
miR-let-7d-5p 
Upregulation and 
Downregulation 
miRNA profiling 
Illumina 
HiSeq 2000 
sequencing 
AD:50 CT:50 
qRT-PCR 
AD:158 
CT:155 
Tan et al. 
2014 
Serum 
miR-125b, 
miR-23a, 
miR-26b 
Downregulation   
Array AD:22 
NINDCs:18 
INDCs:18 
FTD:10 
qRT-PCR 
Galimberti et 
al. 2014 
CSF 
60 miRNAs 
differently 
express 
between 
Braak stage V 
and Braak 
Upregulation and 
Downregulation 
miRNA profiling 
Taqman® 
miRNA qRT-
PCR Braak 
stage V 
AD:10 Braak 
stage I 
  
Cogswell et 
al. 2008 
stage I CT:10 
CSF ECF 
miRNA-9, 
miRNA-125b, 
miR-146a, 
miR-155 
Upregulation 
candidate 
miRNAs 
Microarray 
AD:5 CT:5 
LED-Northern 
dot-blot assay 
using primary 
human 
neuronal-glial 
cell-cultures 
and AD ECF 
Alexandrov et 
al. 2012 
CSF miR-27a-3p Downregulation miRNA profiling 
qRT-PCR AD 
CT 
qRT-PCR 
AD:35 CT:37 
Sala Frigerio 
et al. 2013 
CSF ECF 
miR-146a, 
miR-155 
Upregulation 
candidate 
miRNAs 
Microarray 
AD:5 CT:5 
LED-Northern 
dot-blot assay 
using primary 
human 
neuronal-glial 
cell-cultures 
and AD ECF 
Lukiw et al. 
2012 
CSF miR-let-7b Upregulation 
candidate 
miRNAs 
Taqman® 
miRNA qRT-
PCR AD:13 
CT:11 
mice 
experiments 
Lehmann et 
al. 2012 
CSF 
miR-34a, 
miR-125b, 
miR-146a 
Downregulation 
candidate 
miRNAs 
qRT-PCR   
Kiko et al. 
2014 
CSF 
miR-29a, 
miR-29b 
Upregulation 
candidate 
miRNAs 
qRT-PCR   
Kiko et al. 
2014 
 CSF 
miR-125b, 
miR-26b 
Downregulation miRNA profiling 
miRNA PCR 
array AD:22 
FTD:10 
CT:18 
Taqman 
qRT-PCR 
Galimberti et 
al. 2014 
(PBMC: Peripheral Blood Mononuclear Cells; NEC: Normal Elderly Controls; AD: Alzheimer Disease; 
CT: Control; NINDCs: non-inflammatory neurological controls; INDCs: inflammatory neurological 
controls; MCI: Mild Cognitive Impairment; MS: Multiple Sclerosis; PD: Parkinson Disease; DEP: 
MajorDepression; BD: Bipolar Disorder; Schiz: Schizophrenia; CSF: Cerebrospinal Fluid; ECF: brain 
tissue-derivedextracellular fluid; CY: Young Control; FTD: Frontotemporal Dementia) 
 
 
 
 
Table 2. Parkinson’s Disease and circulating miRNAs 
 
SAMPLE miRNA  TREND 
EXPERIMENTAL 
APPROACH  
PILOT 
STUDY 
VALIDATION REFERENCES 
Total 
peripheral 
blood 
miR-1, miR-
22-5p, miR-29 
distingiush 
non-treated 
PD from 
healthy 
subjects 
Downregulation miRNA profiling 
qRT-PCR 
untreated 
PD: 8 
treated 
PD: 4 
early-
onset PD: 
7 CT:8 
  
Margis et al. 
2011 
Total 
peripheral 
blood 
miR-16-2-3p, 
miR-26a-2-
3p, miR-30a 
distinguish 
treated from 
untreated PD 
Upregulation miRNA profiling 
qRT-PCR 
untreated 
PD: 8 
treated 
PD: 4 
early-
onset PD: 
7 CT:8 
  
Margis et al. 
2011 
PBMC 18 miRNAs Downregulation miRNA profiling 
Microarray 
PD:19 
CT:13 
  
Martins et al. 
2011 
Leukocytes 
16 miRNAs 
differentially 
expressed: 6 
miRNAs 
Downregulation miRNA profiling 
Next 
Generatio
n 
Sequencin
g PD pre-
DBS: 3 PD 
post-DBS: 
3 CT:6 
  
Soreq et al. 
2013 
Leukocytes 
16 miRNAs 
differentially 
expressed: 10 
miRNAs 
Upregulation miRNA profiling 
Next 
Generatio
n 
Sequencin
g PD pre-
DBS: 3 PD 
post-DBS: 
3 CT:6 
  
Soreq et al. 
2013 
Plasma 
miR-1826, 
miR-450b-3p, 
miR-626, 
miR-505 
Upregulation of 
k-Top Scoring 
Pairs (k-TSP1) 
(miR-1826/miR-
450b-3p), miR-
626, miR505 
miRNA profiling 
Agilent 
microarray 
PD:32 
CT:32 
Taqman® 
miRNA qRT-
PCR PD:30 
MSA:4 PSP:5 
CT:8 
Khoo et al. 
2012 
Plasma miR-331-5p Upregulation miRNA profiling 
Taqman® 
miRNA 
qRT-PCR 
  
Cardo et 
al.2013 
PD:31 
CT:25 
Serum 
miR-339-5p, 
miR-652, 
miR-1274A, 
miR-34b Downregulation miRNA profiling 
Taqman®  
Human 
microRNA 
Array PD:6  
MSA:9 
CT:5 
Taqman® 
miRNA qRT-
PCR PD:25 
MSA:25 CT:25 
Vallelunga et 
al. 2014 
Serum 
miR-223*, 
miR-324-3p, 
miR-24, miR-
148b, miR-
30c Upregulation miRNA profiling 
Taqman®  
Human 
microRNA 
Array PD:6  
MSA:9 
CT:5 
Taqman® 
miRNA qRT-
PCR PD:25 
MSA:25 CT:25 
Vallelunga et 
al. 2014 
Serum 
miR-29a, miR-
29c, miR-19a, 
miR-19b Downregulation miRNA profiling 
Taqman®  
Human 
microRNA 
Array 
IPD:10 
PD:10 
CT:10 
Taqman®  
Human 
microRNA 
Array IPD:20 
PD:20 CT:20 
Botta-Orfila et 
al. 2014 
(PD: Parkinson Disease; PSP: Progressive Supranuclear Palsy; MSA: Multiple System Atrophy; DBS: 
Deep Brain Stimulation; IPD: Idiopathic Parkinson’s Disease). 
 
 
Table 3. Amyotrophic Lateral Sclerosis and circulating miRNAs 
SAMPLE miRNA  TREND 
EXP. 
APPROACH 
PILOT 
STUDY 
VALIDATION REFERENCES 
Leukocytes miR-338-3p Upregulation 
miRNA 
profiling 
Microarray 
ALS:8 CT:12 
Taqman® 
miRNA qRT-
PCR ALS:14 
CT:14 
De Felice et al., 
2012 
Leukocytes 
miR-451, 
miR-1275, 
miR-328, 
miR-638, 
miR-149, 
miR-665, 
miR-583 
Downregulation 
miRNA 
profiling 
Microarray 
ALS:8 CT:12 
Taqman® 
miRNA qRT-
PCR ALS:14 
CT:14 
De Felice et al., 
2012 
Monocytes 
miR-27a, 
miR-155, 
miR-146a, 
miR-532-3p 
Upregulation 
miRNA 
profiling 
Microarray 
ALS:8 MS:8 
CT:8 
  
Butovsky et al., 
2012 
(ALS: Amyotrophic lateral sclerosis) 
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Abstract 
 
Progranulin (PGRN) is a secreted protein expressed ubiquitously throughout the body, including the 
brain, where it localizes in neurons and activated microglia. Loss-of-function mutations in the GRN 
gene are an important cause of familial Frontotemporal Lobar Degeneration (FTLD). PGRN has 
neurotrophic and anti-inflammatory activity and it is neuroprotective in several injury conditions, 
such as oxygen or glucose deprivation, oxidative injury and hypoxic stress. Indeed, we have 
previously demonstrated that hypoxia induces the up-regulation of the GRN mRNA transcripts.  
Several studies have shown the involvement of microRNAs in hypoxia. Moreover, in FTLD 
patients with a common genetic variant of GRN (rs5848) the reinforcement of the binding site for 
miR-659-3p has been suggested to be a risk factor. Here, we report that miR-659-3p interacts 
directly with the GRN 3’UTR as shown by luciferase assay and ELISA and Western Blot analysis in 
HeLa cells. Moreover, we demonstrate the physical binding between GRN mRNA and miR-659-3p 
employing a miRNA capture-affinity technology in SK-N-BE cells. In order to study a possible 
involvement of miRNAs in hypoxia-mediated up-regulation of GRN, we evaluated miR-659-3p 
levels in SK-N-BE cells after 24 h of hypoxic treatment finding them inversely correlated to GRN 
transcripts. Furthermore, we extended our experimental work to an animal model of asphyxia 
finding that GRN mRNA levels increased at pnd 1 and pnd 4 in cortices of rats subjected to 20 min 
asphyxia in comparison to control rats and miR-659-3p decreased at pnd 4 just when GRN reached 
the highest levels. In conclusion, our results demonstrate the interaction between miR-659-3p and 
GRN transcript and the involvement of miR-659-3p in GRN up-regulation mediated by 
hypoxic/ischemic insults. 
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1. Introduction 
 
1.1 Progranulin and hypoxia 
 
 
Progranulin (PGRN) is a 65 kDa secreted protein expressed ubiquitously throughout the body, 
including the brain, where it localizes in neurons and activated microglia (Daniel et al., 2003; 
Matsuwaki et al., 2011; Petkau et al., 2010). Loss-of-function mutations in the GRN gene are an 
important cause of familial Frontotemporal Lobar Degeneration (FTLD) with TAR DNA-binding 
protein 43 (TDP-43)-positive inclusions (FTLD-TDP). Biological activities attributed to 
progranulin are numerous, yet their relevance to neurodegeneration is unclear. PGRN has 
neurotrophic and anti-inflammatory activity (Zhu et al., 2002; Kessenbrock et al., 2008; Tang et al., 
2011; Gass et al., 2012; De Muynck et al., 2013) and is neuroprotective in several injury conditions, 
including oxygen glucose deprivation (Yin et al., 2010) and oxidative injury (Martens et al., 2012; 
Xu et al., 2011). In our previous work we described that progranulin is up-regulated by hypoxia in 
neuroblastoma cell lines suggesting that it could exert a protective role in the brain against hypoxic 
stress, one of the main risk factors involved in FTLD pathogenesis (Piscopo et al., 2010). 
It has been hypothesized that ischemia/hypoxia is involved in the pathogenesis of several 
neurodegenerative diseases (Gerst et al., 1999; Martin et al., 2001). In fact, the CNS is particularly 
susceptible to changes in local O2 levels, which can affect neuronal activity (Peña and Ramirez, 
2005), and promote the development of disorders, including dementia (Bazan et al., 2002). Several 
studies have documented that periods of chronic hypoxia predispose individuals to the development 
of dementia (Peers et al., 2009). Our previous study showed that perinatal hypoxia triggers an early 
and transient oxidative stress in rat brain, followed by a biphasic regulation of several molecules 
involved in anti-oxidant defenses, neuroprotection and brain development. The early up-regulation 
of such molecules is likely to represent an adaptive response of the brain to counteract the 
consequences of the hypoxic insult (Piscopo et al., 2008). 
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1.2 Hypoxia and miRNA  
 
 
MicroRNAs (miRNAs) are single-stranded 21-22 nucleotide small noncoding RNAs,  constituting 
the most abundant class of small RNAs in animals. They have an important role in post-
transcriptional regulation of gene expression, by base pairing with target messenger RNAs 
(mRNAs) (Bartel, 2004). miRNAs can act by translational repression or by cleavage in a sequence-
specific manner, depending on the degree of sequence complementarity with their target mRNA 
(Pillai et al., 2007).  
Several studies showed an involvement of miRNAs in different biological processes, such as 
proliferation, cell differentiation and apoptosis. Moreover, miRNAs have been linked to 
neurodegenerative diseases (Grasso et al., 2014; Grasso* et al., 2015). A specific family of miRNAs, 
called hypoxamirs, is altered when cells are in low-oxygen conditions, causing a dysregulation of 
pathways involved in oncogenesis, angiogenesis, apoptosis (Kulshreshtha et al., 2008, 2007; 
Gorospe et al., 2011; Nallamshetty et al., 2013) and in different disorders of the central nervous 
system including stroke, head trauma, neoplasia and neurodegenerative diseases (Acker and Acker, 
2004). Although cancer and neurodegeneration are very different pathologies characterized by 
opposing cell fate, they share an altered oxygen homeostasis and common hypoxia signaling. On 
one side, cancer cells use the hypoxic response to support their growth, while on the other side this 
protective mechanism is destroyed in neurodegenerative diseases (Quaegebeur and Carmeliet, 
2010).  
Hypoxia-activated pathways regulating hypoxamirs are under investigation, but the involvement of 
Hypoxia-Inducible Factor (HIF) is well known in the regulation of transcriptional changes during 
hypoxic stress (Semenza, 2012). Several other transcription factors such as NF-κB, PU.1, and p53 
also have important roles in the presence of low-oxygen conditions (Cummins and Taylor, 2005), 
therefore it can be hypothesized that in the regulation of hypoxamirs expression following hypoxia 
both HIF-dependent and HIF-independent (Nallamshetty et al., 2013) pathways intervene. 
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1.3 PGRN and miRNAs 
FTLD shows several distinct clinical presentations differing not only among mutations, but also 
within a single mutation and even within individual families, suggesting the involvement of post-
transcriptional regulation mechanisms. Recent findings suggest that GRN is under the control of 
miRNAs. In FTLD patients with a common genetic variant of GRN (rs5848) the reinforcement of a 
miR-659-3p binding site due to the presence of T-variant has been suggested to be a risk factor 
(Rademakers et al., 2008). miR-29b has a role in the regulation of GRN expression levels in stable 
cell line (hPGRN-3T3) expressing full-length human GRN cDNA (including the 3′UTR) (Jiao et al., 
2010). GRN expression is also under post-transcriptional control of miR-107, a member of a 
miRNA group including miR-15, miR-16, miR-103, miR-195, miR-424, miR-497, miR-503, and 
miR-646, with implications for brain disorders (Wang et al., 2010). Moreover, a profile of miRNA 
expression in the frontal cortex of a population of FTLD-TDP patients with GRN mutations has 
been identified (Kocerha et al., 2011). More recently, it was demonstrated that decreased levels of 
miR-132/212 lead to transmembrane protein 106B (TMEM106B) up-regulation and, consequently, 
a perturbation of PGRN pathways and increased risk to develop FTLD-TDP (Chen-Plotkin et al., 
2012). 
 
The aim of the present study is to examine the role of miR-659-3p in progranulin post-
transcriptional regulation and the involvement of this miRNA in GRN up-regulation mediated by 
hypoxic/ischemic insults comparing different in vitro and in vivo models, to verify the hypothesis 
of a mechanistic link between hypoxic stress and miRNA-mediated modulation of the GRN gene. 
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2. Materials and methods  
2.1 miRNA target sites prediction 
The prediction of miRNA target sites was performed using the algorithm Targetscan 
(http://www.targetscan.org/ Version 6.2). 
 
2.2 HeLa cell cultures and transfection 
The human cervical carcinoma HeLa cell line was grown in DMEM medium (Gibco®, Life 
Technologies) supplemented with 2 mM L-Glutamine, Penicillin/Streptomycin and 10% Fetal 
Bovine Serum (FBS). Cell cultures were maintained at 37 °C in a humidified atmosphere of 5% 
CO2. Cells were seeded on 24-well dishes (Luciferase Assay) and 6-well dishes (Western Blotting 
and ELISA assay) and transfected at 80% confluence with Lipofectamine LTX and Plus reagent 
(Life Technologies). 
 
2.3 Generation of GRN 3’UTR reporter construct and miRNAs-overexpressing plasmids  
In order to generate pGLO-GRN-3'UTR reporter construct, GRN 3’UTR forward and reverse primers 
(Table 1) were used to amplify human GRN 3’UTR from human genomic DNA (#G1471 Promega) 
and then cloned into pGLO Vector (Promega). This vector is based on Promega Dual-Luciferase 
technology, with firefly luciferase (luc2) used as primary reporter and Renilla luciferase (hRluc-
neo) as a control reporter for normalization. 
The miRNA constitutive-expression cassettes for miR-659 and miR-181a (negative control) were 
generated by PCR amplification of human genomic DNA (#G1471 Promega) and primers reported 
in Table 1. The genomic fragment containing the pre-miRNA was cloned in the BglII and XhoI 
sites of pSiUx plasmid (Denti et al., 2004). 
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2.4 Luciferase Assay  
75.000 cells per well were seeded in 24-well dishes and transfected at 80% confluence using 
Lipofectamine LTX and Plus reagent (Life Technologies) with 15 ng of the pGLO-GRN-3′UTR and 
435 ng of miRNA-overexpressing plasmids. The pGLO vector is designed to analyze miRNA 
activity by the insertion of miRNA target sites downstream of the firefly luciferase gene (luc2). 
miRNA binding to the target sequence will produce a reduced firefly luciferase expression. 24 and 
48h after transfection cells were lysed with Luciferase Assay Reagent (Promega), and Renilla and 
Firefly luciferase activity were measured using Dual-Glo Luciferase Assay System (Promega) in the 
Infinite® M200 (Tecan) plate reader. 
 
2.5 Western blotting and ELISA assay  
HeLa cells were seeded in a 6-well plate and transfected using Lipofectamine LTX and Plus reagent 
(Life Technologies) with 2.2 µg of miRNA-overexpressing plasmids. After 48h, proteins were 
extracted by Radioimmunoprecipitation Assay Buffer (RIPA) supplemented with a protease 
inhibitor cocktail (Sigma-Aldrich) and analyzed by Western Blotting and ELISA assays. 
20 µg of proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
and transferred on nitrocellulose membrane by using the iBlot® Dry Blotting System (Life 
Technologies) at 20V for 7 minutes. Blots were first blocked with 5% non-fat powdered milk in 
TBS/Tween 0.1%, then probed overnight at 4 °C with mouse monoclonal anti-GRN (Abcam® no. 
ab55167, 1:500), and rabbit polyclonal anti-HPRT (FL-218) (Santa Cruz Biotechnology® no. sc-
20975, 1:500). Membranes were washed, incubated with IRDye® 680LT Donkey anti-Mouse IgG 
and IRDye® 800CW Goat Anti-Rabbit IgG secondary antibodies (LI-COR Biosciences, 1:10.000). 
Membranes were scanned with the LI-COR Odyssey Infrared Imaging System according to the 
manufacturer’s instructions. Densitometric analysis was performed using ImageJ. 
1.5 µg of proteins were used to perform ELISA assay (Adipogen). Standards and samples were 
pipetted into the wells of a 96-well plate for binding to the pre-coated polyclonal antibody specific 
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for PGRN. After washing to remove unbound samples, PGRN was recognized by the addition of a 
biotinylated polyclonal antibody. After removal of excess biotinylated antibody, streptavidin 
labeled with HRP was added. After a final wash, peroxidase activity was quantified using the 
substrate 3,3’,5,5’-tetramethylbenzidine (TMB) and the intensity of the color reaction, directly 
proportional to the concentration of GRN in the samples, was measured at 450 nm. 
 
2.6 miR-CATCH technique  
A miRNA:target pull down protocol was performed to isolate GRN mRNA with its bound miRNAs 
using a technique described in a recent publication (Hassan et al., 2013) with modifications. Briefly, 
5’ biotin-modified DNA oligonucleotides (5’-TCTTCAAGGCTTGTGGGTCTGGCAGG-3’) 
(Table 1) complementary to GRN mRNA were designed using Mfold 
(http://mfold.rna.albany.edu/?q=mfold) and synthesized. Three T75 flasks of SK-N-BE cells at full 
confluence were harvested, cross-linked with 1% formaldehyde for 15 minutes at room temperature 
after which the reaction was stopped with 0.2 M glycine. After a triple wash with ice cold PBS, the 
cells were mechanically disrupted in FA-lysis buffer (50mM HEPES pH 7.5, 140mM NaCl, 1mM 
EDTA, 1% Triton, 0.1 % sodium deoxycholate). Lysates were incubated with oligonucleotide-
conjugated streptavidin-coated magnetic beads (Dynabeads MyOne Streptavidin C1) in 50% v/v 
hybridization buffer (2X Tris-EDTA, 1 M LiCl) for 90 minutes at 37°C. A separate sample was 
incubated similarly, but with beads conjugated with a non-targeting scrambled control 
oligonucleotide (Table 1). After three 37°C washes with Wash buffer A (1X Tris-EDTA, 0.15 M 
LiCl, 0.5% sodium dodecyl sulphate) and two washes with Wash buffer B (1X Tris-EDTA, 0.15 M 
LiCl), the mRNA:microRNAs complexes were eluted from the magnetic beads and the samples 
were incubated at 70°C for 45 minutes to reverse the crosslinks. Quantative real time PCR (RT-
PCR) was performed to check for the presence of the GRN mRNA and exclude possible 
contamination of other mRNAs and Taqman miRNA assay on miR-659-3p was used to analyze the 
presence and abundance of this miRNA compared to the scramble non-specific control. 
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Table 1. Primer sequences 
OLIGO SEQUENCE 
Primer Forward GRN 3’UTR 5'-AAATCTAGAGGGACAGTACTGAAG-3' 
Primer Reverse GRN 3’UTR 5’- ATCTAGAGAAAGTGTACAAACTTTATTG-3’ 
Primer Forward miR-659 5'-ACTGCTCGAGCACTGTCATTATTTTCTCAC-3' 
Primer Reverse miR-659 5'-ACTGAGATCTGCGTTCTTGTTTTGTGTTTC-3' 
Primer Forward miR-181a 5'-ACTGAGATCTACCATTCAAAGACATTTTCT-3' 
Primer Reverse miR-181a 5'-ACTGCTCGAGCTCCTTACCTTGTTGAAATG-3' 
Oligo Capture GRN 5’-TCTTCAAGGCTTGTGGGTCTGGCAGG-3’ 
Scrambled 5’-ATATATTAGATTGCGTATAATTAGG-3’ 
Primer Forward GRN 5'-TTCTGGACAAATGGCCCAC-3' 
Primer Reverse GRN 5'-ACCCACGGAGTTGTTACCTG-3' 
Primer Forward GAPDH 5'-TCTCCTCTGACTTCAACAGC-3' 
Primer Reverse GAPDH 5'-CGTTGTCATACCAGGAAATGA-3' 
 
2.7 SK-N-BE cell cultures and treatments  
Human neuroblastoma cell lines SK-N-BE were cultivated in RPMI-1640 medium (Euroclone). All 
growth media were supplemented with 10% heat-inactivated (v/v) Foetal Bovine Serum (FBS), 5 
mM L-glutamine, penicillin (100 IU/ml) and streptomycin (100 µg/ml). Cell cultures were 
maintained at 37°C in a humidified atmosphere of 5% CO2. For experiments, cells were seeded on 
60 mm plastic culture dishes at a density of 1x104/cm2 and grown to 80% confluence, at which 
point, the medium was changed. The general morphology of cell monolayers, before and after 
treatments, was monitored by light microscopy. Cell proliferation was estimated by counting the 
total number of cells in each dish with use of a hematocytometer. Cell viability was determined by 
Trypan blue dye exclusion test (Sigma-Aldrich). We also evaluated the number of cells that 
detached from the substrate and were found to be freely floating in cell medium. 
For stimulating hypoxia, we used a hypoxic/anaerobic chamber (BBL™ GasPak™, USA). The 
system was set up at 37°C in 5% CO2, 95% N2. Cells were transferred into the humidified chamber 
and incubated with the appropriate media for up to 24 h then, lysed for RNA isolation (below). 
Control cells were maintained in the incubator under normoxic conditions. 
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2.8 Animal model  
Wistar rats were purchased from Charles River (Calco, Italy) and kept in the Animal Facility of the 
Istituto Superiore di Sanità in an air-conditioned room at 21±1°C and 60 ± 10 % relative humidity, 
with a white/red light cycle (white light on from 8.30 to 20.30). One week after the arrival of the 
rats, breeding pairs were formed, and after 48 hours, females were individually housed until the 22nd 
day of gestation, when the caesarean section was carried out. 
The experimental protocol was conducted according to the EC guidelines (EU Directive 26/2010) 
and the Italian legislation, and under permission of the Italian Ministry of Health. Asphyxia was 
induced in pups delivered by caesarean section on pregnant Wistar rats, as described by Bjelke et al. 
(1991). Time-mated female rats within the last day of gestation were decapitated and the entire 
uterus was quickly removed. Use of anesthetic in the dam was avoided because maternal anesthesia 
affects the degree of CNS hypoxia experienced by the neonate. Immediately after hysterectomy, 
four pups were delivered to be considered caesarean-delivered (0 min asphyxia) controls, then the 
uterus horns, still containing the fetuses were placed in a saline bath maintained at 37°C. Pups from 
the same uterus were then removed after 20 min and stimulated to breath by gently touching them 
around the oral and genital areas for approximately ten minutes. Fetuses were assigned randomly to 
the different asphyxia condition. Pups were then left to recover for approximately 1 h in a humidity- 
and temperature-controlled incubator at 30±1°C (Elmed Ginevri 0GB 1000, Rome, Italy) until 
fostered by surrogate mothers that had given birth to healthy litters within 24 h. One male and one 
female from each asphyxia condition (0 min, 20 min) were assigned to a foster dam, (8 pups/litter). 
Pups were sacrificed for molecular and biochemical studies at three time points: post-natal day 
(pnd) 1, 4 or 11. At least 4 animals per groups were used at each time points.  
 
2.9 Quantitative RT-PCR  
Total RNA was extracted from cell and brain samples using the Invisorb SpinCell RNA kit 
(Invitek). For progranulin expression cDNA was synthesized by retrotranscription using 
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SuperScript III first-strand cDNA synthesis kit (Invitrogen Inc., Carlsbad, CA) with random primers, 
according to the manufacturer’s protocol. Reverse transcription quantitative real-time PCR (RT-
qPCR) was performed using a specific TaqMan Gene expression assay (Applied Biosystems); 18S 
rRNA was chosen as a reference gene. The parameters for PCR amplification were: 50 °C for 2 min, 
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. PCR was performed 
in triplicate for each sample; 18S rRNA was chosen as reference gene.  
Total RNA was extracted from SK-N-BE cells using TRIzol reagent (Invitrogen), according to the 
manufacturer’s instruction. For the quantification of GRN transcripts, cDNA was synthesized by 
retrotranscription using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) with 
oligo(dT) primers, according to the manufacturer’s protocol. Real-Time PCR (RT-qPCR) was 
performed using Kapa SYBR fast qPCR master mix (Kapa Biosystem) and specific primer reported 
in Table 1. The expression of GRN mRNA was normalized by GAPDH reference. 
TaqMan MicroRNA Reverse Transcription kit (Life Technologies) was used for miRNAs 
quantification in SK-N-BE and Hela cells. Starting from total RNA (10 ng), we converted miRNA 
to cDNA using reverse transcriptase and miRNA-specific stem–loop primers: hsa-miR-659-3p 
(001514), hsa-miR-181a-5p (000480), and endogenous controls RNU44 (001094) and 
RNU48 (001006). Rat miR-659-3p was quantified using TaqMan MicroRNA Reverse Transcription 
kit for hsa-miR-659-3p (001514) and endogenous controls RNU44 (001094) and RNU48 (001006). 
The PCR reaction (20 µl), containing 1.33 µl of cDNA, 10 µl of TaqMan 2X Universal PCR Master 
Mix, 1 µl of TaqMan MicroRNA Assay (20X) containing probes specific for the miRNAs of 
interest, was incubated at 95°C for 10 min, and then at 95°C for 15 s and 60°C for 60 s for 40 cycles.  
The relative expression of mRNAs and miRNAs was calculated by using the comparative Ct 
method. Data were expressed as fold-change relative to the mean of endogenous controls. 
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2.10 Sequencing  
HeLa and SK-N-BE 3’UTR region of GRN gene was sequenced with specific primers (Table 1) by 
using the BMR-Genomics sequencing service (BMR Genomics, University of Padova, Padova, 
Italy, http://www.bmr-genomics.it). 
2.11 Statistical analysis  
Data are expressed as mean±SEM. Comparisons among groups were made using Student's t-test 
with significance set at p<0.05. Spearman’s rank correlation coefficient was calculated to assess 
association between levels of mRNA and miRNA. 
 
3. Results 
3.1 Bioinformatic prediction of miR-659-3p target site in GRN 3’UTR  
With the aim of identifying miRNAs regulating GRN, its 3‘UTR was analysed using the algorithm 
Targetscan. Among several miRNA binding sites, Targetscan predicted the presence of a miR-659-
3p binding site in the 3’UTR of GRN. It has been previously observed that in FTLD patients with a 
common genetic variant of GRN (rs5848) there is a nucleotide substitution from C- to T-allele in the 
miR-659-3p binding site that should strengthen the binding of miR-659-3p to the GRN mRNA 
(Rademakers et al., 2008). Rademakers and colleagues described that depending on the presence of 
the C-allele or the T-allele, the positioning of miR-659-3p with respect to the miRNA binding site 
in GRN was expected to shift, resulting in the formation of three additional base-pairs at the 5’ end 
of the miRNA when the risk T-allele of rs5848 was present. The stronger binding of miR-659-3p to 
the GRN mRNA containing the T-allele was expected to result in a more efficient inhibition of 
PGRN translation leading to reduced PGRN expression levels.  
However, luciferase assays in the work by Rademakers and colleagues suggest that miR-659-3p 
only binds the transcript of the T allele. To investigate the binding of miR-659-3p to either the C 
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allele or T allele GRN transcript and to calculate the hybridization minimum free energy in both 
cases we analysed both sequences with RNAhybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid) (Rehmsmeier et al., 2004). The in silico analysis confirmed that miR-659-3p 
can bind the GRN mRNA C allele with a DeltaG of -23.5 kcal/mol (Fig.1A) although the binding is 
stronger to the T allele transcript (DeltaG = -25.6 kcal/mol) (Fig. 1B). 
 
A 
mfe: -23.5 kcal/mol 
 
target 5'    A  A      CCU     A  3' 
              GC CCUCCC   AACCA      
              UG GGAGGG   UUGGU      
miRNA  3' CCCC         AC      UC 5' 
 
 
 
B 
mfe: -25.6 kcal/mol 
 
target 5'    C   U            A  3' 
              ACC CUCCCU AACCA      
              UGG GAGGGA UUGGU      
miRNA  3' CCCC          C     UC 5' 
 
Figure 1. Thermodynamics of miR-659-3p binding to GRN transcript.  
Comparison between base-pairing in the presence of wild-type C-allele (A) or risk T-allele (B). The 
presence of the risk T-allele results in a stronger binding (DeltaG = -25.6 kcal/mol).  
MFE, minimum free energy change (∆G). 
 
3.2 Functional assays to validate the predicted miR-659-3p target site 
To verify that miR-659-3p binds the C-allele GRN 3‘UTR, HeLa cells were co-transfected with a 
miR-659-overexpressing plasmid (pSiUx-miR-659) and pGLO-GRN-3’UTR (a pGLO plasmid 
containing the C-allele GRN 3’-UTR cloned downstream of the firefly luciferase gene). A plasmid 
overexpressing miR-181a (pSiUx-miR-181a) was used as negative control, since no binding site for 
miR-181a-5p was predicted on GRN 3’-UTR. The levels of miR-659-3p, were significantly 
increased at 24 hours and 48 hours, as measured by qRT-PCR on mature miRNAs (Fig. 2). The 
levels of miR-181a-5p, already present in HeLa cells, were also increased at 24 hours and 48 hours 
albeit by smaller amounts. 
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Figure 2. Upon transfection of pSiUx-miR-659 and pSiUx-miR-181a, miRNAs are 
overexpressed. expression levels of miRNAs measured by qRT-PCR after 24h and 48h from 
transfection. Mean ± SEM of two biological replicates is shown (N=6, *** p < 0.001 vs. miRNAs 
basal expression levels). 
 
 
The co-transfection of HeLa cells with these constructs showed that miR-659-3p but not miR-181a-
5p overexpression led to a significant decrease in luciferase expression from the pGLO-GRN-
3’UTR reporter compared to cells transfected with pSiUx-empty (Fig. 3). Moreover, miR-659-3p 
overexpression induced a reduction of luciferase activity at 24h (Fig. 3A) and 48h (Fig. 3B), 
compared to the luciferase activity measured in the same cells transfected with miR-181a-
overespressing plasmid. These results suggest a direct binding of miR-659-3p on the C-allele GRN 
3’-UTR. 
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 Figure 3. Luciferase assays confirm the interaction between miR-659-3p and the C-allele GRN 
3‘UTR. 
GRN 3’-UTR was cloned downstream of the firefly luciferase gene in pGLO vector and co-
transfected with miR-659 and miR-181a-overexpressing plasmids in HeLa cells. Luciferase activity 
was assessed 24h (A) and 48h (B) after transfection (N=3; * p < 0.05). 
 
 
In order to characterize the HeLa cell model system with respect to SNP rs5848, GRN 3’UTR 
region of HeLa cells was sequenced. In Fig. 4A is shown that this cell line presented a CC genotype.  
To further validate the effect of miR-659-3p on the expression of the 
endogenous PGRN expression, HeLa cells were transfected with either pSiUx-miR-659 or pSiUx-
miR-181a. 48h after transfection, a ~25% reduction of C-allele PGRN measured by ELISA assay 
was observed in cells overexpressing miR-659-3p, compared to cells transfected with the negative 
control pSiUx-miR-181a (Fig. 4B). A similar result was shown by Western Blot analysis, in which 
the transfection of miR-659-overexpressing plasmid caused a ~15% reduction of HeLa endogenous 
C-allele PGRN (Fig. 4C). 
HeLa cells were chosen for these experiments since they have a low basal expression of miR-659-
3p (Fig. 1). 
 
 
 
A B 
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Figure 4. Inverse correlation between PGRN expression levels and miR-659-3p in HeLa cells. 
HeLa 3'UTR sequencing showing a CC genotype (A). ELISA assay (B) for PGRN quantification in 
protein extracts from HeLa cells (N=4; ** p < 0.01). 
Western blot analysis (C) for PGRN detection in protein extracts from HeLa cells (N=3; ** p < 
0.01). Western Blot image is representative of three biological replicates. Expression of Western 
Blot was normalized on HPRT expression. 
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To confirm the physical interaction between GRN mRNA and miR-659-3p a pull down protocol 
was performed using a technique we described in a recent publication (Hassan et al., 2013). For the 
following experiments, we chose SK-N-BE, a human neuron-like cell culture representing a more 
similar environment to FTLD pathology. Moreover, this neuroblastoma cell line was used in our 
previous work describing the up-regulation of PGRN by hypoxia (Piscopo et al., 2010). 
With the aim of characterizing SK-N-BE cell model system with respect to SNP rs5848, as for 
HeLa cells, GRN 3’UTR region was sequenced in SK-N-BE cell line showing a TC genotype (Fig. 
5A). 
qRT-PCR showed a 23,73-fold enrichment for GRN mRNA using a GRN mRNA-specific capture 
oligonucleotide compared to a scramble oligonucleotide used as negative control (Fig. 5B). In 
parallel, Taqman assay showed a 311,5-fold enrichment of miR-659-3p in samples captured with 
GRN mRNA-specific oligonucleotide (Fig. 5C). 
Taken together, these results suggest that miR-659-3p can affect PGRN expression in HeLa and 
SK-N-BE cells. 
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Figure 5. mRNA:miRNA isolation technique for GRN mRNA from SK-N-BE cells.  
SK-N-BE 3'UTR sequencing showing a TC genotype (A). A capture anti-sense DNA 
oligonucleotide with a biotin modification at the 5’ end was designed to pull-down GRN mRNA. 
qRT-PCR showed enrichment of GRN mRNA (B) and of miR-659-3p (C) in samples captured with 
GRN mRNA-specific oligonucleotide compared to a scramble oligonucleotide used as negative 
control. mRNA expression was quantified with the 2−∆∆Ct method using GAPDH as housekeeping 
gene; miRNA expression was quantified using the 2−∆Ct method. 
Mean ± SEM of three biological replicates is shown (N=9, * p < 0.05; *** p < 0.001 vs. scramble 
non specific control). 
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3.3 miR-659-3p levels are correlated with GRN mRNA expression in SK-N-BE  
 
In order to test the effect of hypoxia on the miR-659-3p-mediated regulation of PGRN, the levels of 
PGRN transcript and protein and of miR-659-3p were analysed in SK-N-BE under normoxic and 
hypoxic conditions. As a marker of hypoxia, the expression of glucose transporter GLUT1, which is 
regulated under hypoxic condition (Fisk et al., 2007), was measured. As shown in Fig. 6, GLUT1 
levels were up-regulated in response to hypoxia, with a dramatical increase at 24 h of incubation. 
Moreover, 24 h of hypoxic treatment was not cytotoxic for the cells, at least under the assay 
conditions we have used here. In fact, the number of cells treated with hypoxia did not differ by 
more than 5% from the number of control cells, without any decrease in cell viability (96±2 %) 
(data not shown). In the same samples, GRN mRNA was increased 2.44±0.15-fold (Fig. 6). 
20 
 
 
Figure 6. Twenty-four hours of hypoxia treatment affect GLUT-1 and GRN gene expression in SK-
N-BE cell lines (A, B). The histograms show mRNA levels of GLUT-1 (A) and GRN (B) after 
hypoxia administration. Data, compared to 18S rRNA, are expressed as fold changes relative to the 
control at each treatment. Mean ± SEM of six experiments is shown. 
**P< 0.01 and *P< 0.05 vs. untreated normoxic cells. 
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The levels of miR-659-3p were also analysed and a possible correlation between miR-659-3p 
expression and GRN mRNA was investigated. We observed a negative correlation between GRN 
mRNA and miR-659-3p expression levels (Spearman’s rank correlation coefficient = -0.96, p = 
0.0005) (Fig. 7). 
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Figure 7. Negative correlation between GRN and miR-659-3p expression levels in SK-N-BE.  
 
 
3.5 GRN increase and miR-659-3p decrease in a rat model of global perinatal asphyxia  
 
In order to evaluate whether the hypoxia-induced miR-659-mediated regulation of PGRN takes 
place also in vivo, GRN mRNA and miR-659-3p levels were measured in a rat model of global 
perinatal asphyxia. We have previously shown that 20 min of global asphyxia are required for 
inducing significant brain oxidative stress, measured as increased levels of the lipid peroxidation 
product F2-isoprostane, and alterations in the spontaneous motor behavior (Calamandrei et al., 
2004). Shorter times of asphyxia (5, 10 or 15 min) did not cause significant alterations at 
biochemical and behavioral levels, whereas longer periods of asphyxia (>25 min) were 
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characterized by low survival rates. Thus, in the present study we adopted two exposure conditions: 
0 and 20 min of asphyxia. In these conditions, survival rate was 100% and 95% in the 0 min and 20 
min of asphyxia group, respectively; body weight on pnd 11 was lower in pups subjected to 20 min 
perinatal asphyxia in comparison to control rats (approximately 8% decrease), as previously 
described (Calamandrei et al., 2004). The qRT-PCR on GRN transcripts was performed in rat 
cortical samples at pnd 1, 4 and 11. 20 min perinatal asphyxia was found to increase GRN mRNA 
levels compared to controls. In particular, hypoxia at birth increased GRN levels at pnd1 
(2.91±0.21-fold p=0.004) and pnd 4 (increased 3.97±0.49-fold p=0.04) (Fig. 8A). Reciprocally, 
miR-659-3p levels significantly decrease at pnd 4 (p=0.05) (Fig. 8B). 
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Figure 8. Levels of GRN mRNA (A) and miR-659-3p (B) in cortex of control and asphyctic 
newborn rats at different time points after global perinatal asphyxia. Data, expressed as 2-∆Ct, are 
means±SEM. N=5 
 
4. Discussion 
This study outlines an interaction between miR-659-3p and the GRN transcript and indicates a role 
for this miRNA in the post-transcriptional regulation of GRN expression. This claim is supported by 
multiple findings. First, we found that miR-659-3p interacts directly with the GRN 3’-UTR as 
shown by luciferase assay. Second, we showed by ELISA and Western Blot analysis that miR-659-
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3p regulates the expression levels of the endogenous GRN in HeLa cells. Finally, we demonstrated 
the binding between GRN mRNA and miR-659-3p in a more physiological condition with a 
miRNA capture affinity technology (miR-CATCH) in SK-N-BE cells.  
Moreover, we found that the interaction between miR-659-3p and the GRN transcript participates in 
the regulatory scheme responsible for the control of GRN levels in SK-N-BE cells after hypoxic 
treatment. In a previous study, we evaluated the expression of progranulin after hypoxic treatment 
in neuroblastoma cell lines and we found that progranulin is up-regulated by hypoxia suggesting 
that it could exert a protective role in the brain against hypoxic stress, one of main risk factors 
involved in dementia (Piscopo et al., 2010). In order to study a possible involvement of miRNAs in 
hypoxia-mediated up-regulation of GRN, we evaluated miR-659-3p levels in SK-N-BE cells after 
24 h of hypoxic treatment finding them inversely correlated to GRN transcripts. In the miR-659-3p 
target site on GRN 3‘UTR, Rademakers and colleagues described an allelic variant associated to 
FTLD (Rademakers et al., 2008). They described that homozygous carriers of SNP rs5848 T-allele 
had a 3.2-fold increased risk to develop FTLD compared with homozygous C-allele carriers. We 
analysed GRN 3’UTR region in our cell lines and found that HeLa cells have a CC- and SK-N-BE 
cells a CT-genotype. Therefore, we observed a translational repression (shown by Luciferase, 
Western Blot and ELISA assays) and a physical interaction (using miR-CATCH) of wild-type C-
allele with miR-659-3p. In Rademakers work, using a different cell-based system and different 
conditions, miR-659-3p seems to bind only the risk T-allele, as demonstrated by luciferase assays 
and in vivo studies (Rademakers et al., 2008). Our results add new finding in the regulation of 
PGRN mediated by miRNAs, showing that also the binding of wild-type C-allele has a role in the 
post-transcriptional regulation of PGRN.  
In order to validate the role of PGRN and miR-659-3p in hypoxic conditions, we extended our 
experimental work in vitro to an animal model of asphyxia. We found that GRN mRNA levels were 
increased at pnd 1 and pnd 4 in cortices of rats subjected to 20 min asphyxia in comparison to 
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control rats; moreover, although uncharacterized in rat to date, our data indicates that miR-659-3p is 
decreased at pnd 4 when PGRN reached the highest levels.  
These data are strongly consistent with the observation obtained from the SK-N-BE cells after 
hypoxic treatment. The fact that we observed a significant modulation of miR-659-3p expression 
only at pnd 4 requires further investigation to fully elucidate the mechanisms regulating PGRN 
expression. For instance, TDP-43, a DNA and RNA binding protein, was shown to specifically bind 
GRN 3’UTR with a role in the control of GRN mRNA stability (Polymenidou et al., 2011; 
Colombrita et al., 2012). The transmembrane protein TMEM106B has been identified as a potential 
PGRN regulator considering that TMEM106B up-regulation seems to sequester PGRN in 
TMEM106B positive late endosomes or lysosomes, and increase intracellular levels of PGRN 
(Chen-Plotkin et al., 2012). Moreover, a recent work shows that GRN mRNA with short and long 
5’-UTR is differentially expressed via post-transcriptional and translational repression (Capell et al., 
2014).  
Taken together these results suggest a possible involvement of miR-659-3p in GRN up-regulation 
mediated by hypoxic/ischemic insults and confirm the importance to study the regulation 
mechanism of GRN expression after hypoxic insult in order to understand its role in dementia. 
It has been demonstrated that chronic hypoxia causes a deficiency of Dicer (DICER1) expression 
and activity, with a resulting deregulation of miRNAs biogenesis (Ho et al., 2012). The 
downregulation of miR-659-3p after hypoxia observed in our samples could indeed be due to a 
down-regulation of Dicer expression as shown in Ho and colleagues work (Ho et al, 2012). 
However, we believe that the effect we observed is not due to a widespread down-regulation, since, 
after hypoxic treatment, together with a miR-659-3p decrease, we observe other miRNAs, which 
are up-regulated or non-responsive to hypoxia (data not shown). According to this observation, 
Caruso and coworkers (Caruso et al., 2010) showed that, during the onset of pulmonary arterial 
hypertension (PAH) after hypoxia, there is a reduced Dicer expression leading to miR-22, miR-30, 
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and let-7f down-regulation and, at the same time, to miR-322 and miR-451 up-regulation in two 
different PAH rat models. 
The alteration of miRNAs in neurodegenerative diseases is probably the sum of different factors, 
but several evidences showed that hypoxia could have a significant impact. Strategies adopting 
combined approaches including Chromatin Immunoprecipitation (ChIP) or in vitro processing assay 
could help to understand the response to hypoxia and the pathways leading to miRNAs 
deregulation. A recent evidence showed that the processing of pre-miR-139 is blocked by inhibitors 
induced by Hypoxic Ischemia (HI), resulting in the down-regulation of mature miR-139-5p and a 
consequent up-regulation of Human Growth and Transformation Dependent Protein (HGTD-P), a 
proapoptotic protein (Qu et al., 2014). The hypothesis of a similar mechanism involving miR-659-
3p processing mediated by hypoxia needs to be investigated in our in vitro models in further work. 
As final consideration, it should be noted that in neurodegeneration we suppose that the up-
regulation of PGRN could be linked to neuroprotection in the case of neurodegenerative disorders 
but also to a more general protective role. This is supported by our previous work in which we 
described that progranulin exerts a protective role against hypoxic stress in neuoblastoma cell lines 
(Piscopo et al., 2010). Therefore, it is shown that progranulin is a neuroprotective growth factor, 
expressed within motor neurons and promoting neuronal cell survival (Ryan et al., 2009). 
Moreover, it is also part of a fibroblast stress response and cytoprotection to acidotic stress (Guerra 
et al., 2007) and, very recently, it has been demonstrated that PGRN protects against hypoxia-
induced inflammation in a mouse model of renal ischemia/reperfusion injury (Zhou et al., 2015).  
However, elevated levels of PGRN in cancer positively stimulate pathways involved in 
proliferation, migration and invasiveness. The first evidence in cancer showed a role for PGRN as 
autocrine growth stimulus for an aggressive murine teratoma (Zhou et al., 1993). Then, it was 
demonstrated an involvement of GRN mRNA expression levels in breast cancer (Lu and Serrero, 
2000; Swamydas et al., 2011), liver cancer (Cheung et al., 2004), squamous esophageal cancer 
(Chen et al., 2008), glioblastoma (Bandey et al., 2014), and gastrointestinal cancer (Demorrow, 
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2013). More recently, other works showed also a role for PGRN as a possible diagnostic and 
prognostic cancer biomarker (Han et al., 2011; Wang et al., 2012; Wei et al., 2015). Thus, 
neurodegeneration shares with cancer an altered oxygen homeostasis and common hypoxia 
signaling, and although these two pathologies are entirely distinct and have opposite outcome 
(cancer leads to cellular growth and neurodegeneration resulting in cell death), a better 
characterization of altered molecular pathways involving PGRN and response to hypoxia is very 
important for the development of effective therapies for both diseases. 
In conclusion, our results demonstrate the interaction between miR-659-3p and GRN transcript and 
the involvement of miR-659-3p in GRN up-regulation mediated by hypoxic/ischemic insults. 
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